id	sid	tid	token	lemma	pos
cord-003403-ypefqm71	1	1	key	key	JJ
cord-003403-ypefqm71	1	2	:	:	:
cord-003403-ypefqm71	1	3	cord-003403-ypefqm71	cord-003403-ypefqm71	ADD
cord-003403-ypefqm71	2	1	authors	author	NNS
cord-003403-ypefqm71	2	2	:	:	:
cord-003403-ypefqm71	2	3	Roberts	Roberts	NNP
cord-003403-ypefqm71	2	4	,	,	,
cord-003403-ypefqm71	2	5	Christine	Christine	NNP
cord-003403-ypefqm71	2	6	C.	C.	NNP
cord-003403-ypefqm71	2	7	;	;	:
cord-003403-ypefqm71	2	8	Maslow	Maslow	NNP
cord-003403-ypefqm71	2	9	,	,	,
cord-003403-ypefqm71	2	10	Joel	Joel	NNP
cord-003403-ypefqm71	2	11	N.	N.	NNP
cord-003403-ypefqm71	2	12	title	title	NN
cord-003403-ypefqm71	2	13	:	:	:
cord-003403-ypefqm71	3	1	Assay	assay	NN
cord-003403-ypefqm71	3	2	Challenges	challenge	NNS
cord-003403-ypefqm71	3	3	for	for	IN
cord-003403-ypefqm71	3	4	Emerging	emerge	VBG
cord-003403-ypefqm71	3	5	Infectious	Infectious	NNP
cord-003403-ypefqm71	3	6	Diseases	Diseases	NNPS
cord-003403-ypefqm71	3	7	:	:	:
cord-003403-ypefqm71	4	1	The	the	DT
cord-003403-ypefqm71	4	2	Zika	Zika	NNP
cord-003403-ypefqm71	4	3	Experience	experience	NN
cord-003403-ypefqm71	4	4	date	date	NN
cord-003403-ypefqm71	4	5	:	:	:
cord-003403-ypefqm71	4	6	2018	2018	CD
cord-003403-ypefqm71	4	7	-	-	SYM
cord-003403-ypefqm71	4	8	10	10	CD
cord-003403-ypefqm71	4	9	-	-	SYM
cord-003403-ypefqm71	4	10	02	02	CD
cord-003403-ypefqm71	4	11	journal	journal	NN
cord-003403-ypefqm71	4	12	:	:	:
cord-003403-ypefqm71	5	1	Vaccines	vaccine	NNS
cord-003403-ypefqm71	5	2	(	(	-LRB-
cord-003403-ypefqm71	5	3	Basel	Basel	NNP
cord-003403-ypefqm71	5	4	)	)	-RRB-
cord-003403-ypefqm71	5	5	DOI	DOI	NNP
cord-003403-ypefqm71	5	6	:	:	:
cord-003403-ypefqm71	6	1	10.3390	10.3390	CD
cord-003403-ypefqm71	7	1	/vaccines6040070	/vaccines6040070	NFP
cord-003403-ypefqm71	7	2	sha	sha	NN
cord-003403-ypefqm71	7	3	:	:	:
cord-003403-ypefqm71	7	4	88b18a2771249ead085fdebfab0aea7839176e05	88b18a2771249ead085fdebfab0aea7839176e05	CD
cord-003403-ypefqm71	7	5	doc_id	doc_id	CD
cord-003403-ypefqm71	7	6	:	:	:
cord-003403-ypefqm71	7	7	3403	3403	CD
cord-003403-ypefqm71	7	8	cord_uid	cord_uid	NNS
cord-003403-ypefqm71	7	9	:	:	:
cord-003403-ypefqm71	7	10	ypefqm71	ypefqm71	NN
cord-003403-ypefqm71	8	1	From	from	IN
cord-003403-ypefqm71	8	2	the	the	DT
cord-003403-ypefqm71	8	3	perspective	perspective	NN
cord-003403-ypefqm71	8	4	of	of	IN
cord-003403-ypefqm71	8	5	vaccine	vaccine	NN
cord-003403-ypefqm71	8	6	development	development	NN
cord-003403-ypefqm71	8	7	,	,	,
cord-003403-ypefqm71	8	8	it	-PRON-	PRP
cord-003403-ypefqm71	8	9	is	be	VBZ
cord-003403-ypefqm71	8	10	imperative	imperative	JJ
cord-003403-ypefqm71	8	11	to	to	TO
cord-003403-ypefqm71	8	12	accurately	accurately	RB
cord-003403-ypefqm71	8	13	diagnose	diagnose	VB
cord-003403-ypefqm71	8	14	target	target	NN
cord-003403-ypefqm71	8	15	infections	infection	NNS
cord-003403-ypefqm71	8	16	in	in	IN
cord-003403-ypefqm71	8	17	order	order	NN
cord-003403-ypefqm71	8	18	to	to	TO
cord-003403-ypefqm71	8	19	exclude	exclude	VB
cord-003403-ypefqm71	8	20	subjects	subject	NNS
cord-003403-ypefqm71	8	21	with	with	IN
cord-003403-ypefqm71	8	22	prior	prior	JJ
cord-003403-ypefqm71	8	23	exposure	exposure	NN
cord-003403-ypefqm71	8	24	from	from	IN
cord-003403-ypefqm71	8	25	evaluations	evaluation	NNS
cord-003403-ypefqm71	8	26	of	of	IN
cord-003403-ypefqm71	8	27	vaccine	vaccine	NN
cord-003403-ypefqm71	8	28	effectiveness	effectiveness	NN
cord-003403-ypefqm71	8	29	,	,	,
cord-003403-ypefqm71	8	30	to	to	TO
cord-003403-ypefqm71	8	31	track	track	VB
cord-003403-ypefqm71	8	32	incident	incident	NN
cord-003403-ypefqm71	8	33	infection	infection	NN
cord-003403-ypefqm71	8	34	during	during	IN
cord-003403-ypefqm71	8	35	the	the	DT
cord-003403-ypefqm71	8	36	course	course	NN
cord-003403-ypefqm71	8	37	of	of	IN
cord-003403-ypefqm71	8	38	a	a	DT
cord-003403-ypefqm71	8	39	clinical	clinical	JJ
cord-003403-ypefqm71	8	40	trial	trial	NN
cord-003403-ypefqm71	8	41	and	and	CC
cord-003403-ypefqm71	8	42	to	to	TO
cord-003403-ypefqm71	8	43	differentiate	differentiate	VB
cord-003403-ypefqm71	8	44	immune	immune	JJ
cord-003403-ypefqm71	8	45	reactions	reaction	NNS
cord-003403-ypefqm71	8	46	due	due	IN
cord-003403-ypefqm71	8	47	to	to	IN
cord-003403-ypefqm71	8	48	natural	natural	JJ
cord-003403-ypefqm71	8	49	infections	infection	NNS
cord-003403-ypefqm71	8	50	from	from	IN
cord-003403-ypefqm71	8	51	responses	response	NNS
cord-003403-ypefqm71	8	52	that	that	WDT
cord-003403-ypefqm71	8	53	are	be	VBP
cord-003403-ypefqm71	8	54	vaccine	vaccine	NN
cord-003403-ypefqm71	8	55	related	relate	VBN
cord-003403-ypefqm71	8	56	.	.	.
cord-003403-ypefqm71	9	1	When	when	WRB
cord-003403-ypefqm71	9	2	vaccine	vaccine	NN
cord-003403-ypefqm71	9	3	development	development	NN
cord-003403-ypefqm71	9	4	is	be	VBZ
cord-003403-ypefqm71	9	5	accelerated	accelerate	VBN
cord-003403-ypefqm71	9	6	to	to	IN
cord-003403-ypefqm71	9	7	a	a	DT
cord-003403-ypefqm71	9	8	rapid	rapid	JJ
cord-003403-ypefqm71	9	9	pace	pace	NN
cord-003403-ypefqm71	9	10	in	in	IN
cord-003403-ypefqm71	9	11	response	response	NN
cord-003403-ypefqm71	9	12	to	to	IN
cord-003403-ypefqm71	9	13	emerging	emerge	VBG
cord-003403-ypefqm71	9	14	infectious	infectious	JJ
cord-003403-ypefqm71	9	15	disease	disease	NN
cord-003403-ypefqm71	9	16	threats	threat	NNS
cord-003403-ypefqm71	9	17	,	,	,
cord-003403-ypefqm71	9	18	the	the	DT
cord-003403-ypefqm71	9	19	challenges	challenge	NNS
cord-003403-ypefqm71	9	20	to	to	TO
cord-003403-ypefqm71	9	21	develop	develop	VB
cord-003403-ypefqm71	9	22	such	such	JJ
cord-003403-ypefqm71	9	23	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	9	24	tools	tool	NNS
cord-003403-ypefqm71	9	25	is	be	VBZ
cord-003403-ypefqm71	9	26	even	even	RB
cord-003403-ypefqm71	9	27	greater	great	JJR
cord-003403-ypefqm71	9	28	.	.	.
cord-003403-ypefqm71	10	1	This	this	DT
cord-003403-ypefqm71	10	2	was	be	VBD
cord-003403-ypefqm71	10	3	observed	observe	VBN
cord-003403-ypefqm71	10	4	through	through	IN
cord-003403-ypefqm71	10	5	the	the	DT
cord-003403-ypefqm71	10	6	recent	recent	JJ
cord-003403-ypefqm71	10	7	expansion	expansion	NN
cord-003403-ypefqm71	10	8	of	of	IN
cord-003403-ypefqm71	10	9	Zika	Zika	NNP
cord-003403-ypefqm71	10	10	virus	virus	NN
cord-003403-ypefqm71	10	11	infections	infection	NNS
cord-003403-ypefqm71	10	12	into	into	IN
cord-003403-ypefqm71	10	13	the	the	DT
cord-003403-ypefqm71	10	14	Western	Western	NNP
cord-003403-ypefqm71	10	15	Hemisphere	Hemisphere	NNP
cord-003403-ypefqm71	10	16	in	in	IN
cord-003403-ypefqm71	10	17	2014–2017	2014–2017	CD
cord-003403-ypefqm71	10	18	.	.	.
cord-003403-ypefqm71	11	1	When	when	WRB
cord-003403-ypefqm71	11	2	initial	initial	JJ
cord-003403-ypefqm71	11	3	Zika	Zika	NNP
cord-003403-ypefqm71	11	4	vaccine	vaccine	NN
cord-003403-ypefqm71	11	5	clinical	clinical	JJ
cord-003403-ypefqm71	11	6	trials	trial	NNS
cord-003403-ypefqm71	11	7	were	be	VBD
cord-003403-ypefqm71	11	8	being	be	VBG
cord-003403-ypefqm71	11	9	designed	design	VBN
cord-003403-ypefqm71	11	10	and	and	CC
cord-003403-ypefqm71	11	11	launched	launch	VBN
cord-003403-ypefqm71	11	12	in	in	IN
cord-003403-ypefqm71	11	13	response	response	NN
cord-003403-ypefqm71	11	14	to	to	IN
cord-003403-ypefqm71	11	15	the	the	DT
cord-003403-ypefqm71	11	16	outbreak	outbreak	NN
cord-003403-ypefqm71	11	17	,	,	,
cord-003403-ypefqm71	11	18	there	there	EX
cord-003403-ypefqm71	11	19	were	be	VBD
cord-003403-ypefqm71	11	20	no	no	DT
cord-003403-ypefqm71	11	21	standardized	standardized	JJ
cord-003403-ypefqm71	11	22	sets	set	NNS
cord-003403-ypefqm71	11	23	of	of	IN
cord-003403-ypefqm71	11	24	viral	viral	JJ
cord-003403-ypefqm71	11	25	and	and	CC
cord-003403-ypefqm71	11	26	immunological	immunological	JJ
cord-003403-ypefqm71	11	27	assays	assay	NNS
cord-003403-ypefqm71	11	28	,	,	,
cord-003403-ypefqm71	11	29	and	and	CC
cord-003403-ypefqm71	11	30	no	no	DT
cord-003403-ypefqm71	11	31	approved	approve	VBN
cord-003403-ypefqm71	11	32	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	11	33	tests	test	NNS
cord-003403-ypefqm71	11	34	for	for	IN
cord-003403-ypefqm71	11	35	Zika	Zika	NNP
cord-003403-ypefqm71	11	36	virus	virus	NN
cord-003403-ypefqm71	11	37	infection	infection	NN
cord-003403-ypefqm71	11	38	.	.	.
cord-003403-ypefqm71	12	1	The	the	DT
cord-003403-ypefqm71	12	2	diagnosis	diagnosis	NN
cord-003403-ypefqm71	12	3	of	of	IN
cord-003403-ypefqm71	12	4	Zika	Zika	NNP
cord-003403-ypefqm71	12	5	virus	virus	NN
cord-003403-ypefqm71	12	6	infection	infection	NN
cord-003403-ypefqm71	12	7	is	be	VBZ
cord-003403-ypefqm71	12	8	still	still	RB
cord-003403-ypefqm71	12	9	an	an	DT
cord-003403-ypefqm71	12	10	area	area	NN
cord-003403-ypefqm71	12	11	of	of	IN
cord-003403-ypefqm71	12	12	active	active	JJ
cord-003403-ypefqm71	12	13	research	research	NN
cord-003403-ypefqm71	12	14	and	and	CC
cord-003403-ypefqm71	12	15	development	development	NN
cord-003403-ypefqm71	12	16	on	on	IN
cord-003403-ypefqm71	12	17	many	many	JJ
cord-003403-ypefqm71	12	18	fronts	front	NNS
cord-003403-ypefqm71	12	19	.	.	.
cord-003403-ypefqm71	13	1	Here	here	RB
cord-003403-ypefqm71	13	2	we	-PRON-	PRP
cord-003403-ypefqm71	13	3	review	review	VBP
cord-003403-ypefqm71	13	4	emerging	emerge	VBG
cord-003403-ypefqm71	13	5	infectious	infectious	JJ
cord-003403-ypefqm71	13	6	disease	disease	NN
cord-003403-ypefqm71	13	7	vaccine	vaccine	NN
cord-003403-ypefqm71	13	8	clinical	clinical	JJ
cord-003403-ypefqm71	13	9	assay	assay	NN
cord-003403-ypefqm71	13	10	development	development	NN
cord-003403-ypefqm71	13	11	and	and	CC
cord-003403-ypefqm71	13	12	trial	trial	NN
cord-003403-ypefqm71	13	13	execution	execution	NN
cord-003403-ypefqm71	13	14	with	with	IN
cord-003403-ypefqm71	13	15	a	a	DT
cord-003403-ypefqm71	13	16	special	special	JJ
cord-003403-ypefqm71	13	17	focus	focus	NN
cord-003403-ypefqm71	13	18	on	on	IN
cord-003403-ypefqm71	13	19	the	the	DT
cord-003403-ypefqm71	13	20	state	state	NN
cord-003403-ypefqm71	13	21	of	of	IN
cord-003403-ypefqm71	13	22	Zika	Zika	NNP
cord-003403-ypefqm71	13	23	virus	virus	NN
cord-003403-ypefqm71	13	24	clinical	clinical	JJ
cord-003403-ypefqm71	13	25	assays	assay	NNS
cord-003403-ypefqm71	13	26	and	and	CC
cord-003403-ypefqm71	13	27	diagnostics	diagnostic	NNS
cord-003403-ypefqm71	13	28	.	.	.
cord-003403-ypefqm71	14	1	The	the	DT
cord-003403-ypefqm71	14	2	declaration	declaration	NN
cord-003403-ypefqm71	14	3	by	by	IN
cord-003403-ypefqm71	14	4	the	the	DT
cord-003403-ypefqm71	14	5	World	World	NNP
cord-003403-ypefqm71	14	6	Health	Health	NNP
cord-003403-ypefqm71	14	7	Organization	Organization	NNP
cord-003403-ypefqm71	14	8	(	(	-LRB-
cord-003403-ypefqm71	14	9	WHO	who	WP
cord-003403-ypefqm71	14	10	)	)	-RRB-
cord-003403-ypefqm71	14	11	that	that	IN
cord-003403-ypefqm71	14	12	Zika	Zika	NNP
cord-003403-ypefqm71	14	13	is	be	VBZ
cord-003403-ypefqm71	14	14	a	a	DT
cord-003403-ypefqm71	14	15	public	public	JJ
cord-003403-ypefqm71	14	16	health	health	NN
cord-003403-ypefqm71	14	17	emergency	emergency	NN
cord-003403-ypefqm71	14	18	of	of	IN
cord-003403-ypefqm71	14	19	international	international	JJ
cord-003403-ypefqm71	14	20	concern	concern	NN
cord-003403-ypefqm71	14	21	in	in	IN
cord-003403-ypefqm71	14	22	February	February	NNP
cord-003403-ypefqm71	14	23	2016	2016	CD
cord-003403-ypefqm71	14	24	led	lead	VBD
cord-003403-ypefqm71	14	25	to	to	IN
cord-003403-ypefqm71	14	26	a	a	DT
cord-003403-ypefqm71	14	27	global	global	JJ
cord-003403-ypefqm71	14	28	effort	effort	NN
cord-003403-ypefqm71	14	29	to	to	TO
cord-003403-ypefqm71	14	30	support	support	VB
cord-003403-ypefqm71	14	31	vaccine	vaccine	NN
cord-003403-ypefqm71	14	32	development	development	NN
cord-003403-ypefqm71	14	33	and	and	CC
cord-003403-ypefqm71	14	34	control	control	VB
cord-003403-ypefqm71	14	35	the	the	DT
cord-003403-ypefqm71	14	36	spread	spread	NN
cord-003403-ypefqm71	14	37	of	of	IN
cord-003403-ypefqm71	14	38	Zika	Zika	NNP
cord-003403-ypefqm71	14	39	virus	virus	NN
cord-003403-ypefqm71	14	40	(	(	-LRB-
cord-003403-ypefqm71	14	41	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	14	42	)	)	-RRB-
cord-003403-ypefqm71	14	43	.	.	.
cord-003403-ypefqm71	15	1	Our	-PRON-	PRP$
cord-003403-ypefqm71	15	2	collaborative	collaborative	JJ
cord-003403-ypefqm71	15	3	DNA	dna	NN
cord-003403-ypefqm71	15	4	vaccine	vaccine	NN
cord-003403-ypefqm71	15	5	consortium	consortium	NN
cord-003403-ypefqm71	15	6	focused	focus	VBD
cord-003403-ypefqm71	15	7	and	and	CC
cord-003403-ypefqm71	15	8	accelerated	accelerated	JJ
cord-003403-ypefqm71	15	9	pre	pre	JJ
cord-003403-ypefqm71	15	10	-	-	JJ
cord-003403-ypefqm71	15	11	clinical	clinical	JJ
cord-003403-ypefqm71	15	12	,	,	,
cord-003403-ypefqm71	15	13	manufacturing	manufacturing	NN
cord-003403-ypefqm71	15	14	and	and	CC
cord-003403-ypefqm71	15	15	early	early	JJ
cord-003403-ypefqm71	15	16	clinical	clinical	JJ
cord-003403-ypefqm71	15	17	development	development	NN
cord-003403-ypefqm71	15	18	efforts	effort	NNS
cord-003403-ypefqm71	15	19	to	to	TO
cord-003403-ypefqm71	15	20	bring	bring	VB
cord-003403-ypefqm71	15	21	forward	forward	RB
cord-003403-ypefqm71	15	22	the	the	DT
cord-003403-ypefqm71	15	23	first	first	JJ
cord-003403-ypefqm71	15	24	Zika	Zika	NNP
cord-003403-ypefqm71	15	25	vaccine	vaccine	NN
cord-003403-ypefqm71	15	26	,	,	,
cord-003403-ypefqm71	15	27	GLS-5700	GLS-5700	NNP
cord-003403-ypefqm71	15	28	,	,	,
cord-003403-ypefqm71	15	29	into	into	IN
cord-003403-ypefqm71	15	30	human	human	JJ
cord-003403-ypefqm71	15	31	clinical	clinical	JJ
cord-003403-ypefqm71	15	32	trials	trial	NNS
cord-003403-ypefqm71	15	33	[	[	-LRB-
cord-003403-ypefqm71	15	34	1	1	CD
cord-003403-ypefqm71	15	35	]	]	-RRB-
cord-003403-ypefqm71	16	1	[	[	-LRB-
cord-003403-ypefqm71	16	2	2	2	LS
cord-003403-ypefqm71	16	3	]	]	-RRB-
cord-003403-ypefqm71	16	4	[	[	-LRB-
cord-003403-ypefqm71	16	5	3	3	CD
cord-003403-ypefqm71	16	6	]	]	-RRB-
cord-003403-ypefqm71	16	7	.	.	.
cord-003403-ypefqm71	17	1	At	at	IN
cord-003403-ypefqm71	17	2	the	the	DT
cord-003403-ypefqm71	17	3	outset	outset	NN
cord-003403-ypefqm71	17	4	,	,	,
cord-003403-ypefqm71	17	5	it	-PRON-	PRP
cord-003403-ypefqm71	17	6	was	be	VBD
cord-003403-ypefqm71	17	7	clear	clear	JJ
cord-003403-ypefqm71	17	8	that	that	IN
cord-003403-ypefqm71	17	9	gaps	gap	NNS
cord-003403-ypefqm71	17	10	would	would	MD
cord-003403-ypefqm71	17	11	need	need	VB
cord-003403-ypefqm71	17	12	to	to	TO
cord-003403-ypefqm71	17	13	be	be	VB
cord-003403-ypefqm71	17	14	filled	fill	VBN
cord-003403-ypefqm71	17	15	as	as	IN
cord-003403-ypefqm71	17	16	the	the	DT
cord-003403-ypefqm71	17	17	public	public	JJ
cord-003403-ypefqm71	17	18	health	health	NN
cord-003403-ypefqm71	17	19	and	and	CC
cord-003403-ypefqm71	17	20	science	science	NN
cord-003403-ypefqm71	17	21	communities	community	NNS
cord-003403-ypefqm71	17	22	learned	learn	VBD
cord-003403-ypefqm71	17	23	and	and	CC
cord-003403-ypefqm71	17	24	shared	share	VBD
cord-003403-ypefqm71	17	25	new	new	JJ
cord-003403-ypefqm71	17	26	information	information	NN
cord-003403-ypefqm71	17	27	on	on	IN
cord-003403-ypefqm71	17	28	Zika	Zika	NNP
cord-003403-ypefqm71	17	29	.	.	.
cord-003403-ypefqm71	18	1	One	one	CD
cord-003403-ypefqm71	18	2	of	of	IN
cord-003403-ypefqm71	18	3	the	the	DT
cord-003403-ypefqm71	18	4	clear	clear	JJ
cord-003403-ypefqm71	18	5	gaps	gap	NNS
cord-003403-ypefqm71	18	6	affecting	affect	VBG
cord-003403-ypefqm71	18	7	both	both	DT
cord-003403-ypefqm71	18	8	public	public	JJ
cord-003403-ypefqm71	18	9	health	health	NN
cord-003403-ypefqm71	18	10	efforts	effort	NNS
cord-003403-ypefqm71	18	11	and	and	CC
cord-003403-ypefqm71	18	12	vaccine	vaccine	NN
cord-003403-ypefqm71	18	13	development	development	NN
cord-003403-ypefqm71	18	14	programs	program	NNS
cord-003403-ypefqm71	18	15	was	be	VBD
cord-003403-ypefqm71	18	16	a	a	DT
cord-003403-ypefqm71	18	17	lack	lack	NN
cord-003403-ypefqm71	18	18	of	of	IN
cord-003403-ypefqm71	18	19	standardized	standardized	JJ
cord-003403-ypefqm71	18	20	reagents	reagent	NNS
cord-003403-ypefqm71	18	21	and	and	CC
cord-003403-ypefqm71	18	22	methods	method	NNS
cord-003403-ypefqm71	18	23	to	to	TO
cord-003403-ypefqm71	18	24	test	test	VB
cord-003403-ypefqm71	18	25	for	for	IN
cord-003403-ypefqm71	18	26	evidence	evidence	NN
cord-003403-ypefqm71	18	27	of	of	IN
cord-003403-ypefqm71	18	28	current	current	JJ
cord-003403-ypefqm71	18	29	or	or	CC
cord-003403-ypefqm71	18	30	prior	prior	JJ
cord-003403-ypefqm71	18	31	Zika	Zika	NNP
cord-003403-ypefqm71	18	32	infection	infection	NN
cord-003403-ypefqm71	18	33	.	.	.
cord-003403-ypefqm71	19	1	The	the	DT
cord-003403-ypefqm71	19	2	need	need	NN
cord-003403-ypefqm71	19	3	for	for	IN
cord-003403-ypefqm71	19	4	fast	fast	JJ
cord-003403-ypefqm71	19	5	and	and	CC
cord-003403-ypefqm71	19	6	accurate	accurate	JJ
cord-003403-ypefqm71	19	7	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	19	8	tests	test	NNS
cord-003403-ypefqm71	19	9	of	of	IN
cord-003403-ypefqm71	19	10	infection	infection	NN
cord-003403-ypefqm71	19	11	in	in	IN
cord-003403-ypefqm71	19	12	an	an	DT
cord-003403-ypefqm71	19	13	outbreak	outbreak	NN
cord-003403-ypefqm71	19	14	situation	situation	NN
cord-003403-ypefqm71	19	15	is	be	VBZ
cord-003403-ypefqm71	19	16	obvious	obvious	JJ
cord-003403-ypefqm71	19	17	:	:	:
cord-003403-ypefqm71	19	18	identify	identify	VB
cord-003403-ypefqm71	19	19	the	the	DT
cord-003403-ypefqm71	19	20	source	source	NN
cord-003403-ypefqm71	19	21	or	or	CC
cord-003403-ypefqm71	19	22	epicenter	epicenter	NN
cord-003403-ypefqm71	19	23	so	so	IN
cord-003403-ypefqm71	19	24	that	that	IN
cord-003403-ypefqm71	19	25	appropriate	appropriate	JJ
cord-003403-ypefqm71	19	26	healthcare	healthcare	NN
cord-003403-ypefqm71	19	27	measures	measure	NNS
cord-003403-ypefqm71	19	28	can	can	MD
cord-003403-ypefqm71	19	29	be	be	VB
cord-003403-ypefqm71	19	30	quickly	quickly	RB
cord-003403-ypefqm71	19	31	instituted	institute	VBN
cord-003403-ypefqm71	19	32	.	.	.
cord-003403-ypefqm71	20	1	Expanding	expand	VBG
cord-003403-ypefqm71	20	2	that	that	DT
cord-003403-ypefqm71	20	3	concept	concept	NN
cord-003403-ypefqm71	20	4	to	to	IN
cord-003403-ypefqm71	20	5	the	the	DT
cord-003403-ypefqm71	20	6	public	public	JJ
cord-003403-ypefqm71	20	7	health	health	NN
cord-003403-ypefqm71	20	8	scale	scale	NN
cord-003403-ypefqm71	20	9	and	and	CC
cord-003403-ypefqm71	20	10	attaining	attain	VBG
cord-003403-ypefqm71	20	11	accurate	accurate	JJ
cord-003403-ypefqm71	20	12	infectious	infectious	JJ
cord-003403-ypefqm71	20	13	disease	disease	NN
cord-003403-ypefqm71	20	14	diagnoses	diagnosis	NNS
cord-003403-ypefqm71	20	15	allows	allow	VBZ
cord-003403-ypefqm71	20	16	for	for	IN
cord-003403-ypefqm71	20	17	better	well	JJR
cord-003403-ypefqm71	20	18	understanding	understanding	NN
cord-003403-ypefqm71	20	19	of	of	IN
cord-003403-ypefqm71	20	20	the	the	DT
cord-003403-ypefqm71	20	21	course	course	NN
cord-003403-ypefqm71	20	22	and	and	CC
cord-003403-ypefqm71	20	23	severity	severity	NN
cord-003403-ypefqm71	20	24	of	of	IN
cord-003403-ypefqm71	20	25	an	an	DT
cord-003403-ypefqm71	20	26	outbreak	outbreak	NN
cord-003403-ypefqm71	20	27	and	and	CC
cord-003403-ypefqm71	20	28	aids	aids	NNP
cord-003403-ypefqm71	20	29	decision	decision	NN
cord-003403-ypefqm71	20	30	-	-	HYPH
cord-003403-ypefqm71	20	31	making	making	NN
cord-003403-ypefqm71	20	32	for	for	IN
cord-003403-ypefqm71	20	33	population	population	NN
cord-003403-ypefqm71	20	34	-	-	HYPH
cord-003403-ypefqm71	20	35	level	level	NN
cord-003403-ypefqm71	20	36	countermeasure	countermeasure	NN
cord-003403-ypefqm71	20	37	implementation	implementation	NN
cord-003403-ypefqm71	20	38	.	.	.
cord-003403-ypefqm71	21	1	The	the	DT
cord-003403-ypefqm71	21	2	clinical	clinical	JJ
cord-003403-ypefqm71	21	3	assays	assay	NNS
cord-003403-ypefqm71	21	4	with	with	IN
cord-003403-ypefqm71	21	5	which	which	WDT
cord-003403-ypefqm71	21	6	the	the	DT
cord-003403-ypefqm71	21	7	immune	immune	JJ
cord-003403-ypefqm71	21	8	response	response	NN
cord-003403-ypefqm71	21	9	and	and	CC
cord-003403-ypefqm71	21	10	pathogen	pathogen	NN
cord-003403-ypefqm71	21	11	presence	presence	NN
cord-003403-ypefqm71	21	12	are	be	VBP
cord-003403-ypefqm71	21	13	measured	measure	VBN
cord-003403-ypefqm71	21	14	in	in	IN
cord-003403-ypefqm71	21	15	vaccine	vaccine	NN
cord-003403-ypefqm71	21	16	trials	trial	NNS
cord-003403-ypefqm71	21	17	become	become	VBP
cord-003403-ypefqm71	21	18	part	part	NN
cord-003403-ypefqm71	21	19	of	of	IN
cord-003403-ypefqm71	21	20	the	the	DT
cord-003403-ypefqm71	21	21	basis	basis	NN
cord-003403-ypefqm71	21	22	for	for	IN
cord-003403-ypefqm71	21	23	licensure	licensure	NN
cord-003403-ypefqm71	21	24	for	for	IN
cord-003403-ypefqm71	21	25	all	all	DT
cord-003403-ypefqm71	21	26	vaccine	vaccine	NN
cord-003403-ypefqm71	21	27	products	product	NNS
cord-003403-ypefqm71	21	28	[	[	-LRB-
cord-003403-ypefqm71	21	29	4	4	CD
cord-003403-ypefqm71	21	30	]	]	-RRB-
cord-003403-ypefqm71	21	31	.	.	.
cord-003403-ypefqm71	22	1	Because	because	IN
cord-003403-ypefqm71	22	2	vaccines	vaccine	NNS
cord-003403-ypefqm71	22	3	are	be	VBP
cord-003403-ypefqm71	22	4	tested	test	VBN
cord-003403-ypefqm71	22	5	in	in	IN
cord-003403-ypefqm71	22	6	healthy	healthy	JJ
cord-003403-ypefqm71	22	7	populations	population	NNS
cord-003403-ypefqm71	22	8	through	through	IN
cord-003403-ypefqm71	22	9	all	all	DT
cord-003403-ypefqm71	22	10	phases	phase	NNS
cord-003403-ypefqm71	22	11	of	of	IN
cord-003403-ypefqm71	22	12	clinical	clinical	JJ
cord-003403-ypefqm71	22	13	development	development	NN
cord-003403-ypefqm71	22	14	for	for	IN
cord-003403-ypefqm71	22	15	immune	immune	JJ
cord-003403-ypefqm71	22	16	response	response	NN
cord-003403-ypefqm71	22	17	and/or	and/or	CC
cord-003403-ypefqm71	22	18	pathogen	pathogen	NN
cord-003403-ypefqm71	22	19	presence	presence	NN
cord-003403-ypefqm71	22	20	whereas	whereas	IN
cord-003403-ypefqm71	22	21	drugs	drug	NNS
cord-003403-ypefqm71	22	22	/	/	SYM
cord-003403-ypefqm71	22	23	biologics	biologic	NNS
cord-003403-ypefqm71	22	24	(	(	-LRB-
cord-003403-ypefqm71	22	25	post	post	JJ
cord-003403-ypefqm71	22	26	-	-	NN
cord-003403-ypefqm71	22	27	Phase	phase	NN
cord-003403-ypefqm71	22	28	I	i	NN
cord-003403-ypefqm71	22	29	)	)	-RRB-
cord-003403-ypefqm71	22	30	are	be	VBP
cord-003403-ypefqm71	22	31	most	most	RBS
cord-003403-ypefqm71	22	32	often	often	RB
cord-003403-ypefqm71	22	33	tested	test	VBN
cord-003403-ypefqm71	22	34	in	in	IN
cord-003403-ypefqm71	22	35	a	a	DT
cord-003403-ypefqm71	22	36	population	population	NN
cord-003403-ypefqm71	22	37	with	with	IN
cord-003403-ypefqm71	22	38	specific	specific	JJ
cord-003403-ypefqm71	22	39	disease	disease	NN
cord-003403-ypefqm71	22	40	to	to	TO
cord-003403-ypefqm71	22	41	demonstrate	demonstrate	VB
cord-003403-ypefqm71	22	42	improvement	improvement	NN
cord-003403-ypefqm71	22	43	,	,	,
cord-003403-ypefqm71	22	44	the	the	DT
cord-003403-ypefqm71	22	45	selected	select	VBN
cord-003403-ypefqm71	22	46	methods	method	NNS
cord-003403-ypefqm71	22	47	to	to	TO
cord-003403-ypefqm71	22	48	measure	measure	VB
cord-003403-ypefqm71	22	49	vaccine	vaccine	NN
cord-003403-ypefqm71	22	50	responses	response	NNS
cord-003403-ypefqm71	22	51	and	and	CC
cord-003403-ypefqm71	22	52	endpoints	endpoint	NNS
cord-003403-ypefqm71	22	53	are	be	VBP
cord-003403-ypefqm71	22	54	of	of	IN
cord-003403-ypefqm71	22	55	the	the	DT
cord-003403-ypefqm71	22	56	utmost	utmost	JJ
cord-003403-ypefqm71	22	57	importance	importance	NN
cord-003403-ypefqm71	22	58	.	.	.
cord-003403-ypefqm71	23	1	The	the	DT
cord-003403-ypefqm71	23	2	identification	identification	NN
cord-003403-ypefqm71	23	3	of	of	IN
cord-003403-ypefqm71	23	4	an	an	DT
cord-003403-ypefqm71	23	5	immune	immune	JJ
cord-003403-ypefqm71	23	6	correlate	correlate	NN
cord-003403-ypefqm71	23	7	of	of	IN
cord-003403-ypefqm71	23	8	protection	protection	NN
cord-003403-ypefqm71	23	9	for	for	IN
cord-003403-ypefqm71	23	10	each	each	DT
cord-003403-ypefqm71	23	11	vaccine	vaccine	NN
cord-003403-ypefqm71	23	12	is	be	VBZ
cord-003403-ypefqm71	23	13	highly	highly	RB
cord-003403-ypefqm71	23	14	desirable	desirable	JJ
cord-003403-ypefqm71	23	15	,	,	,
cord-003403-ypefqm71	23	16	though	though	IN
cord-003403-ypefqm71	23	17	not	not	RB
cord-003403-ypefqm71	23	18	always	always	RB
cord-003403-ypefqm71	23	19	attainable	attainable	JJ
cord-003403-ypefqm71	23	20	[	[	-LRB-
cord-003403-ypefqm71	23	21	5	5	CD
cord-003403-ypefqm71	23	22	]	]	-RRB-
cord-003403-ypefqm71	23	23	.	.	.
cord-003403-ypefqm71	24	1	Here	here	RB
cord-003403-ypefqm71	24	2	we	-PRON-	PRP
cord-003403-ypefqm71	24	3	will	will	MD
cord-003403-ypefqm71	24	4	use	use	VB
cord-003403-ypefqm71	24	5	the	the	DT
cord-003403-ypefqm71	24	6	recent	recent	JJ
cord-003403-ypefqm71	24	7	experience	experience	NN
cord-003403-ypefqm71	24	8	with	with	IN
cord-003403-ypefqm71	24	9	the	the	DT
cord-003403-ypefqm71	24	10	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	24	11	outbreak	outbreak	NN
cord-003403-ypefqm71	24	12	and	and	CC
cord-003403-ypefqm71	24	13	ensuing	ensue	VBG
cord-003403-ypefqm71	24	14	public	public	JJ
cord-003403-ypefqm71	24	15	health	health	NN
cord-003403-ypefqm71	24	16	countermeasures	countermeasure	NNS
cord-003403-ypefqm71	24	17	for	for	IN
cord-003403-ypefqm71	24	18	containment	containment	NN
cord-003403-ypefqm71	24	19	and	and	CC
cord-003403-ypefqm71	24	20	vaccine	vaccine	NN
cord-003403-ypefqm71	24	21	development	development	NN
cord-003403-ypefqm71	24	22	as	as	IN
cord-003403-ypefqm71	24	23	an	an	DT
cord-003403-ypefqm71	24	24	example	example	NN
cord-003403-ypefqm71	24	25	of	of	IN
cord-003403-ypefqm71	24	26	challenges	challenge	NNS
cord-003403-ypefqm71	24	27	faced	face	VBN
cord-003403-ypefqm71	24	28	during	during	IN
cord-003403-ypefqm71	24	29	emerging	emerge	VBG
cord-003403-ypefqm71	24	30	infectious	infectious	JJ
cord-003403-ypefqm71	24	31	disease	disease	NN
cord-003403-ypefqm71	24	32	emergencies	emergency	NNS
cord-003403-ypefqm71	24	33	.	.	.
cord-003403-ypefqm71	25	1	Zika	Zika	NNP
cord-003403-ypefqm71	25	2	virus	virus	NN
cord-003403-ypefqm71	25	3	was	be	VBD
cord-003403-ypefqm71	25	4	discovered	discover	VBN
cord-003403-ypefqm71	25	5	in	in	IN
cord-003403-ypefqm71	25	6	1947	1947	CD
cord-003403-ypefqm71	25	7	during	during	IN
cord-003403-ypefqm71	25	8	a	a	DT
cord-003403-ypefqm71	25	9	survey	survey	NN
cord-003403-ypefqm71	25	10	to	to	TO
cord-003403-ypefqm71	25	11	map	map	VB
cord-003403-ypefqm71	25	12	the	the	DT
cord-003403-ypefqm71	25	13	extent	extent	NN
cord-003403-ypefqm71	25	14	of	of	IN
cord-003403-ypefqm71	25	15	yellow	yellow	JJ
cord-003403-ypefqm71	25	16	fever	fever	NN
cord-003403-ypefqm71	25	17	in	in	IN
cord-003403-ypefqm71	25	18	the	the	DT
cord-003403-ypefqm71	25	19	Entebbe	Entebbe	NNP
cord-003403-ypefqm71	25	20	region	region	NN
cord-003403-ypefqm71	25	21	of	of	IN
cord-003403-ypefqm71	25	22	Uganda	Uganda	NNP
cord-003403-ypefqm71	25	23	.	.	.
cord-003403-ypefqm71	26	1	The	the	DT
cord-003403-ypefqm71	26	2	virus	virus	NN
cord-003403-ypefqm71	26	3	was	be	VBD
cord-003403-ypefqm71	26	4	cultured	culture	VBN
cord-003403-ypefqm71	26	5	from	from	IN
cord-003403-ypefqm71	26	6	the	the	DT
cord-003403-ypefqm71	26	7	serum	serum	NN
cord-003403-ypefqm71	26	8	of	of	IN
cord-003403-ypefqm71	26	9	a	a	DT
cord-003403-ypefqm71	26	10	sentinel	sentinel	JJ
cord-003403-ypefqm71	26	11	macaque	macaque	NN
cord-003403-ypefqm71	26	12	placed	place	VBN
cord-003403-ypefqm71	26	13	in	in	IN
cord-003403-ypefqm71	26	14	the	the	DT
cord-003403-ypefqm71	26	15	Zika	Zika	NNP
cord-003403-ypefqm71	26	16	forest	forest	NN
cord-003403-ypefqm71	26	17	that	that	WDT
cord-003403-ypefqm71	26	18	developed	develop	VBD
cord-003403-ypefqm71	26	19	fever	fever	NN
cord-003403-ypefqm71	26	20	but	but	CC
cord-003403-ypefqm71	26	21	was	be	VBD
cord-003403-ypefqm71	26	22	otherwise	otherwise	RB
cord-003403-ypefqm71	26	23	well	well	RB
cord-003403-ypefqm71	26	24	.	.	.
cord-003403-ypefqm71	27	1	Initially	initially	RB
cord-003403-ypefqm71	27	2	restricted	restrict	VBN
cord-003403-ypefqm71	27	3	to	to	IN
cord-003403-ypefqm71	27	4	equatorial	equatorial	JJ
cord-003403-ypefqm71	27	5	regions	region	NNS
cord-003403-ypefqm71	27	6	of	of	IN
cord-003403-ypefqm71	27	7	Africa	Africa	NNP
cord-003403-ypefqm71	27	8	and	and	CC
cord-003403-ypefqm71	27	9	Asia	Asia	NNP
cord-003403-ypefqm71	27	10	,	,	,
cord-003403-ypefqm71	27	11	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	27	12	started	start	VBD
cord-003403-ypefqm71	27	13	to	to	TO
cord-003403-ypefqm71	27	14	spread	spread	VB
cord-003403-ypefqm71	27	15	eastward	eastward	RB
cord-003403-ypefqm71	27	16	across	across	IN
cord-003403-ypefqm71	27	17	the	the	DT
cord-003403-ypefqm71	27	18	Pacific	Pacific	NNP
cord-003403-ypefqm71	27	19	Ocean	Ocean	NNP
cord-003403-ypefqm71	27	20	with	with	IN
cord-003403-ypefqm71	27	21	an	an	DT
cord-003403-ypefqm71	27	22	outbreak	outbreak	NN
cord-003403-ypefqm71	27	23	on	on	IN
cord-003403-ypefqm71	27	24	Yap	Yap	NNP
cord-003403-ypefqm71	27	25	Island	Island	NNP
cord-003403-ypefqm71	27	26	,	,	,
cord-003403-ypefqm71	27	27	Micronesia	Micronesia	NNP
cord-003403-ypefqm71	27	28	in	in	IN
cord-003403-ypefqm71	27	29	2007	2007	CD
cord-003403-ypefqm71	27	30	[	[	-LRB-
cord-003403-ypefqm71	27	31	6	6	CD
cord-003403-ypefqm71	27	32	]	]	-RRB-
cord-003403-ypefqm71	27	33	,	,	,
cord-003403-ypefqm71	27	34	in	in	IN
cord-003403-ypefqm71	27	35	French	French	NNP
cord-003403-ypefqm71	27	36	Polynesia	Polynesia	NNP
cord-003403-ypefqm71	27	37	in	in	IN
cord-003403-ypefqm71	27	38	2014	2014	CD
cord-003403-ypefqm71	27	39	[	[	-LRB-
cord-003403-ypefqm71	27	40	7	7	CD
cord-003403-ypefqm71	27	41	]	]	-RRB-
cord-003403-ypefqm71	27	42	,	,	,
cord-003403-ypefqm71	27	43	and	and	CC
cord-003403-ypefqm71	27	44	reaching	reach	VBG
cord-003403-ypefqm71	27	45	Brazil	Brazil	NNP
cord-003403-ypefqm71	27	46	in	in	IN
cord-003403-ypefqm71	27	47	late	late	JJ
cord-003403-ypefqm71	27	48	2014	2014	CD
cord-003403-ypefqm71	27	49	or	or	CC
cord-003403-ypefqm71	27	50	early	early	JJ
cord-003403-ypefqm71	27	51	2015	2015	CD
cord-003403-ypefqm71	27	52	[	[	-LRB-
cord-003403-ypefqm71	27	53	8	8	CD
cord-003403-ypefqm71	27	54	]	]	-RRB-
cord-003403-ypefqm71	27	55	.	.	.
cord-003403-ypefqm71	28	1	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	28	2	infection	infection	NN
cord-003403-ypefqm71	28	3	typically	typically	RB
cord-003403-ypefqm71	28	4	causes	cause	VBZ
cord-003403-ypefqm71	28	5	a	a	DT
cord-003403-ypefqm71	28	6	self	self	NN
cord-003403-ypefqm71	28	7	-	-	HYPH
cord-003403-ypefqm71	28	8	limited	limit	VBN
cord-003403-ypefqm71	28	9	illness	illness	NN
cord-003403-ypefqm71	28	10	that	that	WDT
cord-003403-ypefqm71	28	11	is	be	VBZ
cord-003403-ypefqm71	28	12	minimally	minimally	RB
cord-003403-ypefqm71	28	13	symptomatic	symptomatic	JJ
cord-003403-ypefqm71	28	14	for	for	IN
cord-003403-ypefqm71	28	15	most	most	JJS
cord-003403-ypefqm71	28	16	individuals	individual	NNS
cord-003403-ypefqm71	28	17	.	.	.
cord-003403-ypefqm71	29	1	Zika	Zika	NNP
cord-003403-ypefqm71	29	2	infection	infection	NN
cord-003403-ypefqm71	29	3	presents	present	VBZ
cord-003403-ypefqm71	29	4	similarly	similarly	RB
cord-003403-ypefqm71	29	5	to	to	IN
cord-003403-ypefqm71	29	6	dengue	dengue	NN
cord-003403-ypefqm71	29	7	or	or	CC
cord-003403-ypefqm71	29	8	chikungunya	chikungunya	NN
cord-003403-ypefqm71	29	9	with	with	IN
cord-003403-ypefqm71	29	10	fever	fever	NN
cord-003403-ypefqm71	29	11	in	in	IN
cord-003403-ypefqm71	29	12	most	most	JJS
cord-003403-ypefqm71	29	13	,	,	,
cord-003403-ypefqm71	29	14	rash	rash	JJ
cord-003403-ypefqm71	29	15	,	,	,
cord-003403-ypefqm71	29	16	malaise	malaise	NN
cord-003403-ypefqm71	29	17	,	,	,
cord-003403-ypefqm71	29	18	myalgia	myalgia	NN
cord-003403-ypefqm71	29	19	,	,	,
cord-003403-ypefqm71	29	20	conjunctivitis	conjunctivitis	NN
cord-003403-ypefqm71	29	21	and	and	CC
cord-003403-ypefqm71	29	22	retro	retro	JJ
cord-003403-ypefqm71	29	23	-	-	HYPH
cord-003403-ypefqm71	29	24	orbital	orbital	JJ
cord-003403-ypefqm71	29	25	pain	pain	NN
cord-003403-ypefqm71	29	26	but	but	CC
cord-003403-ypefqm71	29	27	may	may	MD
cord-003403-ypefqm71	29	28	present	present	VB
cord-003403-ypefqm71	29	29	with	with	IN
cord-003403-ypefqm71	29	30	few	few	JJ
cord-003403-ypefqm71	29	31	,	,	,
cord-003403-ypefqm71	29	32	if	if	IN
cord-003403-ypefqm71	29	33	any	any	DT
cord-003403-ypefqm71	29	34	,	,	,
cord-003403-ypefqm71	29	35	discernable	discernable	JJ
cord-003403-ypefqm71	29	36	symptoms	symptom	NNS
cord-003403-ypefqm71	29	37	[	[	-LRB-
cord-003403-ypefqm71	29	38	9	9	CD
cord-003403-ypefqm71	29	39	]	]	-RRB-
cord-003403-ypefqm71	29	40	.	.	.
cord-003403-ypefqm71	30	1	However	however	RB
cord-003403-ypefqm71	30	2	,	,	,
cord-003403-ypefqm71	30	3	documentation	documentation	NN
cord-003403-ypefqm71	30	4	in	in	IN
cord-003403-ypefqm71	30	5	Brazil	Brazil	NNP
cord-003403-ypefqm71	30	6	of	of	IN
cord-003403-ypefqm71	30	7	severe	severe	JJ
cord-003403-ypefqm71	30	8	neurologic	neurologic	JJ
cord-003403-ypefqm71	30	9	complications	complication	NNS
cord-003403-ypefqm71	30	10	associated	associate	VBN
cord-003403-ypefqm71	30	11	with	with	IN
cord-003403-ypefqm71	30	12	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	30	13	infection	infection	NN
cord-003403-ypefqm71	30	14	beginning	begin	VBG
cord-003403-ypefqm71	30	15	around	around	IN
cord-003403-ypefqm71	30	16	October	October	NNP
cord-003403-ypefqm71	30	17	2015	2015	CD
cord-003403-ypefqm71	30	18	raised	raise	VBD
cord-003403-ypefqm71	30	19	worldwide	worldwide	RB
cord-003403-ypefqm71	30	20	alert	alert	NN
cord-003403-ypefqm71	30	21	.	.	.
cord-003403-ypefqm71	31	1	The	the	DT
cord-003403-ypefqm71	31	2	most	most	RBS
cord-003403-ypefqm71	31	3	publicized	publicized	JJ
cord-003403-ypefqm71	31	4	and	and	CC
cord-003403-ypefqm71	31	5	dramatic	dramatic	JJ
cord-003403-ypefqm71	31	6	complications	complication	NNS
cord-003403-ypefqm71	31	7	are	be	VBP
cord-003403-ypefqm71	31	8	those	those	DT
cord-003403-ypefqm71	31	9	that	that	WDT
cord-003403-ypefqm71	31	10	occur	occur	VBP
cord-003403-ypefqm71	31	11	during	during	IN
cord-003403-ypefqm71	31	12	fetal	fetal	JJ
cord-003403-ypefqm71	31	13	development	development	NN
cord-003403-ypefqm71	31	14	.	.	.
cord-003403-ypefqm71	32	1	They	-PRON-	PRP
cord-003403-ypefqm71	32	2	include	include	VBP
cord-003403-ypefqm71	32	3	microcephaly	microcephaly	NNS
cord-003403-ypefqm71	32	4	,	,	,
cord-003403-ypefqm71	32	5	intra	intra	JJ
cord-003403-ypefqm71	32	6	-	-	JJ
cord-003403-ypefqm71	32	7	uterine	uterine	JJ
cord-003403-ypefqm71	32	8	growth	growth	NN
cord-003403-ypefqm71	32	9	retardation	retardation	NN
cord-003403-ypefqm71	32	10	,	,	,
cord-003403-ypefqm71	32	11	cerebral	cerebral	JJ
cord-003403-ypefqm71	32	12	calcifications	calcification	NNS
cord-003403-ypefqm71	32	13	,	,	,
cord-003403-ypefqm71	32	14	ocular	ocular	JJ
cord-003403-ypefqm71	32	15	calcifications	calcification	NNS
cord-003403-ypefqm71	32	16	and	and	CC
cord-003403-ypefqm71	32	17	other	other	JJ
cord-003403-ypefqm71	32	18	ocular	ocular	JJ
cord-003403-ypefqm71	32	19	abnormalities	abnormality	NNS
cord-003403-ypefqm71	32	20	-	-	:
cord-003403-ypefqm71	32	21	with	with	IN
cord-003403-ypefqm71	32	22	an	an	DT
cord-003403-ypefqm71	32	23	attack	attack	NN
cord-003403-ypefqm71	32	24	rate	rate	NN
cord-003403-ypefqm71	32	25	estimated	estimate	VBN
cord-003403-ypefqm71	32	26	at	at	IN
cord-003403-ypefqm71	32	27	1	1	CD
cord-003403-ypefqm71	32	28	-	-	SYM
cord-003403-ypefqm71	32	29	2	2	CD
cord-003403-ypefqm71	32	30	%	%	NN
cord-003403-ypefqm71	32	31	of	of	IN
cord-003403-ypefqm71	32	32	women	woman	NNS
cord-003403-ypefqm71	32	33	who	who	WP
cord-003403-ypefqm71	32	34	become	become	VBP
cord-003403-ypefqm71	32	35	infected	infect	VBN
cord-003403-ypefqm71	32	36	during	during	IN
cord-003403-ypefqm71	32	37	pregnancy	pregnancy	NN
cord-003403-ypefqm71	32	38	[	[	-LRB-
cord-003403-ypefqm71	32	39	10	10	CD
cord-003403-ypefqm71	32	40	]	]	-RRB-
cord-003403-ypefqm71	32	41	.	.	.
cord-003403-ypefqm71	33	1	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	33	2	can	can	MD
cord-003403-ypefqm71	33	3	also	also	RB
cord-003403-ypefqm71	33	4	directly	directly	RB
cord-003403-ypefqm71	33	5	infect	infect	VB
cord-003403-ypefqm71	33	6	the	the	DT
cord-003403-ypefqm71	33	7	placenta	placenta	NN
cord-003403-ypefqm71	33	8	and	and	CC
cord-003403-ypefqm71	33	9	can	can	MD
cord-003403-ypefqm71	33	10	result	result	VB
cord-003403-ypefqm71	33	11	in	in	IN
cord-003403-ypefqm71	33	12	spontaneous	spontaneous	JJ
cord-003403-ypefqm71	33	13	miscarriage	miscarriage	NN
cord-003403-ypefqm71	33	14	with	with	IN
cord-003403-ypefqm71	33	15	an	an	DT
cord-003403-ypefqm71	33	16	unknown	unknown	JJ
cord-003403-ypefqm71	33	17	prevalence	prevalence	NN
cord-003403-ypefqm71	33	18	[	[	-LRB-
cord-003403-ypefqm71	33	19	11	11	CD
cord-003403-ypefqm71	33	20	]	]	-RRB-
cord-003403-ypefqm71	33	21	[	[	-LRB-
cord-003403-ypefqm71	33	22	12	12	CD
cord-003403-ypefqm71	33	23	]	]	-RRB-
cord-003403-ypefqm71	33	24	[	[	-LRB-
cord-003403-ypefqm71	33	25	13	13	CD
cord-003403-ypefqm71	33	26	]	]	-RRB-
cord-003403-ypefqm71	33	27	[	[	-LRB-
cord-003403-ypefqm71	33	28	14	14	CD
cord-003403-ypefqm71	33	29	]	]	-RRB-
cord-003403-ypefqm71	33	30	.	.	.
cord-003403-ypefqm71	34	1	In	in	IN
cord-003403-ypefqm71	34	2	adults	adult	NNS
cord-003403-ypefqm71	34	3	,	,	,
cord-003403-ypefqm71	34	4	the	the	DT
cord-003403-ypefqm71	34	5	most	most	RBS
cord-003403-ypefqm71	34	6	common	common	JJ
cord-003403-ypefqm71	34	7	complication	complication	NN
cord-003403-ypefqm71	34	8	of	of	IN
cord-003403-ypefqm71	34	9	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	34	10	infection	infection	NN
cord-003403-ypefqm71	34	11	is	be	VBZ
cord-003403-ypefqm71	34	12	Guillain	Guillain	NNP
cord-003403-ypefqm71	34	13	-	-	HYPH
cord-003403-ypefqm71	34	14	Barré	Barré	NNP
cord-003403-ypefqm71	34	15	syndrome	syndrome	NN
cord-003403-ypefqm71	34	16	occurring	occur	VBG
cord-003403-ypefqm71	34	17	at	at	IN
cord-003403-ypefqm71	34	18	an	an	DT
cord-003403-ypefqm71	34	19	estimated	estimate	VBN
cord-003403-ypefqm71	34	20	rate	rate	NN
cord-003403-ypefqm71	34	21	of	of	IN
cord-003403-ypefqm71	34	22	1	1	CD
cord-003403-ypefqm71	34	23	in	in	IN
cord-003403-ypefqm71	34	24	5000	5000	CD
cord-003403-ypefqm71	34	25	cases	case	NNS
cord-003403-ypefqm71	34	26	[	[	-LRB-
cord-003403-ypefqm71	34	27	10	10	CD
cord-003403-ypefqm71	34	28	]	]	-RRB-
cord-003403-ypefqm71	34	29	.	.	.
cord-003403-ypefqm71	35	1	Zika	Zika	NNP
cord-003403-ypefqm71	35	2	has	have	VBZ
cord-003403-ypefqm71	35	3	also	also	RB
cord-003403-ypefqm71	35	4	resulted	result	VBN
cord-003403-ypefqm71	35	5	in	in	IN
cord-003403-ypefqm71	35	6	deaths	death	NNS
cord-003403-ypefqm71	35	7	among	among	IN
cord-003403-ypefqm71	35	8	adults	adult	NNS
cord-003403-ypefqm71	35	9	with	with	IN
cord-003403-ypefqm71	35	10	and	and	CC
cord-003403-ypefqm71	35	11	without	without	IN
cord-003403-ypefqm71	35	12	other	other	JJ
cord-003403-ypefqm71	35	13	complicating	complicate	VBG
cord-003403-ypefqm71	35	14	factors	factor	NNS
cord-003403-ypefqm71	35	15	[	[	-LRB-
cord-003403-ypefqm71	35	16	15	15	CD
cord-003403-ypefqm71	35	17	,	,	,
cord-003403-ypefqm71	35	18	16	16	CD
cord-003403-ypefqm71	35	19	]	]	-RRB-
cord-003403-ypefqm71	35	20	.	.	.
cord-003403-ypefqm71	36	1	There	there	EX
cord-003403-ypefqm71	36	2	are	be	VBP
cord-003403-ypefqm71	36	3	no	no	DT
cord-003403-ypefqm71	36	4	approved	approve	VBN
cord-003403-ypefqm71	36	5	therapies	therapy	NNS
cord-003403-ypefqm71	36	6	or	or	CC
cord-003403-ypefqm71	36	7	vaccines	vaccine	NNS
cord-003403-ypefqm71	36	8	for	for	IN
cord-003403-ypefqm71	36	9	ZIKV	zikv	NN
cord-003403-ypefqm71	36	10	infection	infection	NN
cord-003403-ypefqm71	36	11	.	.	.
cord-003403-ypefqm71	37	1	There	there	EX
cord-003403-ypefqm71	37	2	have	have	VBP
cord-003403-ypefqm71	37	3	been	be	VBN
cord-003403-ypefqm71	37	4	a	a	DT
cord-003403-ypefqm71	37	5	number	number	NN
cord-003403-ypefqm71	37	6	of	of	IN
cord-003403-ypefqm71	37	7	vaccines	vaccine	NNS
cord-003403-ypefqm71	37	8	developed	develop	VBN
cord-003403-ypefqm71	37	9	for	for	IN
cord-003403-ypefqm71	37	10	other	other	JJ
cord-003403-ypefqm71	37	11	flavivirus	flavivirus	JJ
cord-003403-ypefqm71	37	12	infections	infection	NNS
cord-003403-ypefqm71	37	13	.	.	.
cord-003403-ypefqm71	38	1	Live	live	JJ
cord-003403-ypefqm71	38	2	virus	virus	NN
cord-003403-ypefqm71	38	3	vaccines	vaccine	NNS
cord-003403-ypefqm71	38	4	utilizing	utilize	VBG
cord-003403-ypefqm71	38	5	chimeric	chimeric	JJ
cord-003403-ypefqm71	38	6	viral	viral	JJ
cord-003403-ypefqm71	38	7	constructs	construct	NNS
cord-003403-ypefqm71	38	8	have	have	VBP
cord-003403-ypefqm71	38	9	been	be	VBN
cord-003403-ypefqm71	38	10	approved	approve	VBN
cord-003403-ypefqm71	38	11	for	for	IN
cord-003403-ypefqm71	38	12	use	use	NN
cord-003403-ypefqm71	38	13	to	to	TO
cord-003403-ypefqm71	38	14	prevent	prevent	VB
cord-003403-ypefqm71	38	15	yellow	yellow	JJ
cord-003403-ypefqm71	38	16	fever	fever	NN
cord-003403-ypefqm71	38	17	and	and	CC
cord-003403-ypefqm71	38	18	dengue	dengue	NN
cord-003403-ypefqm71	38	19	.	.	.
cord-003403-ypefqm71	39	1	DNA	dna	NN
cord-003403-ypefqm71	39	2	vaccines	vaccine	NNS
cord-003403-ypefqm71	39	3	have	have	VBP
cord-003403-ypefqm71	39	4	been	be	VBN
cord-003403-ypefqm71	39	5	developed	develop	VBN
cord-003403-ypefqm71	39	6	and	and	CC
cord-003403-ypefqm71	39	7	published	publish	VBN
cord-003403-ypefqm71	39	8	for	for	IN
cord-003403-ypefqm71	39	9	dengue	dengue	NN
cord-003403-ypefqm71	39	10	[	[	-LRB-
cord-003403-ypefqm71	39	11	17	17	CD
cord-003403-ypefqm71	39	12	,	,	,
cord-003403-ypefqm71	39	13	18	18	CD
cord-003403-ypefqm71	39	14	]	]	-RRB-
cord-003403-ypefqm71	40	1	,	,	,
cord-003403-ypefqm71	40	2	West	West	NNP
cord-003403-ypefqm71	40	3	Nile	Nile	NNP
cord-003403-ypefqm71	40	4	virus	virus	NN
cord-003403-ypefqm71	40	5	[	[	-LRB-
cord-003403-ypefqm71	40	6	18	18	CD
cord-003403-ypefqm71	40	7	]	]	-RRB-
cord-003403-ypefqm71	40	8	[	[	-LRB-
cord-003403-ypefqm71	40	9	19	19	CD
cord-003403-ypefqm71	40	10	]	]	-RRB-
cord-003403-ypefqm71	40	11	[	[	-LRB-
cord-003403-ypefqm71	40	12	20	20	CD
cord-003403-ypefqm71	40	13	]	]	-RRB-
cord-003403-ypefqm71	40	14	[	[	-LRB-
cord-003403-ypefqm71	40	15	21	21	CD
cord-003403-ypefqm71	40	16	]	]	-RRB-
cord-003403-ypefqm71	40	17	[	[	-LRB-
cord-003403-ypefqm71	40	18	22	22	CD
cord-003403-ypefqm71	40	19	]	]	-RRB-
cord-003403-ypefqm71	40	20	,	,	,
cord-003403-ypefqm71	40	21	and	and	CC
cord-003403-ypefqm71	40	22	Japanese	japanese	JJ
cord-003403-ypefqm71	40	23	encephalitis	encephalitis	NN
cord-003403-ypefqm71	40	24	virus	virus	NN
cord-003403-ypefqm71	40	25	[	[	-LRB-
cord-003403-ypefqm71	40	26	21	21	CD
cord-003403-ypefqm71	40	27	]	]	-RRB-
cord-003403-ypefqm71	40	28	.	.	.
cord-003403-ypefqm71	41	1	Notably	notably	RB
cord-003403-ypefqm71	41	2	,	,	,
cord-003403-ypefqm71	41	3	DNA	DNA	NNP
cord-003403-ypefqm71	41	4	vaccines	vaccine	NNS
cord-003403-ypefqm71	41	5	targeting	target	VBG
cord-003403-ypefqm71	41	6	West	West	NNP
cord-003403-ypefqm71	41	7	Nile	Nile	NNP
cord-003403-ypefqm71	41	8	virus	virus	NN
cord-003403-ypefqm71	41	9	[	[	-LRB-
cord-003403-ypefqm71	41	10	19	19	CD
cord-003403-ypefqm71	41	11	,	,	,
cord-003403-ypefqm71	41	12	20	20	CD
cord-003403-ypefqm71	41	13	]	]	-RRB-
cord-003403-ypefqm71	41	14	and	and	CC
cord-003403-ypefqm71	41	15	dengue	dengue	NN
cord-003403-ypefqm71	41	16	virus	virus	NN
cord-003403-ypefqm71	41	17	[	[	-LRB-
cord-003403-ypefqm71	41	18	17	17	CD
cord-003403-ypefqm71	41	19	]	]	-RRB-
cord-003403-ypefqm71	41	20	have	have	VBP
cord-003403-ypefqm71	41	21	been	be	VBN
cord-003403-ypefqm71	41	22	tested	test	VBN
cord-003403-ypefqm71	41	23	as	as	IN
cord-003403-ypefqm71	41	24	part	part	NN
cord-003403-ypefqm71	41	25	of	of	IN
cord-003403-ypefqm71	41	26	Phase	phase	NN
cord-003403-ypefqm71	41	27	I	-PRON-	PRP
cord-003403-ypefqm71	41	28	clinical	clinical	JJ
cord-003403-ypefqm71	41	29	trials	trial	NNS
cord-003403-ypefqm71	41	30	without	without	IN
cord-003403-ypefqm71	41	31	vaccine	vaccine	NN
cord-003403-ypefqm71	41	32	associated	associate	VBD
cord-003403-ypefqm71	41	33	toxicity	toxicity	NN
cord-003403-ypefqm71	41	34	.	.	.
cord-003403-ypefqm71	42	1	Currently	currently	RB
cord-003403-ypefqm71	42	2	,	,	,
cord-003403-ypefqm71	42	3	as	as	IN
cord-003403-ypefqm71	42	4	recently	recently	RB
cord-003403-ypefqm71	42	5	reviewed	review	VBN
cord-003403-ypefqm71	42	6	elsewhere	elsewhere	RB
cord-003403-ypefqm71	42	7	,	,	,
cord-003403-ypefqm71	42	8	a	a	DT
cord-003403-ypefqm71	42	9	number	number	NN
cord-003403-ypefqm71	42	10	of	of	IN
cord-003403-ypefqm71	42	11	vaccine	vaccine	NN
cord-003403-ypefqm71	42	12	modalities	modality	NNS
cord-003403-ypefqm71	42	13	targeting	target	VBG
cord-003403-ypefqm71	42	14	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	42	15	have	have	VBP
cord-003403-ypefqm71	42	16	reached	reach	VBN
cord-003403-ypefqm71	42	17	early	early	JJ
cord-003403-ypefqm71	42	18	stage	stage	NN
cord-003403-ypefqm71	42	19	clinical	clinical	JJ
cord-003403-ypefqm71	42	20	trials	trial	NNS
cord-003403-ypefqm71	42	21	and	and	CC
cord-003403-ypefqm71	42	22	even	even	RB
cord-003403-ypefqm71	42	23	more	more	JJR
cord-003403-ypefqm71	42	24	are	be	VBP
cord-003403-ypefqm71	42	25	in	in	IN
cord-003403-ypefqm71	42	26	preclinical	preclinical	JJ
cord-003403-ypefqm71	42	27	development	development	NN
cord-003403-ypefqm71	42	28	[	[	-LRB-
cord-003403-ypefqm71	42	29	23	23	CD
cord-003403-ypefqm71	42	30	]	]	-RRB-
cord-003403-ypefqm71	42	31	[	[	-LRB-
cord-003403-ypefqm71	42	32	24	24	CD
cord-003403-ypefqm71	42	33	]	]	-RRB-
cord-003403-ypefqm71	42	34	[	[	-LRB-
cord-003403-ypefqm71	42	35	25	25	CD
cord-003403-ypefqm71	42	36	]	]	-RRB-
cord-003403-ypefqm71	42	37	.	.	.
cord-003403-ypefqm71	43	1	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	43	2	is	be	VBZ
cord-003403-ypefqm71	43	3	spread	spread	VBN
cord-003403-ypefqm71	43	4	primarily	primarily	RB
cord-003403-ypefqm71	43	5	through	through	IN
cord-003403-ypefqm71	43	6	Aedes	Aedes	NNP
cord-003403-ypefqm71	43	7	species	species	NN
cord-003403-ypefqm71	43	8	mosquitoes	mosquito	NNS
cord-003403-ypefqm71	43	9	,	,	,
cord-003403-ypefqm71	43	10	mainly	mainly	RB
cord-003403-ypefqm71	43	11	Aedes	Aedes	NNP
cord-003403-ypefqm71	43	12	aegypti	aegypti	NNS
cord-003403-ypefqm71	43	13	,	,	,
cord-003403-ypefqm71	43	14	but	but	CC
cord-003403-ypefqm71	43	15	can	can	MD
cord-003403-ypefqm71	43	16	be	be	VB
cord-003403-ypefqm71	43	17	carried	carry	VBN
cord-003403-ypefqm71	43	18	by	by	IN
cord-003403-ypefqm71	43	19	other	other	JJ
cord-003403-ypefqm71	43	20	mosquito	mosquito	NN
cord-003403-ypefqm71	43	21	species	specie	NNS
cord-003403-ypefqm71	43	22	[	[	-LRB-
cord-003403-ypefqm71	43	23	26	26	CD
cord-003403-ypefqm71	43	24	]	]	-RRB-
cord-003403-ypefqm71	43	25	and	and	CC
cord-003403-ypefqm71	43	26	does	do	VBZ
cord-003403-ypefqm71	43	27	not	not	RB
cord-003403-ypefqm71	43	28	appear	appear	VB
cord-003403-ypefqm71	43	29	to	to	TO
cord-003403-ypefqm71	43	30	be	be	VB
cord-003403-ypefqm71	43	31	transmission	transmission	NN
cord-003403-ypefqm71	43	32	competent	competent	JJ
cord-003403-ypefqm71	43	33	except	except	IN
cord-003403-ypefqm71	43	34	for	for	IN
cord-003403-ypefqm71	43	35	Aedes	Aedes	NNP
cord-003403-ypefqm71	43	36	species	specie	NNS
cord-003403-ypefqm71	43	37	[	[	-LRB-
cord-003403-ypefqm71	43	38	26	26	CD
cord-003403-ypefqm71	43	39	]	]	-RRB-
cord-003403-ypefqm71	43	40	[	[	-LRB-
cord-003403-ypefqm71	43	41	27	27	CD
cord-003403-ypefqm71	43	42	]	]	-RRB-
cord-003403-ypefqm71	43	43	[	[	-LRB-
cord-003403-ypefqm71	43	44	28	28	CD
cord-003403-ypefqm71	43	45	]	]	-RRB-
cord-003403-ypefqm71	43	46	[	[	-LRB-
cord-003403-ypefqm71	43	47	29	29	CD
cord-003403-ypefqm71	43	48	]	]	-RRB-
cord-003403-ypefqm71	43	49	[	[	-LRB-
cord-003403-ypefqm71	43	50	30	30	CD
cord-003403-ypefqm71	43	51	]	]	-RRB-
cord-003403-ypefqm71	43	52	[	[	-LRB-
cord-003403-ypefqm71	43	53	31	31	CD
cord-003403-ypefqm71	43	54	]	]	-RRB-
cord-003403-ypefqm71	43	55	.	.	.
cord-003403-ypefqm71	44	1	Aedes	Aedes	NNP
cord-003403-ypefqm71	44	2	mosquitoes	mosquito	NNS
cord-003403-ypefqm71	44	3	also	also	RB
cord-003403-ypefqm71	44	4	transmit	transmit	VBP
cord-003403-ypefqm71	44	5	other	other	JJ
cord-003403-ypefqm71	44	6	arboviruses	arbovirus	NNS
cord-003403-ypefqm71	44	7	such	such	JJ
cord-003403-ypefqm71	44	8	as	as	IN
cord-003403-ypefqm71	44	9	dengue	dengue	NN
cord-003403-ypefqm71	44	10	and	and	CC
cord-003403-ypefqm71	44	11	chikungunya	chikungunya	NN
cord-003403-ypefqm71	44	12	[	[	-LRB-
cord-003403-ypefqm71	44	13	30	30	CD
cord-003403-ypefqm71	44	14	,	,	,
cord-003403-ypefqm71	44	15	32	32	CD
cord-003403-ypefqm71	44	16	]	]	-RRB-
cord-003403-ypefqm71	44	17	.	.	.
cord-003403-ypefqm71	45	1	In	in	IN
cord-003403-ypefqm71	45	2	fact	fact	NN
cord-003403-ypefqm71	45	3	,	,	,
cord-003403-ypefqm71	45	4	these	these	DT
cord-003403-ypefqm71	45	5	infections	infection	NNS
cord-003403-ypefqm71	45	6	are	be	VBP
cord-003403-ypefqm71	45	7	co	co	JJ
cord-003403-ypefqm71	45	8	-	-	JJ
cord-003403-ypefqm71	45	9	endemic	endemic	JJ
cord-003403-ypefqm71	45	10	in	in	IN
cord-003403-ypefqm71	45	11	most	most	JJS
cord-003403-ypefqm71	45	12	regions	region	NNS
cord-003403-ypefqm71	45	13	and	and	CC
cord-003403-ypefqm71	45	14	may	may	MD
cord-003403-ypefqm71	45	15	cause	cause	VB
cord-003403-ypefqm71	45	16	concurrent	concurrent	JJ
cord-003403-ypefqm71	45	17	infections	infection	NNS
cord-003403-ypefqm71	45	18	[	[	-LRB-
cord-003403-ypefqm71	45	19	33	33	CD
cord-003403-ypefqm71	45	20	]	]	-RRB-
cord-003403-ypefqm71	45	21	[	[	-LRB-
cord-003403-ypefqm71	45	22	34	34	CD
cord-003403-ypefqm71	45	23	]	]	-RRB-
cord-003403-ypefqm71	45	24	[	[	-LRB-
cord-003403-ypefqm71	45	25	35	35	CD
cord-003403-ypefqm71	45	26	]	]	-RRB-
cord-003403-ypefqm71	45	27	[	[	-LRB-
cord-003403-ypefqm71	45	28	36	36	CD
cord-003403-ypefqm71	45	29	]	]	-RRB-
cord-003403-ypefqm71	45	30	.	.	.
cord-003403-ypefqm71	46	1	Alternative	alternative	JJ
cord-003403-ypefqm71	46	2	nonmosquito	nonmosquito	NN
cord-003403-ypefqm71	46	3	-	-	HYPH
cord-003403-ypefqm71	46	4	borne	bear	VBN
cord-003403-ypefqm71	46	5	routes	route	NNS
cord-003403-ypefqm71	46	6	of	of	IN
cord-003403-ypefqm71	46	7	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	46	8	spread	spread	VBN
cord-003403-ypefqm71	46	9	include	include	VBP
cord-003403-ypefqm71	46	10	:	:	:
cord-003403-ypefqm71	46	11	blood	blood	NN
cord-003403-ypefqm71	46	12	transfusions	transfusion	NNS
cord-003403-ypefqm71	46	13	,	,	,
cord-003403-ypefqm71	46	14	breast	breast	NN
cord-003403-ypefqm71	46	15	milk	milk	NN
cord-003403-ypefqm71	46	16	[	[	-LRB-
cord-003403-ypefqm71	46	17	37	37	CD
cord-003403-ypefqm71	46	18	]	]	-RRB-
cord-003403-ypefqm71	46	19	,	,	,
cord-003403-ypefqm71	46	20	sexual	sexual	JJ
cord-003403-ypefqm71	46	21	transmission	transmission	NN
cord-003403-ypefqm71	46	22	[	[	-LRB-
cord-003403-ypefqm71	46	23	38	38	CD
cord-003403-ypefqm71	46	24	]	]	-RRB-
cord-003403-ypefqm71	46	25	[	[	-LRB-
cord-003403-ypefqm71	46	26	39	39	CD
cord-003403-ypefqm71	46	27	]	]	-RRB-
cord-003403-ypefqm71	46	28	[	[	-LRB-
cord-003403-ypefqm71	46	29	40	40	CD
cord-003403-ypefqm71	46	30	]	]	-RRB-
cord-003403-ypefqm71	46	31	,	,	,
cord-003403-ypefqm71	46	32	and	and	CC
cord-003403-ypefqm71	46	33	may	may	MD
cord-003403-ypefqm71	46	34	include	include	VB
cord-003403-ypefqm71	46	35	urine	urine	NN
cord-003403-ypefqm71	46	36	and	and	CC
cord-003403-ypefqm71	46	37	saliva	saliva	NN
cord-003403-ypefqm71	46	38	[	[	-LRB-
cord-003403-ypefqm71	46	39	41	41	CD
cord-003403-ypefqm71	46	40	]	]	-RRB-
cord-003403-ypefqm71	46	41	[	[	-LRB-
cord-003403-ypefqm71	46	42	42	42	CD
cord-003403-ypefqm71	46	43	]	]	-RRB-
cord-003403-ypefqm71	46	44	[	[	-LRB-
cord-003403-ypefqm71	46	45	43	43	CD
cord-003403-ypefqm71	46	46	]	]	-RRB-
cord-003403-ypefqm71	46	47	[	[	-LRB-
cord-003403-ypefqm71	46	48	44	44	CD
cord-003403-ypefqm71	46	49	]	]	-RRB-
cord-003403-ypefqm71	46	50	.	.	.
cord-003403-ypefqm71	47	1	The	the	DT
cord-003403-ypefqm71	47	2	additional	additional	JJ
cord-003403-ypefqm71	47	3	potential	potential	JJ
cord-003403-ypefqm71	47	4	routes	route	NNS
cord-003403-ypefqm71	47	5	of	of	IN
cord-003403-ypefqm71	47	6	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	47	7	transmission	transmission	NN
cord-003403-ypefqm71	47	8	have	have	VBP
cord-003403-ypefqm71	47	9	increased	increase	VBN
cord-003403-ypefqm71	47	10	the	the	DT
cord-003403-ypefqm71	47	11	need	need	NN
cord-003403-ypefqm71	47	12	for	for	IN
cord-003403-ypefqm71	47	13	definitive	definitive	JJ
cord-003403-ypefqm71	47	14	monitoring	monitoring	NN
cord-003403-ypefqm71	47	15	and	and	CC
cord-003403-ypefqm71	47	16	a	a	DT
cord-003403-ypefqm71	47	17	variety	variety	NN
cord-003403-ypefqm71	47	18	of	of	IN
cord-003403-ypefqm71	47	19	surveillance	surveillance	NN
cord-003403-ypefqm71	47	20	strategies	strategy	NNS
cord-003403-ypefqm71	47	21	to	to	TO
cord-003403-ypefqm71	47	22	prevent	prevent	VB
cord-003403-ypefqm71	47	23	disease	disease	NN
cord-003403-ypefqm71	47	24	spread	spread	VBN
cord-003403-ypefqm71	47	25	[	[	-LRB-
cord-003403-ypefqm71	47	26	45	45	CD
cord-003403-ypefqm71	47	27	]	]	-RRB-
cord-003403-ypefqm71	47	28	[	[	-LRB-
cord-003403-ypefqm71	47	29	46	46	CD
cord-003403-ypefqm71	47	30	]	]	-RRB-
cord-003403-ypefqm71	48	1	[	[	-LRB-
cord-003403-ypefqm71	48	2	47	47	CD
cord-003403-ypefqm71	48	3	]	]	-RRB-
cord-003403-ypefqm71	49	1	[	[	-LRB-
cord-003403-ypefqm71	49	2	48	48	CD
cord-003403-ypefqm71	49	3	]	]	-RRB-
cord-003403-ypefqm71	49	4	[	[	-LRB-
cord-003403-ypefqm71	49	5	49	49	CD
cord-003403-ypefqm71	49	6	]	]	-RRB-
cord-003403-ypefqm71	49	7	.	.	.
cord-003403-ypefqm71	50	1	In	in	IN
cord-003403-ypefqm71	50	2	an	an	DT
cord-003403-ypefqm71	50	3	outbreak	outbreak	NN
cord-003403-ypefqm71	50	4	situation	situation	NN
cord-003403-ypefqm71	50	5	,	,	,
cord-003403-ypefqm71	50	6	such	such	JJ
cord-003403-ypefqm71	50	7	as	as	IN
cord-003403-ypefqm71	50	8	with	with	IN
cord-003403-ypefqm71	50	9	Zika	Zika	NNP
cord-003403-ypefqm71	50	10	,	,	,
cord-003403-ypefqm71	50	11	it	-PRON-	PRP
cord-003403-ypefqm71	50	12	is	be	VBZ
cord-003403-ypefqm71	50	13	important	important	JJ
cord-003403-ypefqm71	50	14	to	to	TO
cord-003403-ypefqm71	50	15	have	have	VB
cord-003403-ypefqm71	50	16	the	the	DT
cord-003403-ypefqm71	50	17	ability	ability	NN
cord-003403-ypefqm71	50	18	to	to	TO
cord-003403-ypefqm71	50	19	quickly	quickly	RB
cord-003403-ypefqm71	50	20	develop	develop	VB
cord-003403-ypefqm71	50	21	both	both	DT
cord-003403-ypefqm71	50	22	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	50	23	kits	kit	NNS
cord-003403-ypefqm71	50	24	for	for	IN
cord-003403-ypefqm71	50	25	public	public	JJ
cord-003403-ypefqm71	50	26	health	health	NN
cord-003403-ypefqm71	50	27	purposes	purpose	NNS
cord-003403-ypefqm71	50	28	and	and	CC
cord-003403-ypefqm71	50	29	vaccine	vaccine	NN
cord-003403-ypefqm71	50	30	clinical	clinical	JJ
cord-003403-ypefqm71	50	31	assays	assay	NNS
cord-003403-ypefqm71	50	32	to	to	TO
cord-003403-ypefqm71	50	33	support	support	VB
cord-003403-ypefqm71	50	34	pre	pre	JJ
cord-003403-ypefqm71	50	35	-	-	JJ
cord-003403-ypefqm71	50	36	clinical	clinical	JJ
cord-003403-ypefqm71	50	37	studies	study	NNS
cord-003403-ypefqm71	50	38	and	and	CC
cord-003403-ypefqm71	50	39	early	early	JJ
cord-003403-ypefqm71	50	40	stage	stage	NN
cord-003403-ypefqm71	50	41	clinical	clinical	JJ
cord-003403-ypefqm71	50	42	trials	trial	NNS
cord-003403-ypefqm71	50	43	.	.	.
cord-003403-ypefqm71	51	1	Both	both	DT
cord-003403-ypefqm71	51	2	were	be	VBD
cord-003403-ypefqm71	51	3	largely	largely	RB
cord-003403-ypefqm71	51	4	unavailable	unavailable	JJ
cord-003403-ypefqm71	51	5	on	on	IN
cord-003403-ypefqm71	51	6	a	a	DT
cord-003403-ypefqm71	51	7	commercial	commercial	JJ
cord-003403-ypefqm71	51	8	scale	scale	NN
cord-003403-ypefqm71	51	9	or	or	CC
cord-003403-ypefqm71	51	10	for	for	IN
cord-003403-ypefqm71	51	11	widespread	widespread	JJ
cord-003403-ypefqm71	51	12	use	use	NN
cord-003403-ypefqm71	51	13	at	at	IN
cord-003403-ypefqm71	51	14	the	the	DT
cord-003403-ypefqm71	51	15	outset	outset	NN
cord-003403-ypefqm71	51	16	of	of	IN
cord-003403-ypefqm71	51	17	the	the	DT
cord-003403-ypefqm71	51	18	Zika	Zika	NNP
cord-003403-ypefqm71	51	19	outbreak	outbreak	NN
cord-003403-ypefqm71	51	20	,	,	,
cord-003403-ypefqm71	51	21	though	though	IN
cord-003403-ypefqm71	51	22	development	development	NN
cord-003403-ypefqm71	51	23	ensued	ensue	VBD
cord-003403-ypefqm71	51	24	at	at	IN
cord-003403-ypefqm71	51	25	a	a	DT
cord-003403-ypefqm71	51	26	rapid	rapid	JJ
cord-003403-ypefqm71	51	27	pace	pace	NN
cord-003403-ypefqm71	51	28	upon	upon	IN
cord-003403-ypefqm71	51	29	the	the	DT
cord-003403-ypefqm71	51	30	declaration	declaration	NN
cord-003403-ypefqm71	51	31	of	of	IN
cord-003403-ypefqm71	51	32	a	a	DT
cord-003403-ypefqm71	51	33	worldwide	worldwide	JJ
cord-003403-ypefqm71	51	34	public	public	JJ
cord-003403-ypefqm71	51	35	health	health	NN
cord-003403-ypefqm71	51	36	emergency	emergency	NN
cord-003403-ypefqm71	51	37	.	.	.
cord-003403-ypefqm71	52	1	Because	because	IN
cord-003403-ypefqm71	52	2	there	there	EX
cord-003403-ypefqm71	52	3	is	be	VBZ
cord-003403-ypefqm71	52	4	significant	significant	JJ
cord-003403-ypefqm71	52	5	homology	homology	NN
cord-003403-ypefqm71	52	6	between	between	IN
cord-003403-ypefqm71	52	7	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	52	8	and	and	CC
cord-003403-ypefqm71	52	9	other	other	JJ
cord-003403-ypefqm71	52	10	cocirculating	cocirculate	VBG
cord-003403-ypefqm71	52	11	flaviviruses	flavivirus	NNS
cord-003403-ypefqm71	52	12	,	,	,
cord-003403-ypefqm71	52	13	detection	detection	NN
cord-003403-ypefqm71	52	14	and	and	CC
cord-003403-ypefqm71	52	15	diagnosis	diagnosis	NN
cord-003403-ypefqm71	52	16	has	have	VBZ
cord-003403-ypefqm71	52	17	had	have	VBN
cord-003403-ypefqm71	52	18	the	the	DT
cord-003403-ypefqm71	52	19	extra	extra	JJ
cord-003403-ypefqm71	52	20	challenge	challenge	NN
cord-003403-ypefqm71	52	21	of	of	IN
cord-003403-ypefqm71	52	22	avoiding	avoid	VBG
cord-003403-ypefqm71	52	23	cross	cross	NN
cord-003403-ypefqm71	52	24	-	-	NN
cord-003403-ypefqm71	52	25	reactivity	reactivity	NN
cord-003403-ypefqm71	52	26	without	without	IN
cord-003403-ypefqm71	52	27	sacrificing	sacrifice	VBG
cord-003403-ypefqm71	52	28	sensitivity	sensitivity	NN
cord-003403-ypefqm71	52	29	.	.	.
cord-003403-ypefqm71	53	1	While	while	IN
cord-003403-ypefqm71	53	2	the	the	DT
cord-003403-ypefqm71	53	3	avoidance	avoidance	NN
cord-003403-ypefqm71	53	4	of	of	IN
cord-003403-ypefqm71	53	5	cross	cross	NN
cord-003403-ypefqm71	53	6	-	-	NN
cord-003403-ypefqm71	53	7	reactivity	reactivity	NN
cord-003403-ypefqm71	53	8	is	be	VBZ
cord-003403-ypefqm71	53	9	more	more	RBR
cord-003403-ypefqm71	53	10	easily	easily	RB
cord-003403-ypefqm71	53	11	engineered	engineer	VBN
cord-003403-ypefqm71	53	12	into	into	IN
cord-003403-ypefqm71	53	13	molecular	molecular	JJ
cord-003403-ypefqm71	53	14	tests	test	NNS
cord-003403-ypefqm71	53	15	of	of	IN
cord-003403-ypefqm71	53	16	virus	virus	NN
cord-003403-ypefqm71	53	17	RNA	RNA	NNP
cord-003403-ypefqm71	53	18	because	because	IN
cord-003403-ypefqm71	53	19	primers	primer	NNS
cord-003403-ypefqm71	53	20	or	or	CC
cord-003403-ypefqm71	53	21	probes	probe	NNS
cord-003403-ypefqm71	53	22	can	can	MD
cord-003403-ypefqm71	53	23	be	be	VB
cord-003403-ypefqm71	53	24	designed	design	VBN
cord-003403-ypefqm71	53	25	to	to	TO
cord-003403-ypefqm71	53	26	be	be	VB
cord-003403-ypefqm71	53	27	virus-	virus-	NN
cord-003403-ypefqm71	53	28	,	,	,
cord-003403-ypefqm71	53	29	antigen	antigen	NN
cord-003403-ypefqm71	53	30	-	-	HYPH
cord-003403-ypefqm71	53	31	and	and	CC
cord-003403-ypefqm71	53	32	serotype	serotype	NN
cord-003403-ypefqm71	53	33	-	-	HYPH
cord-003403-ypefqm71	53	34	specific	specific	JJ
cord-003403-ypefqm71	53	35	[	[	-LRB-
cord-003403-ypefqm71	53	36	41	41	CD
cord-003403-ypefqm71	53	37	,	,	,
cord-003403-ypefqm71	53	38	[	[	-LRB-
cord-003403-ypefqm71	53	39	50	50	CD
cord-003403-ypefqm71	53	40	]	]	-RRB-
cord-003403-ypefqm71	53	41	[	[	-LRB-
cord-003403-ypefqm71	53	42	51	51	CD
cord-003403-ypefqm71	53	43	]	]	-RRB-
cord-003403-ypefqm71	53	44	[	[	-LRB-
cord-003403-ypefqm71	53	45	52	52	CD
cord-003403-ypefqm71	53	46	]	]	-RRB-
cord-003403-ypefqm71	53	47	[	[	-LRB-
cord-003403-ypefqm71	53	48	53	53	CD
cord-003403-ypefqm71	53	49	]	]	-RRB-
cord-003403-ypefqm71	53	50	[	[	-LRB-
cord-003403-ypefqm71	53	51	54	54	CD
cord-003403-ypefqm71	53	52	]	]	-RRB-
cord-003403-ypefqm71	53	53	[	[	-LRB-
cord-003403-ypefqm71	53	54	55	55	CD
cord-003403-ypefqm71	53	55	]	]	-RRB-
cord-003403-ypefqm71	53	56	[	[	-LRB-
cord-003403-ypefqm71	53	57	56	56	CD
cord-003403-ypefqm71	53	58	]	]	-RRB-
cord-003403-ypefqm71	53	59	[	[	-LRB-
cord-003403-ypefqm71	53	60	57	57	CD
cord-003403-ypefqm71	53	61	]	]	-RRB-
cord-003403-ypefqm71	53	62	,	,	,
cord-003403-ypefqm71	53	63	it	-PRON-	PRP
cord-003403-ypefqm71	53	64	is	be	VBZ
cord-003403-ypefqm71	53	65	not	not	RB
cord-003403-ypefqm71	53	66	as	as	RB
cord-003403-ypefqm71	53	67	easily	easily	RB
cord-003403-ypefqm71	53	68	achieved	achieve	VBN
cord-003403-ypefqm71	53	69	for	for	IN
cord-003403-ypefqm71	53	70	immunoassays	immunoassays	NNP
cord-003403-ypefqm71	53	71	[	[	-LRB-
cord-003403-ypefqm71	53	72	58	58	CD
cord-003403-ypefqm71	53	73	]	]	-RRB-
cord-003403-ypefqm71	54	1	[	[	-LRB-
cord-003403-ypefqm71	54	2	59	59	CD
cord-003403-ypefqm71	54	3	]	]	-RRB-
cord-003403-ypefqm71	54	4	[	[	-LRB-
cord-003403-ypefqm71	54	5	60	60	CD
cord-003403-ypefqm71	54	6	]	]	-RRB-
cord-003403-ypefqm71	54	7	[	[	-LRB-
cord-003403-ypefqm71	54	8	61	61	CD
cord-003403-ypefqm71	54	9	]	]	-RRB-
cord-003403-ypefqm71	55	1	[	[	-LRB-
cord-003403-ypefqm71	55	2	62	62	CD
cord-003403-ypefqm71	55	3	]	]	-RRB-
cord-003403-ypefqm71	55	4	[	[	-LRB-
cord-003403-ypefqm71	55	5	63	63	CD
cord-003403-ypefqm71	55	6	]	]	-RRB-
cord-003403-ypefqm71	55	7	.	.	.
cord-003403-ypefqm71	56	1	Diagnostic	diagnostic	JJ
cord-003403-ypefqm71	56	2	assays	assay	NNS
cord-003403-ypefqm71	56	3	are	be	VBP
cord-003403-ypefqm71	56	4	often	often	RB
cord-003403-ypefqm71	56	5	the	the	DT
cord-003403-ypefqm71	56	6	same	same	JJ
cord-003403-ypefqm71	56	7	style	style	NN
cord-003403-ypefqm71	56	8	tests	test	NNS
cord-003403-ypefqm71	56	9	as	as	IN
cord-003403-ypefqm71	56	10	those	those	DT
cord-003403-ypefqm71	56	11	used	use	VBN
cord-003403-ypefqm71	56	12	in	in	IN
cord-003403-ypefqm71	56	13	vaccine	vaccine	NN
cord-003403-ypefqm71	56	14	development	development	NN
cord-003403-ypefqm71	56	15	,	,	,
cord-003403-ypefqm71	56	16	but	but	CC
cord-003403-ypefqm71	56	17	are	be	VBP
cord-003403-ypefqm71	56	18	for	for	IN
cord-003403-ypefqm71	56	19	the	the	DT
cord-003403-ypefqm71	56	20	intended	intended	JJ
cord-003403-ypefqm71	56	21	purpose	purpose	NN
cord-003403-ypefqm71	56	22	of	of	IN
cord-003403-ypefqm71	56	23	identifying	identify	VBG
cord-003403-ypefqm71	56	24	the	the	DT
cord-003403-ypefqm71	56	25	source	source	NN
cord-003403-ypefqm71	56	26	of	of	IN
cord-003403-ypefqm71	56	27	a	a	DT
cord-003403-ypefqm71	56	28	patient	patient	NN
cord-003403-ypefqm71	56	29	's	's	POS
cord-003403-ypefqm71	56	30	illness	illness	NN
cord-003403-ypefqm71	56	31	to	to	TO
cord-003403-ypefqm71	56	32	enable	enable	VB
cord-003403-ypefqm71	56	33	the	the	DT
cord-003403-ypefqm71	56	34	initiation	initiation	NN
cord-003403-ypefqm71	56	35	of	of	IN
cord-003403-ypefqm71	56	36	appropriate	appropriate	JJ
cord-003403-ypefqm71	56	37	treatments	treatment	NNS
cord-003403-ypefqm71	56	38	by	by	IN
cord-003403-ypefqm71	56	39	healthcare	healthcare	NN
cord-003403-ypefqm71	56	40	professionals	professional	NNS
cord-003403-ypefqm71	56	41	.	.	.
cord-003403-ypefqm71	57	1	The	the	DT
cord-003403-ypefqm71	57	2	need	need	NN
cord-003403-ypefqm71	57	3	for	for	IN
cord-003403-ypefqm71	57	4	sensitivity	sensitivity	NN
cord-003403-ypefqm71	57	5	and	and	CC
cord-003403-ypefqm71	57	6	specificity	specificity	NN
cord-003403-ypefqm71	57	7	as	as	IN
cord-003403-ypefqm71	57	8	it	-PRON-	PRP
cord-003403-ypefqm71	57	9	relates	relate	VBZ
cord-003403-ypefqm71	57	10	to	to	IN
cord-003403-ypefqm71	57	11	clinical	clinical	JJ
cord-003403-ypefqm71	57	12	disease	disease	NN
cord-003403-ypefqm71	57	13	identification	identification	NN
cord-003403-ypefqm71	57	14	for	for	IN
cord-003403-ypefqm71	57	15	patient	patient	JJ
cord-003403-ypefqm71	57	16	treatment	treatment	NN
cord-003403-ypefqm71	57	17	is	be	VBZ
cord-003403-ypefqm71	57	18	of	of	IN
cord-003403-ypefqm71	57	19	the	the	DT
cord-003403-ypefqm71	57	20	utmost	utmost	JJ
cord-003403-ypefqm71	57	21	concern	concern	NN
cord-003403-ypefqm71	57	22	.	.	.
cord-003403-ypefqm71	58	1	Early	early	RB
cord-003403-ypefqm71	58	2	in	in	IN
cord-003403-ypefqm71	58	3	the	the	DT
cord-003403-ypefqm71	58	4	Zika	Zika	NNP
cord-003403-ypefqm71	58	5	outbreak	outbreak	NN
cord-003403-ypefqm71	58	6	,	,	,
cord-003403-ypefqm71	58	7	the	the	DT
cord-003403-ypefqm71	58	8	US	US	NNP
cord-003403-ypefqm71	58	9	Centers	Centers	NNPS
cord-003403-ypefqm71	58	10	for	for	IN
cord-003403-ypefqm71	58	11	Disease	Disease	NNP
cord-003403-ypefqm71	58	12	Control	Control	NNP
cord-003403-ypefqm71	58	13	and	and	CC
cord-003403-ypefqm71	58	14	some	some	DT
cord-003403-ypefqm71	58	15	academic	academic	JJ
cord-003403-ypefqm71	58	16	laboratories	laboratory	NNS
cord-003403-ypefqm71	58	17	studying	study	VBG
cord-003403-ypefqm71	58	18	flaviviruses	flavivirus	NNS
cord-003403-ypefqm71	58	19	had	have	VBD
cord-003403-ypefqm71	58	20	assays	assay	NNS
cord-003403-ypefqm71	58	21	developed	develop	VBN
cord-003403-ypefqm71	58	22	for	for	IN
cord-003403-ypefqm71	58	23	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	58	24	that	that	WDT
cord-003403-ypefqm71	58	25	generally	generally	RB
cord-003403-ypefqm71	58	26	supported	support	VBD
cord-003403-ypefqm71	58	27	their	-PRON-	PRP$
cord-003403-ypefqm71	58	28	own	own	JJ
cord-003403-ypefqm71	58	29	research	research	NN
cord-003403-ypefqm71	58	30	interests	interest	NNS
cord-003403-ypefqm71	58	31	[	[	-LRB-
cord-003403-ypefqm71	58	32	64	64	CD
cord-003403-ypefqm71	58	33	]	]	-RRB-
cord-003403-ypefqm71	59	1	[	[	-LRB-
cord-003403-ypefqm71	59	2	65	65	CD
cord-003403-ypefqm71	59	3	]	]	-RRB-
cord-003403-ypefqm71	60	1	[	[	-LRB-
cord-003403-ypefqm71	60	2	66	66	CD
cord-003403-ypefqm71	60	3	]	]	-RRB-
cord-003403-ypefqm71	61	1	[	[	-LRB-
cord-003403-ypefqm71	61	2	67	67	CD
cord-003403-ypefqm71	61	3	]	]	-RRB-
cord-003403-ypefqm71	62	1	[	[	-LRB-
cord-003403-ypefqm71	62	2	68	68	CD
cord-003403-ypefqm71	62	3	]	]	-RRB-
cord-003403-ypefqm71	62	4	[	[	-LRB-
cord-003403-ypefqm71	62	5	69	69	CD
cord-003403-ypefqm71	62	6	]	]	-RRB-
cord-003403-ypefqm71	62	7	[	[	-LRB-
cord-003403-ypefqm71	62	8	70	70	CD
cord-003403-ypefqm71	62	9	]	]	-RRB-
cord-003403-ypefqm71	62	10	.	.	.
cord-003403-ypefqm71	63	1	Making	make	VBG
cord-003403-ypefqm71	63	2	sufficient	sufficient	JJ
cord-003403-ypefqm71	63	3	quantities	quantity	NNS
cord-003403-ypefqm71	63	4	of	of	IN
cord-003403-ypefqm71	63	5	these	these	DT
cord-003403-ypefqm71	63	6	tests	test	NNS
cord-003403-ypefqm71	63	7	available	available	JJ
cord-003403-ypefqm71	63	8	for	for	IN
cord-003403-ypefqm71	63	9	public	public	JJ
cord-003403-ypefqm71	63	10	health	health	NN
cord-003403-ypefqm71	63	11	use	use	NN
cord-003403-ypefqm71	63	12	while	while	IN
cord-003403-ypefqm71	63	13	ensuring	ensure	VBG
cord-003403-ypefqm71	63	14	consistency	consistency	NN
cord-003403-ypefqm71	63	15	and	and	CC
cord-003403-ypefqm71	63	16	quality	quality	NN
cord-003403-ypefqm71	63	17	was	be	VBD
cord-003403-ypefqm71	63	18	a	a	DT
cord-003403-ypefqm71	63	19	significant	significant	JJ
cord-003403-ypefqm71	63	20	challenge	challenge	NN
cord-003403-ypefqm71	63	21	.	.	.
cord-003403-ypefqm71	64	1	Additionally	additionally	RB
cord-003403-ypefqm71	64	2	,	,	,
cord-003403-ypefqm71	64	3	cross	cross	NN
cord-003403-ypefqm71	64	4	-	-	NN
cord-003403-ypefqm71	64	5	reactivity	reactivity	NN
cord-003403-ypefqm71	64	6	in	in	IN
cord-003403-ypefqm71	64	7	a	a	DT
cord-003403-ypefqm71	64	8	number	number	NN
cord-003403-ypefqm71	64	9	of	of	IN
cord-003403-ypefqm71	64	10	immunological	immunological	JJ
cord-003403-ypefqm71	64	11	assays	assay	NNS
cord-003403-ypefqm71	64	12	and	and	CC
cord-003403-ypefqm71	64	13	the	the	DT
cord-003403-ypefqm71	64	14	short	short	JJ
cord-003403-ypefqm71	64	15	time	time	NN
cord-003403-ypefqm71	64	16	frame	frame	NN
cord-003403-ypefqm71	64	17	in	in	IN
cord-003403-ypefqm71	64	18	which	which	WDT
cord-003403-ypefqm71	64	19	viremia	viremia	NN
cord-003403-ypefqm71	64	20	can	can	MD
cord-003403-ypefqm71	64	21	be	be	VB
cord-003403-ypefqm71	64	22	detected	detect	VBN
cord-003403-ypefqm71	64	23	in	in	IN
cord-003403-ypefqm71	64	24	bodily	bodily	JJ
cord-003403-ypefqm71	64	25	fluids	fluid	NNS
cord-003403-ypefqm71	64	26	necessitated	necessitate	VBD
cord-003403-ypefqm71	64	27	the	the	DT
cord-003403-ypefqm71	64	28	institution	institution	NN
cord-003403-ypefqm71	64	29	of	of	IN
cord-003403-ypefqm71	64	30	an	an	DT
cord-003403-ypefqm71	64	31	algorithm	algorithm	NN
cord-003403-ypefqm71	64	32	to	to	TO
cord-003403-ypefqm71	64	33	confirm	confirm	VB
cord-003403-ypefqm71	64	34	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	64	35	infection	infection	NN
cord-003403-ypefqm71	64	36	that	that	WDT
cord-003403-ypefqm71	64	37	was	be	VBD
cord-003403-ypefqm71	64	38	based	base	VBN
cord-003403-ypefqm71	64	39	on	on	IN
cord-003403-ypefqm71	64	40	a	a	DT
cord-003403-ypefqm71	64	41	combination	combination	NN
cord-003403-ypefqm71	64	42	of	of	IN
cord-003403-ypefqm71	64	43	risk	risk	NN
cord-003403-ypefqm71	64	44	factors	factor	NNS
cord-003403-ypefqm71	64	45	,	,	,
cord-003403-ypefqm71	64	46	clinical	clinical	JJ
cord-003403-ypefqm71	64	47	symptoms	symptom	NNS
cord-003403-ypefqm71	64	48	and	and	CC
cord-003403-ypefqm71	64	49	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	64	50	test	test	NN
cord-003403-ypefqm71	64	51	results	result	NNS
cord-003403-ypefqm71	64	52	[	[	-LRB-
cord-003403-ypefqm71	64	53	71	71	CD
cord-003403-ypefqm71	64	54	]	]	-RRB-
cord-003403-ypefqm71	64	55	.	.	.
cord-003403-ypefqm71	65	1	The	the	DT
cord-003403-ypefqm71	65	2	Centers	Centers	NNPS
cord-003403-ypefqm71	65	3	for	for	IN
cord-003403-ypefqm71	65	4	Disease	Disease	NNP
cord-003403-ypefqm71	65	5	Control	Control	NNP
cord-003403-ypefqm71	65	6	(	(	-LRB-
cord-003403-ypefqm71	65	7	CDC	CDC	NNP
cord-003403-ypefqm71	65	8	)	)	-RRB-
cord-003403-ypefqm71	65	9	issued	issue	VBD
cord-003403-ypefqm71	65	10	testing	test	VBG
cord-003403-ypefqm71	65	11	guidance	guidance	NN
cord-003403-ypefqm71	65	12	for	for	IN
cord-003403-ypefqm71	65	13	healthcare	healthcare	NN
cord-003403-ypefqm71	65	14	providers	provider	NNS
cord-003403-ypefqm71	65	15	using	use	VBG
cord-003403-ypefqm71	65	16	algorithms	algorithm	NNS
cord-003403-ypefqm71	65	17	that	that	WDT
cord-003403-ypefqm71	65	18	included	include	VBD
cord-003403-ypefqm71	65	19	use	use	NN
cord-003403-ypefqm71	65	20	of	of	IN
cord-003403-ypefqm71	65	21	molecular	molecular	JJ
cord-003403-ypefqm71	65	22	testing	testing	NN
cord-003403-ypefqm71	65	23	for	for	IN
cord-003403-ypefqm71	65	24	pregnant	pregnant	JJ
cord-003403-ypefqm71	65	25	or	or	CC
cord-003403-ypefqm71	65	26	non	non	JJ
cord-003403-ypefqm71	65	27	-	-	JJ
cord-003403-ypefqm71	65	28	pregnant	pregnant	JJ
cord-003403-ypefqm71	65	29	and	and	CC
cord-003403-ypefqm71	65	30	symptomatic	symptomatic	JJ
cord-003403-ypefqm71	65	31	or	or	CC
cord-003403-ypefqm71	65	32	non	non	JJ
cord-003403-ypefqm71	65	33	-	-	JJ
cord-003403-ypefqm71	65	34	symptomatic	symptomatic	JJ
cord-003403-ypefqm71	65	35	individuals	individual	NNS
cord-003403-ypefqm71	65	36	,	,	,
cord-003403-ypefqm71	65	37	the	the	DT
cord-003403-ypefqm71	65	38	types	type	NNS
cord-003403-ypefqm71	65	39	of	of	IN
cord-003403-ypefqm71	65	40	specimens	specimen	NNS
cord-003403-ypefqm71	65	41	and	and	CC
cord-003403-ypefqm71	65	42	timing	timing	NN
cord-003403-ypefqm71	65	43	of	of	IN
cord-003403-ypefqm71	65	44	collection	collection	NN
cord-003403-ypefqm71	65	45	of	of	IN
cord-003403-ypefqm71	65	46	specimens	specimen	NNS
cord-003403-ypefqm71	65	47	that	that	WDT
cord-003403-ypefqm71	65	48	would	would	MD
cord-003403-ypefqm71	65	49	provide	provide	VB
cord-003403-ypefqm71	65	50	the	the	DT
cord-003403-ypefqm71	65	51	most	most	RBS
cord-003403-ypefqm71	65	52	reliable	reliable	JJ
cord-003403-ypefqm71	65	53	results	result	NNS
cord-003403-ypefqm71	65	54	[	[	-LRB-
cord-003403-ypefqm71	65	55	72	72	CD
cord-003403-ypefqm71	65	56	]	]	-RRB-
cord-003403-ypefqm71	65	57	.	.	.
cord-003403-ypefqm71	66	1	In	in	IN
cord-003403-ypefqm71	66	2	addition	addition	NN
cord-003403-ypefqm71	66	3	,	,	,
cord-003403-ypefqm71	66	4	guidance	guidance	NN
cord-003403-ypefqm71	66	5	algorithms	algorithm	NNS
cord-003403-ypefqm71	66	6	were	be	VBD
cord-003403-ypefqm71	66	7	provided	provide	VBN
cord-003403-ypefqm71	66	8	for	for	IN
cord-003403-ypefqm71	66	9	the	the	DT
cord-003403-ypefqm71	66	10	use	use	NN
cord-003403-ypefqm71	66	11	and	and	CC
cord-003403-ypefqm71	66	12	interpretation	interpretation	NN
cord-003403-ypefqm71	66	13	of	of	IN
cord-003403-ypefqm71	66	14	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	66	15	IgM	IgM	NNP
cord-003403-ypefqm71	66	16	assays	assay	NNS
cord-003403-ypefqm71	66	17	to	to	TO
cord-003403-ypefqm71	66	18	indicate	indicate	VB
cord-003403-ypefqm71	66	19	recent	recent	JJ
cord-003403-ypefqm71	66	20	exposure	exposure	NN
cord-003403-ypefqm71	66	21	with	with	IN
cord-003403-ypefqm71	66	22	or	or	CC
cord-003403-ypefqm71	66	23	without	without	IN
cord-003403-ypefqm71	66	24	accompanying	accompany	VBG
cord-003403-ypefqm71	66	25	molecular	molecular	JJ
cord-003403-ypefqm71	66	26	test	test	NN
cord-003403-ypefqm71	66	27	results	result	NNS
cord-003403-ypefqm71	66	28	[	[	-LRB-
cord-003403-ypefqm71	66	29	72	72	CD
cord-003403-ypefqm71	66	30	]	]	-RRB-
cord-003403-ypefqm71	66	31	.	.	.
cord-003403-ypefqm71	67	1	In	in	IN
cord-003403-ypefqm71	67	2	July	July	NNP
cord-003403-ypefqm71	67	3	of	of	IN
cord-003403-ypefqm71	67	4	2016	2016	CD
cord-003403-ypefqm71	67	5	,	,	,
cord-003403-ypefqm71	67	6	United	United	NNP
cord-003403-ypefqm71	67	7	States	States	NNP
cord-003403-ypefqm71	67	8	(	(	-LRB-
cord-003403-ypefqm71	67	9	US	US	NNP
cord-003403-ypefqm71	67	10	)	)	-RRB-
cord-003403-ypefqm71	67	11	Health	Health	NNP
cord-003403-ypefqm71	67	12	and	and	CC
cord-003403-ypefqm71	67	13	Human	Human	NNP
cord-003403-ypefqm71	67	14	Services	Services	NNPS
cord-003403-ypefqm71	67	15	(	(	-LRB-
cord-003403-ypefqm71	67	16	HHS	HHS	NNP
cord-003403-ypefqm71	67	17	)	)	-RRB-
cord-003403-ypefqm71	67	18	sponsored	sponsor	VBD
cord-003403-ypefqm71	67	19	a	a	DT
cord-003403-ypefqm71	67	20	HHS	HHS	NNP
cord-003403-ypefqm71	67	21	Summit	Summit	NNP
cord-003403-ypefqm71	67	22	to	to	TO
cord-003403-ypefqm71	67	23	Accelerate	accelerate	VB
cord-003403-ypefqm71	67	24	Zika	Zika	NNP
cord-003403-ypefqm71	67	25	Diagnostics	Diagnostics	NNP
cord-003403-ypefqm71	67	26	Development	Development	NNP
cord-003403-ypefqm71	67	27	,	,	,
cord-003403-ypefqm71	67	28	recognizing	recognize	VBG
cord-003403-ypefqm71	67	29	the	the	DT
cord-003403-ypefqm71	67	30	important	important	JJ
cord-003403-ypefqm71	67	31	need	need	NN
cord-003403-ypefqm71	67	32	.	.	.
cord-003403-ypefqm71	68	1	At	at	IN
cord-003403-ypefqm71	68	2	that	that	DT
cord-003403-ypefqm71	68	3	point	point	NN
cord-003403-ypefqm71	68	4	in	in	IN
cord-003403-ypefqm71	68	5	time	time	NN
cord-003403-ypefqm71	68	6	,	,	,
cord-003403-ypefqm71	68	7	very	very	RB
cord-003403-ypefqm71	68	8	few	few	JJ
cord-003403-ypefqm71	68	9	tests	test	NNS
cord-003403-ypefqm71	68	10	had	have	VBD
cord-003403-ypefqm71	68	11	gained	gain	VBN
cord-003403-ypefqm71	68	12	Emergency	Emergency	NNP
cord-003403-ypefqm71	68	13	Use	Use	NNP
cord-003403-ypefqm71	68	14	Authorization	Authorization	NNP
cord-003403-ypefqm71	68	15	(	(	-LRB-
cord-003403-ypefqm71	68	16	EUA	EUA	NNP
cord-003403-ypefqm71	68	17	)	)	-RRB-
cord-003403-ypefqm71	68	18	from	from	IN
cord-003403-ypefqm71	68	19	the	the	DT
cord-003403-ypefqm71	68	20	Food	Food	NNP
cord-003403-ypefqm71	68	21	and	and	CC
cord-003403-ypefqm71	68	22	Drug	Drug	NNP
cord-003403-ypefqm71	68	23	Administration	Administration	NNP
cord-003403-ypefqm71	68	24	(	(	-LRB-
cord-003403-ypefqm71	68	25	FDA	FDA	NNP
cord-003403-ypefqm71	68	26	)	)	-RRB-
cord-003403-ypefqm71	68	27	.	.	.
cord-003403-ypefqm71	69	1	The	the	DT
cord-003403-ypefqm71	69	2	five	five	CD
cord-003403-ypefqm71	69	3	serological	serological	JJ
cord-003403-ypefqm71	69	4	Zika	Zika	NNP
cord-003403-ypefqm71	69	5	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	69	6	kits	kit	NNS
cord-003403-ypefqm71	69	7	currently	currently	RB
cord-003403-ypefqm71	69	8	authorized	authorize	VBN
cord-003403-ypefqm71	69	9	by	by	IN
cord-003403-ypefqm71	69	10	the	the	DT
cord-003403-ypefqm71	69	11	US	US	NNP
cord-003403-ypefqm71	69	12	FDA	FDA	NNP
cord-003403-ypefqm71	69	13	are	be	VBP
cord-003403-ypefqm71	69	14	shown	show	VBN
cord-003403-ypefqm71	69	15	in	in	IN
cord-003403-ypefqm71	69	16	Table	Table	NNP
cord-003403-ypefqm71	69	17	1	1	CD
cord-003403-ypefqm71	69	18	and	and	CC
cord-003403-ypefqm71	69	19	fourteen	fourteen	CD
cord-003403-ypefqm71	69	20	viral	viral	JJ
cord-003403-ypefqm71	69	21	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	69	22	kits	kit	NNS
cord-003403-ypefqm71	69	23	in	in	IN
cord-003403-ypefqm71	69	24	Table	table	NN
cord-003403-ypefqm71	69	25	2	2	CD
cord-003403-ypefqm71	69	26	[	[	-LRB-
cord-003403-ypefqm71	69	27	73	73	CD
cord-003403-ypefqm71	69	28	]	]	-RRB-
cord-003403-ypefqm71	69	29	.	.	.
cord-003403-ypefqm71	70	1	At	at	IN
cord-003403-ypefqm71	70	2	the	the	DT
cord-003403-ypefqm71	70	3	FDA	FDA	NNP
cord-003403-ypefqm71	70	4	Medical	Medical	NNP
cord-003403-ypefqm71	70	5	Countermeasures	Countermeasures	NNPS
cord-003403-ypefqm71	70	6	webpage	webpage	NN
cord-003403-ypefqm71	70	7	,	,	,
cord-003403-ypefqm71	70	8	links	link	NNS
cord-003403-ypefqm71	70	9	can	can	MD
cord-003403-ypefqm71	70	10	also	also	RB
cord-003403-ypefqm71	70	11	be	be	VB
cord-003403-ypefqm71	70	12	found	find	VBN
cord-003403-ypefqm71	70	13	for	for	IN
cord-003403-ypefqm71	70	14	each	each	DT
cord-003403-ypefqm71	70	15	EUA	EUA	NNP
cord-003403-ypefqm71	70	16	approved	approve	VBD
cord-003403-ypefqm71	70	17	molecular	molecular	JJ
cord-003403-ypefqm71	70	18	assay	assay	NN
cord-003403-ypefqm71	70	19	's	's	POS
cord-003403-ypefqm71	70	20	key	key	JJ
cord-003403-ypefqm71	70	21	[	[	-LRB-
cord-003403-ypefqm71	70	22	74	74	CD
cord-003403-ypefqm71	70	23	]	]	-RRB-
cord-003403-ypefqm71	70	24	and	and	CC
cord-003403-ypefqm71	70	25	performance	performance	NN
cord-003403-ypefqm71	70	26	[	[	-LRB-
cord-003403-ypefqm71	70	27	75	75	CD
cord-003403-ypefqm71	70	28	]	]	-RRB-
cord-003403-ypefqm71	70	29	characteristics	characteristic	NNS
cord-003403-ypefqm71	70	30	including	include	VBG
cord-003403-ypefqm71	70	31	instruments	instrument	NNS
cord-003403-ypefqm71	70	32	approved	approve	VBN
cord-003403-ypefqm71	70	33	for	for	IN
cord-003403-ypefqm71	70	34	use	use	NN
cord-003403-ypefqm71	70	35	and	and	CC
cord-003403-ypefqm71	70	36	limits	limit	NNS
cord-003403-ypefqm71	70	37	of	of	IN
cord-003403-ypefqm71	70	38	detection	detection	NN
cord-003403-ypefqm71	70	39	.	.	.
cord-003403-ypefqm71	71	1	Although	although	IN
cord-003403-ypefqm71	71	2	no	no	DT
cord-003403-ypefqm71	71	3	Zika	Zika	NNP
cord-003403-ypefqm71	71	4	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	71	5	kit	kit	NN
cord-003403-ypefqm71	71	6	,	,	,
cord-003403-ypefqm71	71	7	serological	serological	JJ
cord-003403-ypefqm71	71	8	or	or	CC
cord-003403-ypefqm71	71	9	viral	viral	JJ
cord-003403-ypefqm71	71	10	,	,	,
cord-003403-ypefqm71	71	11	has	have	VBZ
cord-003403-ypefqm71	71	12	been	be	VBN
cord-003403-ypefqm71	71	13	fully	fully	RB
cord-003403-ypefqm71	71	14	approved	approve	VBN
cord-003403-ypefqm71	71	15	by	by	IN
cord-003403-ypefqm71	71	16	the	the	DT
cord-003403-ypefqm71	71	17	FDA	FDA	NNP
cord-003403-ypefqm71	71	18	to	to	IN
cord-003403-ypefqm71	71	19	date	date	NN
cord-003403-ypefqm71	71	20	,	,	,
cord-003403-ypefqm71	71	21	the	the	DT
cord-003403-ypefqm71	71	22	FDA	FDA	NNP
cord-003403-ypefqm71	71	23	has	have	VBZ
cord-003403-ypefqm71	71	24	worked	work	VBN
cord-003403-ypefqm71	71	25	collaboratively	collaboratively	RB
cord-003403-ypefqm71	71	26	with	with	IN
cord-003403-ypefqm71	71	27	developers	developer	NNS
cord-003403-ypefqm71	71	28	to	to	TO
cord-003403-ypefqm71	71	29	accelerate	accelerate	VB
cord-003403-ypefqm71	71	30	both	both	DT
cord-003403-ypefqm71	71	31	EUA	EUA	NNP
cord-003403-ypefqm71	71	32	approvals	approval	NNS
cord-003403-ypefqm71	71	33	and	and	CC
cord-003403-ypefqm71	71	34	the	the	DT
cord-003403-ypefqm71	71	35	transition	transition	NN
cord-003403-ypefqm71	71	36	to	to	IN
cord-003403-ypefqm71	71	37	formal	formal	JJ
cord-003403-ypefqm71	71	38	full	full	JJ
cord-003403-ypefqm71	71	39	approvals	approval	NNS
cord-003403-ypefqm71	71	40	of	of	IN
cord-003403-ypefqm71	71	41	Zika	Zika	NNP
cord-003403-ypefqm71	71	42	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	71	43	kits	kit	NNS
cord-003403-ypefqm71	71	44	using	use	VBG
cord-003403-ypefqm71	71	45	standard	standard	JJ
cord-003403-ypefqm71	71	46	review	review	NN
cord-003403-ypefqm71	71	47	timelines	timeline	NNS
cord-003403-ypefqm71	71	48	[	[	-LRB-
cord-003403-ypefqm71	71	49	76	76	CD
cord-003403-ypefqm71	71	50	]	]	-RRB-
cord-003403-ypefqm71	71	51	.	.	.
cord-003403-ypefqm71	72	1	A	a	DT
cord-003403-ypefqm71	72	2	number	number	NN
cord-003403-ypefqm71	72	3	of	of	IN
cord-003403-ypefqm71	72	4	studies	study	NNS
cord-003403-ypefqm71	72	5	have	have	VBP
cord-003403-ypefqm71	72	6	evaluated	evaluate	VBN
cord-003403-ypefqm71	72	7	the	the	DT
cord-003403-ypefqm71	72	8	various	various	JJ
cord-003403-ypefqm71	72	9	EUA	EUA	NNP
cord-003403-ypefqm71	72	10	tests	test	NNS
cord-003403-ypefqm71	72	11	both	both	DT
cord-003403-ypefqm71	72	12	for	for	IN
cord-003403-ypefqm71	72	13	independent	independent	JJ
cord-003403-ypefqm71	72	14	sensitivity	sensitivity	NN
cord-003403-ypefqm71	72	15	and	and	CC
cord-003403-ypefqm71	72	16	specificity	specificity	NN
cord-003403-ypefqm71	72	17	[	[	-LRB-
cord-003403-ypefqm71	72	18	50	50	CD
cord-003403-ypefqm71	72	19	,	,	,
cord-003403-ypefqm71	72	20	52	52	CD
cord-003403-ypefqm71	72	21	,	,	,
cord-003403-ypefqm71	72	22	54	54	CD
cord-003403-ypefqm71	72	23	,	,	,
cord-003403-ypefqm71	72	24	56	56	CD
cord-003403-ypefqm71	72	25	,	,	,
cord-003403-ypefqm71	72	26	60	60	CD
cord-003403-ypefqm71	72	27	,	,	,
cord-003403-ypefqm71	72	28	61	61	CD
cord-003403-ypefqm71	72	29	,	,	,
cord-003403-ypefqm71	72	30	70	70	CD
cord-003403-ypefqm71	72	31	,	,	,
cord-003403-ypefqm71	72	32	77	77	CD
cord-003403-ypefqm71	72	33	]	]	-RRB-
cord-003403-ypefqm71	72	34	assessments	assessment	NNS
cord-003403-ypefqm71	72	35	of	of	IN
cord-003403-ypefqm71	72	36	assay	assay	NN
cord-003403-ypefqm71	72	37	performance	performance	NN
cord-003403-ypefqm71	72	38	and	and	CC
cord-003403-ypefqm71	72	39	as	as	IN
cord-003403-ypefqm71	72	40	part	part	NN
cord-003403-ypefqm71	72	41	of	of	IN
cord-003403-ypefqm71	72	42	comparative	comparative	JJ
cord-003403-ypefqm71	72	43	studies	study	NNS
cord-003403-ypefqm71	72	44	[	[	-LRB-
cord-003403-ypefqm71	72	45	47	47	CD
cord-003403-ypefqm71	72	46	,	,	,
cord-003403-ypefqm71	72	47	[	[	-LRB-
cord-003403-ypefqm71	72	48	78	78	CD
cord-003403-ypefqm71	72	49	]	]	-RRB-
cord-003403-ypefqm71	72	50	[	[	-LRB-
cord-003403-ypefqm71	72	51	79	79	CD
cord-003403-ypefqm71	72	52	]	]	-RRB-
cord-003403-ypefqm71	72	53	[	[	-LRB-
cord-003403-ypefqm71	72	54	80	80	CD
cord-003403-ypefqm71	72	55	]	]	-RRB-
cord-003403-ypefqm71	72	56	[	[	-LRB-
cord-003403-ypefqm71	72	57	81	81	CD
cord-003403-ypefqm71	72	58	]	]	-RRB-
cord-003403-ypefqm71	72	59	to	to	TO
cord-003403-ypefqm71	72	60	determine	determine	VB
cord-003403-ypefqm71	72	61	those	those	DT
cord-003403-ypefqm71	72	62	best	good	JJS
cord-003403-ypefqm71	72	63	to	to	TO
cord-003403-ypefqm71	72	64	use	use	VB
cord-003403-ypefqm71	72	65	for	for	IN
cord-003403-ypefqm71	72	66	the	the	DT
cord-003403-ypefqm71	72	67	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	72	68	or	or	CC
cord-003403-ypefqm71	72	69	epidemiological	epidemiological	JJ
cord-003403-ypefqm71	72	70	surveillance	surveillance	NN
cord-003403-ypefqm71	72	71	need	need	NN
cord-003403-ypefqm71	72	72	.	.	.
cord-003403-ypefqm71	73	1	A	a	DT
cord-003403-ypefqm71	73	2	large	large	JJ
cord-003403-ypefqm71	73	3	number	number	NN
cord-003403-ypefqm71	73	4	of	of	IN
cord-003403-ypefqm71	73	5	companies	company	NNS
cord-003403-ypefqm71	73	6	have	have	VBP
cord-003403-ypefqm71	73	7	also	also	RB
cord-003403-ypefqm71	73	8	developed	develop	VBN
cord-003403-ypefqm71	73	9	tests	test	NNS
cord-003403-ypefqm71	73	10	that	that	WDT
cord-003403-ypefqm71	73	11	remain	remain	VBP
cord-003403-ypefqm71	73	12	classified	classified	JJ
cord-003403-ypefqm71	73	13	as	as	IN
cord-003403-ypefqm71	73	14	"	"	``
cord-003403-ypefqm71	73	15	Research	Research	NNP
cord-003403-ypefqm71	73	16	Use	Use	NNP
cord-003403-ypefqm71	73	17	Only	only	RB
cord-003403-ypefqm71	73	18	"	"	''
cord-003403-ypefqm71	73	19	(	(	-LRB-
cord-003403-ypefqm71	73	20	RUO	RUO	NNP
cord-003403-ypefqm71	73	21	)	)	-RRB-
cord-003403-ypefqm71	73	22	for	for	IN
cord-003403-ypefqm71	73	23	which	which	WDT
cord-003403-ypefqm71	73	24	emergency	emergency	NN
cord-003403-ypefqm71	73	25	authorizations	authorization	NNS
cord-003403-ypefqm71	73	26	have	have	VBP
cord-003403-ypefqm71	73	27	not	not	RB
cord-003403-ypefqm71	73	28	been	be	VBN
cord-003403-ypefqm71	73	29	granted	grant	VBN
cord-003403-ypefqm71	73	30	.	.	.
cord-003403-ypefqm71	74	1	Other	other	JJ
cord-003403-ypefqm71	74	2	authorizations	authorization	NNS
cord-003403-ypefqm71	74	3	for	for	IN
cord-003403-ypefqm71	74	4	emergency	emergency	NN
cord-003403-ypefqm71	74	5	use	use	NN
cord-003403-ypefqm71	74	6	have	have	VBP
cord-003403-ypefqm71	74	7	been	be	VBN
cord-003403-ypefqm71	74	8	granted	grant	VBN
cord-003403-ypefqm71	74	9	to	to	IN
cord-003403-ypefqm71	74	10	different	different	JJ
cord-003403-ypefqm71	74	11	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	74	12	kits	kit	NNS
cord-003403-ypefqm71	74	13	by	by	IN
cord-003403-ypefqm71	74	14	other	other	JJ
cord-003403-ypefqm71	74	15	agencies	agency	NNS
cord-003403-ypefqm71	74	16	,	,	,
cord-003403-ypefqm71	74	17	such	such	JJ
cord-003403-ypefqm71	74	18	as	as	IN
cord-003403-ypefqm71	74	19	WHO	who	WP
cord-003403-ypefqm71	74	20	's	be	VBZ
cord-003403-ypefqm71	74	21	Emergency	Emergency	NNP
cord-003403-ypefqm71	74	22	Use	Use	NNP
cord-003403-ypefqm71	74	23	Assessment	Assessment	NNP
cord-003403-ypefqm71	74	24	and	and	CC
cord-003403-ypefqm71	74	25	Listing	listing	NN
cord-003403-ypefqm71	74	26	procedures	procedure	NNS
cord-003403-ypefqm71	75	1	(	(	-LRB-
cord-003403-ypefqm71	75	2	EUALs	EUALs	NNP
cord-003403-ypefqm71	75	3	)	)	-RRB-
cord-003403-ypefqm71	76	1	[	[	-LRB-
cord-003403-ypefqm71	76	2	82	82	CD
cord-003403-ypefqm71	76	3	]	]	-RRB-
cord-003403-ypefqm71	76	4	.	.	.
cord-003403-ypefqm71	77	1	While	while	IN
cord-003403-ypefqm71	77	2	many	many	JJ
cord-003403-ypefqm71	77	3	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	77	4	kits	kit	NNS
cord-003403-ypefqm71	77	5	use	use	VBP
cord-003403-ypefqm71	77	6	methods	method	NNS
cord-003403-ypefqm71	77	7	similar	similar	JJ
cord-003403-ypefqm71	77	8	or	or	CC
cord-003403-ypefqm71	77	9	identical	identical	JJ
cord-003403-ypefqm71	77	10	to	to	IN
cord-003403-ypefqm71	77	11	those	those	DT
cord-003403-ypefqm71	77	12	that	that	WDT
cord-003403-ypefqm71	77	13	may	may	MD
cord-003403-ypefqm71	77	14	be	be	VB
cord-003403-ypefqm71	77	15	used	use	VBN
cord-003403-ypefqm71	77	16	to	to	TO
cord-003403-ypefqm71	77	17	support	support	VB
cord-003403-ypefqm71	77	18	a	a	DT
cord-003403-ypefqm71	77	19	vaccine	vaccine	NN
cord-003403-ypefqm71	77	20	clinical	clinical	JJ
cord-003403-ypefqm71	77	21	trial	trial	NN
cord-003403-ypefqm71	77	22	,	,	,
cord-003403-ypefqm71	77	23	often	often	RB
cord-003403-ypefqm71	77	24	they	-PRON-	PRP
cord-003403-ypefqm71	77	25	are	be	VBP
cord-003403-ypefqm71	77	26	focused	focus	VBN
cord-003403-ypefqm71	77	27	more	more	RBR
cord-003403-ypefqm71	77	28	toward	toward	IN
cord-003403-ypefqm71	77	29	the	the	DT
cord-003403-ypefqm71	77	30	support	support	NN
cord-003403-ypefqm71	77	31	of	of	IN
cord-003403-ypefqm71	77	32	a	a	DT
cord-003403-ypefqm71	77	33	clinical	clinical	JJ
cord-003403-ypefqm71	77	34	patient	patient	NN
cord-003403-ypefqm71	77	35	diagnosis	diagnosis	NN
cord-003403-ypefqm71	77	36	and	and	CC
cord-003403-ypefqm71	77	37	may	may	MD
cord-003403-ypefqm71	77	38	not	not	RB
cord-003403-ypefqm71	77	39	be	be	VB
cord-003403-ypefqm71	77	40	sensitive	sensitive	JJ
cord-003403-ypefqm71	77	41	enough	enough	RB
cord-003403-ypefqm71	77	42	for	for	IN
cord-003403-ypefqm71	77	43	use	use	NN
cord-003403-ypefqm71	77	44	to	to	TO
cord-003403-ypefqm71	77	45	support	support	VB
cord-003403-ypefqm71	77	46	vaccine	vaccine	NN
cord-003403-ypefqm71	77	47	development	development	NN
cord-003403-ypefqm71	77	48	.	.	.
cord-003403-ypefqm71	78	1	Often	often	RB
cord-003403-ypefqm71	78	2	there	there	EX
cord-003403-ypefqm71	78	3	is	be	VBZ
cord-003403-ypefqm71	78	4	not	not	RB
cord-003403-ypefqm71	78	5	enough	enough	JJ
cord-003403-ypefqm71	78	6	data	datum	NNS
cord-003403-ypefqm71	78	7	at	at	IN
cord-003403-ypefqm71	78	8	the	the	DT
cord-003403-ypefqm71	78	9	outset	outset	NN
cord-003403-ypefqm71	78	10	of	of	IN
cord-003403-ypefqm71	78	11	a	a	DT
cord-003403-ypefqm71	78	12	vaccine	vaccine	NN
cord-003403-ypefqm71	78	13	program	program	NN
cord-003403-ypefqm71	78	14	,	,	,
cord-003403-ypefqm71	78	15	but	but	CC
cord-003403-ypefqm71	78	16	especially	especially	RB
cord-003403-ypefqm71	78	17	in	in	IN
cord-003403-ypefqm71	78	18	the	the	DT
cord-003403-ypefqm71	78	19	case	case	NN
cord-003403-ypefqm71	78	20	of	of	IN
cord-003403-ypefqm71	78	21	emerging	emerge	VBG
cord-003403-ypefqm71	78	22	infectious	infectious	JJ
cord-003403-ypefqm71	78	23	diseases	disease	NNS
cord-003403-ypefqm71	78	24	,	,	,
cord-003403-ypefqm71	78	25	to	to	TO
cord-003403-ypefqm71	78	26	understand	understand	VB
cord-003403-ypefqm71	78	27	what	what	WP
cord-003403-ypefqm71	78	28	assays	assay	NNS
cord-003403-ypefqm71	78	29	will	will	MD
cord-003403-ypefqm71	78	30	be	be	VB
cord-003403-ypefqm71	78	31	most	most	RBS
cord-003403-ypefqm71	78	32	useful	useful	JJ
cord-003403-ypefqm71	78	33	or	or	CC
cord-003403-ypefqm71	78	34	informative	informative	JJ
cord-003403-ypefqm71	78	35	or	or	CC
cord-003403-ypefqm71	78	36	will	will	MD
cord-003403-ypefqm71	78	37	perhaps	perhaps	RB
cord-003403-ypefqm71	78	38	even	even	RB
cord-003403-ypefqm71	78	39	provide	provide	VB
cord-003403-ypefqm71	78	40	a	a	DT
cord-003403-ypefqm71	78	41	correlate	correlate	NN
cord-003403-ypefqm71	78	42	of	of	IN
cord-003403-ypefqm71	78	43	protection	protection	NN
cord-003403-ypefqm71	78	44	for	for	IN
cord-003403-ypefqm71	78	45	the	the	DT
cord-003403-ypefqm71	78	46	vaccine	vaccine	NN
cord-003403-ypefqm71	78	47	into	into	IN
cord-003403-ypefqm71	78	48	the	the	DT
cord-003403-ypefqm71	78	49	future	future	NN
cord-003403-ypefqm71	78	50	.	.	.
cord-003403-ypefqm71	79	1	A	a	DT
cord-003403-ypefqm71	79	2	few	few	JJ
cord-003403-ypefqm71	79	3	general	general	JJ
cord-003403-ypefqm71	79	4	assumptions	assumption	NNS
cord-003403-ypefqm71	79	5	can	can	MD
cord-003403-ypefqm71	79	6	be	be	VB
cord-003403-ypefqm71	79	7	made	make	VBN
cord-003403-ypefqm71	79	8	at	at	IN
cord-003403-ypefqm71	79	9	the	the	DT
cord-003403-ypefqm71	79	10	outset	outset	NN
cord-003403-ypefqm71	79	11	about	about	IN
cord-003403-ypefqm71	79	12	which	which	WDT
cord-003403-ypefqm71	79	13	types	type	NNS
cord-003403-ypefqm71	79	14	of	of	IN
cord-003403-ypefqm71	79	15	assays	assay	NNS
cord-003403-ypefqm71	79	16	will	will	MD
cord-003403-ypefqm71	79	17	be	be	VB
cord-003403-ypefqm71	79	18	needed	need	VBN
cord-003403-ypefqm71	79	19	to	to	TO
cord-003403-ypefqm71	79	20	detect	detect	VB
cord-003403-ypefqm71	79	21	vaccine	vaccine	NN
cord-003403-ypefqm71	79	22	-	-	HYPH
cord-003403-ypefqm71	79	23	induced	induce	VBN
cord-003403-ypefqm71	79	24	humoral	humoral	JJ
cord-003403-ypefqm71	79	25	and	and	CC
cord-003403-ypefqm71	79	26	cellular	cellular	JJ
cord-003403-ypefqm71	79	27	immune	immune	JJ
cord-003403-ypefqm71	79	28	responses	response	NNS
cord-003403-ypefqm71	79	29	and	and	CC
cord-003403-ypefqm71	79	30	these	these	DT
cord-003403-ypefqm71	79	31	will	will	MD
cord-003403-ypefqm71	79	32	evolve	evolve	VB
cord-003403-ypefqm71	79	33	over	over	IN
cord-003403-ypefqm71	79	34	time	time	NN
cord-003403-ypefqm71	79	35	.	.	.
cord-003403-ypefqm71	80	1	The	the	DT
cord-003403-ypefqm71	80	2	typical	typical	JJ
cord-003403-ypefqm71	80	3	go	go	NN
cord-003403-ypefqm71	80	4	-	-	HYPH
cord-003403-ypefqm71	80	5	to	to	NN
cord-003403-ypefqm71	80	6	methods	method	NNS
cord-003403-ypefqm71	80	7	used	use	VBN
cord-003403-ypefqm71	80	8	for	for	IN
cord-003403-ypefqm71	80	9	vaccine	vaccine	NN
cord-003403-ypefqm71	80	10	clinical	clinical	JJ
cord-003403-ypefqm71	80	11	assays	assay	NNS
cord-003403-ypefqm71	80	12	are	be	VBP
cord-003403-ypefqm71	80	13	:	:	:
cord-003403-ypefqm71	80	14	antibody	antibody	NN
cord-003403-ypefqm71	80	15	binding	binding	NN
cord-003403-ypefqm71	80	16	-	-	HYPH
cord-003403-ypefqm71	80	17	enzyme	enzyme	NN
cord-003403-ypefqm71	80	18	-	-	HYPH
cord-003403-ypefqm71	80	19	linked	link	VBN
cord-003403-ypefqm71	80	20	immunosorbent	immunosorbent	JJ
cord-003403-ypefqm71	80	21	assays	assay	NNS
cord-003403-ypefqm71	80	22	(	(	-LRB-
cord-003403-ypefqm71	80	23	ELISA	ELISA	NNP
cord-003403-ypefqm71	80	24	)	)	-RRB-
cord-003403-ypefqm71	80	25	;	;	,
cord-003403-ypefqm71	80	26	functional	functional	JJ
cord-003403-ypefqm71	80	27	-	-	HYPH
cord-003403-ypefqm71	80	28	virus	virus	NN
cord-003403-ypefqm71	80	29	neutralization	neutralization	NN
cord-003403-ypefqm71	80	30	or	or	CC
cord-003403-ypefqm71	80	31	bactericidal	bactericidal	JJ
cord-003403-ypefqm71	80	32	;	;	:
cord-003403-ypefqm71	80	33	cellular	cellular	JJ
cord-003403-ypefqm71	80	34	-	-	HYPH
cord-003403-ypefqm71	80	35	interferon	interferon	NN
cord-003403-ypefqm71	80	36	gamma	gamma	NN
cord-003403-ypefqm71	80	37	enzyme	enzyme	NN
cord-003403-ypefqm71	80	38	-	-	HYPH
cord-003403-ypefqm71	80	39	linked	link	VBN
cord-003403-ypefqm71	80	40	immunospot	immunospot	NN
cord-003403-ypefqm71	80	41	assay	assay	NN
cord-003403-ypefqm71	80	42	(	(	-LRB-
cord-003403-ypefqm71	80	43	IFNγ	ifnγ	NN
cord-003403-ypefqm71	80	44	-	-	HYPH
cord-003403-ypefqm71	80	45	ELISpot	elispot	NN
cord-003403-ypefqm71	80	46	)	)	-RRB-
cord-003403-ypefqm71	80	47	using	use	VBG
cord-003403-ypefqm71	80	48	the	the	DT
cord-003403-ypefqm71	80	49	target	target	NN
cord-003403-ypefqm71	80	50	antigen	antigen	NN
cord-003403-ypefqm71	80	51	or	or	CC
cord-003403-ypefqm71	80	52	antigen	antigen	NN
cord-003403-ypefqm71	80	53	-	-	HYPH
cord-003403-ypefqm71	80	54	derived	derive	VBN
cord-003403-ypefqm71	80	55	peptide	peptide	NN
cord-003403-ypefqm71	80	56	pools	pool	NNS
cord-003403-ypefqm71	80	57	;	;	:
cord-003403-ypefqm71	80	58	and	and	CC
cord-003403-ypefqm71	80	59	molecular	molecular	JJ
cord-003403-ypefqm71	80	60	or	or	CC
cord-003403-ypefqm71	80	61	culture	culture	NN
cord-003403-ypefqm71	80	62	methods	method	NNS
cord-003403-ypefqm71	80	63	to	to	TO
cord-003403-ypefqm71	80	64	detect	detect	VB
cord-003403-ypefqm71	80	65	the	the	DT
cord-003403-ypefqm71	80	66	pathogen	pathogen	NN
cord-003403-ypefqm71	80	67	.	.	.
cord-003403-ypefqm71	81	1	The	the	DT
cord-003403-ypefqm71	81	2	technologies	technology	NNS
cord-003403-ypefqm71	81	3	used	use	VBN
cord-003403-ypefqm71	81	4	to	to	TO
cord-003403-ypefqm71	81	5	develop	develop	VB
cord-003403-ypefqm71	81	6	and	and	CC
cord-003403-ypefqm71	81	7	run	run	VB
cord-003403-ypefqm71	81	8	these	these	DT
cord-003403-ypefqm71	81	9	assays	assay	NNS
cord-003403-ypefqm71	81	10	have	have	VBP
cord-003403-ypefqm71	81	11	improved	improve	VBN
cord-003403-ypefqm71	81	12	over	over	IN
cord-003403-ypefqm71	81	13	the	the	DT
cord-003403-ypefqm71	81	14	years	year	NNS
cord-003403-ypefqm71	81	15	to	to	TO
cord-003403-ypefqm71	81	16	allow	allow	VB
cord-003403-ypefqm71	81	17	for	for	IN
cord-003403-ypefqm71	81	18	higher	high	JJR
cord-003403-ypefqm71	81	19	throughput	throughput	NN
cord-003403-ypefqm71	81	20	,	,	,
cord-003403-ypefqm71	81	21	multiplexing	multiplexing	NN
cord-003403-ypefqm71	81	22	,	,	,
cord-003403-ypefqm71	81	23	reduced	reduce	VBN
cord-003403-ypefqm71	81	24	sample	sample	NN
cord-003403-ypefqm71	81	25	volumes	volume	NNS
cord-003403-ypefqm71	81	26	,	,	,
cord-003403-ypefqm71	81	27	and	and	CC
cord-003403-ypefqm71	81	28	automation	automation	NN
cord-003403-ypefqm71	81	29	.	.	.
cord-003403-ypefqm71	82	1	Often	often	RB
cord-003403-ypefqm71	82	2	,	,	,
cord-003403-ypefqm71	82	3	more	more	JJR
cord-003403-ypefqm71	82	4	tests	test	NNS
cord-003403-ypefqm71	82	5	of	of	IN
cord-003403-ypefqm71	82	6	a	a	DT
cord-003403-ypefqm71	82	7	larger	large	JJR
cord-003403-ypefqm71	82	8	variety	variety	NN
cord-003403-ypefqm71	82	9	are	be	VBP
cord-003403-ypefqm71	82	10	done	do	VBN
cord-003403-ypefqm71	82	11	early	early	RB
cord-003403-ypefqm71	82	12	in	in	IN
cord-003403-ypefqm71	82	13	a	a	DT
cord-003403-ypefqm71	82	14	program	program	NN
cord-003403-ypefqm71	82	15	and	and	CC
cord-003403-ypefqm71	82	16	are	be	VBP
cord-003403-ypefqm71	82	17	then	then	RB
cord-003403-ypefqm71	82	18	whittled	whittle	VBN
cord-003403-ypefqm71	82	19	down	down	RP
cord-003403-ypefqm71	82	20	based	base	VBN
cord-003403-ypefqm71	82	21	on	on	IN
cord-003403-ypefqm71	82	22	the	the	DT
cord-003403-ypefqm71	82	23	usefulness	usefulness	NN
cord-003403-ypefqm71	82	24	of	of	IN
cord-003403-ypefqm71	82	25	the	the	DT
cord-003403-ypefqm71	82	26	data	datum	NNS
cord-003403-ypefqm71	82	27	generated	generate	VBN
cord-003403-ypefqm71	82	28	so	so	IN
cord-003403-ypefqm71	82	29	that	that	IN
cord-003403-ypefqm71	82	30	just	just	RB
cord-003403-ypefqm71	82	31	the	the	DT
cord-003403-ypefqm71	82	32	relevant	relevant	JJ
cord-003403-ypefqm71	82	33	few	few	JJ
cord-003403-ypefqm71	82	34	remain	remain	VBP
cord-003403-ypefqm71	82	35	to	to	TO
cord-003403-ypefqm71	82	36	support	support	VB
cord-003403-ypefqm71	82	37	large	large	JJ
cord-003403-ypefqm71	82	38	trials	trial	NNS
cord-003403-ypefqm71	82	39	and	and	CC
cord-003403-ypefqm71	82	40	licensure	licensure	NN
cord-003403-ypefqm71	82	41	[	[	-LRB-
cord-003403-ypefqm71	82	42	4	4	CD
cord-003403-ypefqm71	82	43	]	]	-RRB-
cord-003403-ypefqm71	82	44	.	.	.
cord-003403-ypefqm71	83	1	When	when	WRB
cord-003403-ypefqm71	83	2	the	the	DT
cord-003403-ypefqm71	83	3	first	first	JJ
cord-003403-ypefqm71	83	4	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	83	5	vaccine	vaccine	NN
cord-003403-ypefqm71	83	6	trials	trial	NNS
cord-003403-ypefqm71	83	7	commenced	commence	VBN
cord-003403-ypefqm71	83	8	in	in	IN
cord-003403-ypefqm71	83	9	late	late	JJ
cord-003403-ypefqm71	83	10	summer	summer	NN
cord-003403-ypefqm71	83	11	of	of	IN
cord-003403-ypefqm71	83	12	2016	2016	CD
cord-003403-ypefqm71	83	13	,	,	,
cord-003403-ypefqm71	83	14	even	even	RB
cord-003403-ypefqm71	83	15	though	though	IN
cord-003403-ypefqm71	83	16	a	a	DT
cord-003403-ypefqm71	83	17	few	few	JJ
cord-003403-ypefqm71	83	18	Zika	Zika	NNP
cord-003403-ypefqm71	83	19	diagnostics	diagnostic	NNS
cord-003403-ypefqm71	83	20	had	have	VBD
cord-003403-ypefqm71	83	21	achieved	achieve	VBN
cord-003403-ypefqm71	83	22	EUA	EUA	NNP
cord-003403-ypefqm71	83	23	status	status	NN
cord-003403-ypefqm71	83	24	,	,	,
cord-003403-ypefqm71	83	25	none	none	NN
cord-003403-ypefqm71	83	26	were	be	VBD
cord-003403-ypefqm71	83	27	commercially	commercially	RB
cord-003403-ypefqm71	83	28	available	available	JJ
cord-003403-ypefqm71	83	29	and	and	CC
cord-003403-ypefqm71	83	30	were	be	VBD
cord-003403-ypefqm71	83	31	initially	initially	RB
cord-003403-ypefqm71	83	32	restricted	restrict	VBN
cord-003403-ypefqm71	83	33	to	to	IN
cord-003403-ypefqm71	83	34	public	public	JJ
cord-003403-ypefqm71	83	35	health	health	NN
cord-003403-ypefqm71	83	36	use	use	NN
cord-003403-ypefqm71	83	37	only	only	RB
cord-003403-ypefqm71	83	38	.	.	.
cord-003403-ypefqm71	84	1	Challenges	challenge	NNS
cord-003403-ypefqm71	84	2	to	to	TO
cord-003403-ypefqm71	84	3	vaccine	vaccine	NN
cord-003403-ypefqm71	84	4	development	development	NN
cord-003403-ypefqm71	84	5	centered	center	VBN
cord-003403-ypefqm71	84	6	around	around	IN
cord-003403-ypefqm71	84	7	the	the	DT
cord-003403-ypefqm71	84	8	determination	determination	NN
cord-003403-ypefqm71	84	9	of	of	IN
cord-003403-ypefqm71	84	10	prior	prior	JJ
cord-003403-ypefqm71	84	11	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	84	12	exposure	exposure	NN
cord-003403-ypefqm71	84	13	and	and	CC
cord-003403-ypefqm71	84	14	immunity	immunity	NN
cord-003403-ypefqm71	84	15	and	and	CC
cord-003403-ypefqm71	84	16	determination	determination	NN
cord-003403-ypefqm71	84	17	of	of	IN
cord-003403-ypefqm71	84	18	incident	incident	NN
cord-003403-ypefqm71	84	19	infection	infection	NN
cord-003403-ypefqm71	84	20	among	among	IN
cord-003403-ypefqm71	84	21	study	study	NN
cord-003403-ypefqm71	84	22	participants	participant	NNS
cord-003403-ypefqm71	84	23	.	.	.
cord-003403-ypefqm71	85	1	Each	each	DT
cord-003403-ypefqm71	85	2	of	of	IN
cord-003403-ypefqm71	85	3	the	the	DT
cord-003403-ypefqm71	85	4	serological	serological	JJ
cord-003403-ypefqm71	85	5	assays	assay	NNS
cord-003403-ypefqm71	85	6	listed	list	VBN
cord-003403-ypefqm71	85	7	in	in	IN
cord-003403-ypefqm71	85	8	Table	Table	NNP
cord-003403-ypefqm71	85	9	1	1	CD
cord-003403-ypefqm71	85	10	detect	detect	VBP
cord-003403-ypefqm71	85	11	IgM	IgM	NNP
cord-003403-ypefqm71	85	12	reflective	reflective	JJ
cord-003403-ypefqm71	85	13	of	of	IN
cord-003403-ypefqm71	85	14	recent	recent	JJ
cord-003403-ypefqm71	85	15	infection	infection	NN
cord-003403-ypefqm71	85	16	,	,	,
cord-003403-ypefqm71	85	17	however	however	RB
cord-003403-ypefqm71	85	18	many	many	JJ
cord-003403-ypefqm71	85	19	,	,	,
cord-003403-ypefqm71	85	20	such	such	JJ
cord-003403-ypefqm71	85	21	as	as	IN
cord-003403-ypefqm71	85	22	the	the	DT
cord-003403-ypefqm71	85	23	MAC	MAC	NNP
cord-003403-ypefqm71	85	24	-	-	HYPH
cord-003403-ypefqm71	85	25	ELISA	ELISA	NNP
cord-003403-ypefqm71	85	26	and	and	CC
cord-003403-ypefqm71	85	27	the	the	DT
cord-003403-ypefqm71	85	28	InBios	InBios	NNP
cord-003403-ypefqm71	85	29	assay	assay	NN
cord-003403-ypefqm71	85	30	,	,	,
cord-003403-ypefqm71	85	31	will	will	MD
cord-003403-ypefqm71	85	32	detect	detect	VB
cord-003403-ypefqm71	85	33	IgM	IgM	NNP
cord-003403-ypefqm71	85	34	against	against	IN
cord-003403-ypefqm71	85	35	the	the	DT
cord-003403-ypefqm71	85	36	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	85	37	envelope	envelope	NN
cord-003403-ypefqm71	85	38	which	which	WDT
cord-003403-ypefqm71	85	39	is	be	VBZ
cord-003403-ypefqm71	85	40	the	the	DT
cord-003403-ypefqm71	85	41	target	target	NN
cord-003403-ypefqm71	85	42	antigen	antigen	NN
cord-003403-ypefqm71	85	43	for	for	IN
cord-003403-ypefqm71	85	44	many	many	JJ
cord-003403-ypefqm71	85	45	vaccines	vaccine	NNS
cord-003403-ypefqm71	85	46	.	.	.
cord-003403-ypefqm71	86	1	IgG	IgG	NNP
cord-003403-ypefqm71	86	2	-	-	HYPH
cord-003403-ypefqm71	86	3	based	base	VBN
cord-003403-ypefqm71	86	4	assays	assay	NNS
cord-003403-ypefqm71	86	5	have	have	VBP
cord-003403-ypefqm71	86	6	not	not	RB
cord-003403-ypefqm71	86	7	yet	yet	RB
cord-003403-ypefqm71	86	8	been	be	VBN
cord-003403-ypefqm71	86	9	validated	validate	VBN
cord-003403-ypefqm71	86	10	primarily	primarily	RB
cord-003403-ypefqm71	86	11	due	due	JJ
cord-003403-ypefqm71	86	12	to	to	IN
cord-003403-ypefqm71	86	13	cross	cross	NN
cord-003403-ypefqm71	86	14	-	-	NN
cord-003403-ypefqm71	86	15	reactivity	reactivity	NN
cord-003403-ypefqm71	86	16	between	between	IN
cord-003403-ypefqm71	86	17	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	86	18	and	and	CC
cord-003403-ypefqm71	86	19	other	other	JJ
cord-003403-ypefqm71	86	20	flaviviruses	flavivirus	NNS
cord-003403-ypefqm71	86	21	,	,	,
cord-003403-ypefqm71	86	22	principally	principally	RB
cord-003403-ypefqm71	86	23	dengue	dengue	NN
cord-003403-ypefqm71	86	24	.	.	.
cord-003403-ypefqm71	87	1	IgM	IgM	NNP
cord-003403-ypefqm71	87	2	immunoassays	immunoassays	NNP
cord-003403-ypefqm71	87	3	targeted	target	VBD
cord-003403-ypefqm71	87	4	to	to	IN
cord-003403-ypefqm71	87	5	the	the	DT
cord-003403-ypefqm71	87	6	NS1	ns1	NN
cord-003403-ypefqm71	87	7	antigen	antigen	NN
cord-003403-ypefqm71	87	8	are	be	VBP
cord-003403-ypefqm71	87	9	generally	generally	RB
cord-003403-ypefqm71	87	10	more	more	RBR
cord-003403-ypefqm71	87	11	specific	specific	JJ
cord-003403-ypefqm71	87	12	than	than	IN
cord-003403-ypefqm71	87	13	those	those	DT
cord-003403-ypefqm71	87	14	directed	direct	VBN
cord-003403-ypefqm71	87	15	to	to	IN
cord-003403-ypefqm71	87	16	the	the	DT
cord-003403-ypefqm71	87	17	viral	viral	JJ
cord-003403-ypefqm71	87	18	envelope	envelope	NN
cord-003403-ypefqm71	87	19	[	[	-LRB-
cord-003403-ypefqm71	87	20	47	47	CD
cord-003403-ypefqm71	87	21	]	]	-RRB-
cord-003403-ypefqm71	87	22	.	.	.
cord-003403-ypefqm71	88	1	In	in	IN
cord-003403-ypefqm71	88	2	September	September	NNP
cord-003403-ypefqm71	88	3	2016	2016	CD
cord-003403-ypefqm71	88	4	,	,	,
cord-003403-ypefqm71	88	5	we	-PRON-	PRP
cord-003403-ypefqm71	88	6	initiated	initiate	VBD
cord-003403-ypefqm71	88	7	the	the	DT
cord-003403-ypefqm71	88	8	first	first	JJ
cord-003403-ypefqm71	88	9	clinical	clinical	JJ
cord-003403-ypefqm71	88	10	trial	trial	NN
cord-003403-ypefqm71	88	11	of	of	IN
cord-003403-ypefqm71	88	12	the	the	DT
cord-003403-ypefqm71	88	13	GLS-5700	GLS-5700	NNP
cord-003403-ypefqm71	88	14	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	88	15	DNA	dna	NN
cord-003403-ypefqm71	88	16	vaccine	vaccine	NN
cord-003403-ypefqm71	88	17	in	in	IN
cord-003403-ypefqm71	88	18	an	an	DT
cord-003403-ypefqm71	88	19	endemic	endemic	JJ
cord-003403-ypefqm71	88	20	region	region	NN
cord-003403-ypefqm71	88	21	,	,	,
cord-003403-ypefqm71	88	22	Puerto	Puerto	NNP
cord-003403-ypefqm71	88	23	Rico	Rico	NNP
cord-003403-ypefqm71	88	24	,	,	,
cord-003403-ypefqm71	88	25	an	an	DT
cord-003403-ypefqm71	88	26	area	area	NN
cord-003403-ypefqm71	88	27	also	also	RB
cord-003403-ypefqm71	88	28	known	know	VBN
cord-003403-ypefqm71	88	29	to	to	TO
cord-003403-ypefqm71	88	30	have	have	VB
cord-003403-ypefqm71	88	31	high	high	JJ
cord-003403-ypefqm71	88	32	rates	rate	NNS
cord-003403-ypefqm71	88	33	of	of	IN
cord-003403-ypefqm71	88	34	exposure	exposure	NN
cord-003403-ypefqm71	88	35	to	to	IN
cord-003403-ypefqm71	88	36	dengue	dengue	NN
cord-003403-ypefqm71	88	37	.	.	.
cord-003403-ypefqm71	89	1	Because	because	IN
cord-003403-ypefqm71	89	2	no	no	DT
cord-003403-ypefqm71	89	3	widely	widely	RB
cord-003403-ypefqm71	89	4	accepted	accept	VBN
cord-003403-ypefqm71	89	5	standardized	standardized	JJ
cord-003403-ypefqm71	89	6	assays	assay	NNS
cord-003403-ypefqm71	89	7	nor	nor	CC
cord-003403-ypefqm71	89	8	any	any	DT
cord-003403-ypefqm71	89	9	international	international	JJ
cord-003403-ypefqm71	89	10	reference	reference	NN
cord-003403-ypefqm71	89	11	standards	standard	NNS
cord-003403-ypefqm71	89	12	or	or	CC
cord-003403-ypefqm71	89	13	reagents	reagent	NNS
cord-003403-ypefqm71	89	14	existed	exist	VBD
cord-003403-ypefqm71	89	15	at	at	IN
cord-003403-ypefqm71	89	16	the	the	DT
cord-003403-ypefqm71	89	17	time	time	NN
cord-003403-ypefqm71	89	18	of	of	IN
cord-003403-ypefqm71	89	19	trial	trial	NN
cord-003403-ypefqm71	89	20	initiation	initiation	NN
cord-003403-ypefqm71	89	21	,	,	,
cord-003403-ypefqm71	89	22	individual	individual	JJ
cord-003403-ypefqm71	89	23	vaccine	vaccine	NN
cord-003403-ypefqm71	89	24	projects	project	NNS
cord-003403-ypefqm71	89	25	needed	need	VBN
cord-003403-ypefqm71	89	26	to	to	TO
cord-003403-ypefqm71	89	27	rely	rely	VB
cord-003403-ypefqm71	89	28	on	on	IN
cord-003403-ypefqm71	89	29	internally	internally	RB
cord-003403-ypefqm71	89	30	developed	develop	VBN
cord-003403-ypefqm71	89	31	clinical	clinical	JJ
cord-003403-ypefqm71	89	32	assays	assay	NNS
cord-003403-ypefqm71	89	33	to	to	TO
cord-003403-ypefqm71	89	34	understand	understand	VB
cord-003403-ypefqm71	89	35	prior	prior	JJ
cord-003403-ypefqm71	89	36	exposure	exposure	NN
cord-003403-ypefqm71	89	37	and	and	CC
cord-003403-ypefqm71	89	38	vaccine	vaccine	NN
cord-003403-ypefqm71	89	39	related	relate	VBN
cord-003403-ypefqm71	89	40	immune	immune	JJ
cord-003403-ypefqm71	89	41	responses	response	NNS
cord-003403-ypefqm71	89	42	.	.	.
cord-003403-ypefqm71	90	1	Similar	similar	JJ
cord-003403-ypefqm71	90	2	to	to	TO
cord-003403-ypefqm71	90	3	patient	patient	VB
cord-003403-ypefqm71	90	4	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	90	5	tests	test	NNS
cord-003403-ypefqm71	90	6	for	for	IN
cord-003403-ypefqm71	90	7	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	90	8	and	and	CC
cord-003403-ypefqm71	90	9	as	as	IN
cord-003403-ypefqm71	90	10	mentioned	mention	VBN
cord-003403-ypefqm71	90	11	above	above	RB
cord-003403-ypefqm71	90	12	,	,	,
cord-003403-ypefqm71	90	13	there	there	EX
cord-003403-ypefqm71	90	14	was	be	VBD
cord-003403-ypefqm71	90	15	no	no	DT
cord-003403-ypefqm71	90	16	accepted	accepted	JJ
cord-003403-ypefqm71	90	17	"	"	``
cord-003403-ypefqm71	90	18	gold	gold	NN
cord-003403-ypefqm71	90	19	standard	standard	NN
cord-003403-ypefqm71	90	20	"	"	''
cord-003403-ypefqm71	90	21	for	for	IN
cord-003403-ypefqm71	90	22	any	any	DT
cord-003403-ypefqm71	90	23	of	of	IN
cord-003403-ypefqm71	90	24	the	the	DT
cord-003403-ypefqm71	90	25	immunoassays	immunoassay	NNS
cord-003403-ypefqm71	91	1	one	one	PRP
cord-003403-ypefqm71	91	2	might	may	MD
cord-003403-ypefqm71	91	3	choose	choose	VB
cord-003403-ypefqm71	91	4	to	to	TO
cord-003403-ypefqm71	91	5	develop	develop	VB
cord-003403-ypefqm71	91	6	or	or	CC
cord-003403-ypefqm71	91	7	use	use	VB
cord-003403-ypefqm71	91	8	in	in	IN
cord-003403-ypefqm71	91	9	a	a	DT
cord-003403-ypefqm71	91	10	vaccine	vaccine	NN
cord-003403-ypefqm71	91	11	program	program	NN
cord-003403-ypefqm71	91	12	.	.	.
cord-003403-ypefqm71	92	1	The	the	DT
cord-003403-ypefqm71	92	2	extensive	extensive	JJ
cord-003403-ypefqm71	92	3	experience	experience	NN
cord-003403-ypefqm71	92	4	of	of	IN
cord-003403-ypefqm71	92	5	our	-PRON-	PRP$
cord-003403-ypefqm71	92	6	collaborative	collaborative	JJ
cord-003403-ypefqm71	92	7	DNA	dna	NN
cord-003403-ypefqm71	92	8	vaccine	vaccine	NN
cord-003403-ypefqm71	92	9	team	team	NN
cord-003403-ypefqm71	92	10	allowed	allow	VBD
cord-003403-ypefqm71	92	11	us	-PRON-	PRP
cord-003403-ypefqm71	92	12	to	to	TO
cord-003403-ypefqm71	92	13	develop	develop	VB
cord-003403-ypefqm71	92	14	ZIKV	zikv	NN
cord-003403-ypefqm71	92	15	-	-	HYPH
cord-003403-ypefqm71	92	16	specific	specific	JJ
cord-003403-ypefqm71	92	17	tests	test	NNS
cord-003403-ypefqm71	92	18	such	such	JJ
cord-003403-ypefqm71	92	19	as	as	IN
cord-003403-ypefqm71	92	20	ELISA	ELISA	NNP
cord-003403-ypefqm71	92	21	,	,	,
cord-003403-ypefqm71	92	22	virus	virus	NN
cord-003403-ypefqm71	92	23	microneutralization	microneutralization	NN
cord-003403-ypefqm71	92	24	and	and	CC
cord-003403-ypefqm71	92	25	ELISpot	elispot	NN
cord-003403-ypefqm71	92	26	around	around	IN
cord-003403-ypefqm71	92	27	the	the	DT
cord-003403-ypefqm71	92	28	development	development	NN
cord-003403-ypefqm71	92	29	and	and	CC
cord-003403-ypefqm71	92	30	pre	pre	JJ
cord-003403-ypefqm71	92	31	-	-	JJ
cord-003403-ypefqm71	92	32	clinical	clinical	JJ
cord-003403-ypefqm71	92	33	testing	testing	NN
cord-003403-ypefqm71	92	34	of	of	IN
cord-003403-ypefqm71	92	35	our	-PRON-	PRP$
cord-003403-ypefqm71	92	36	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	92	37	plasmid	plasmid	NN
cord-003403-ypefqm71	92	38	DNA	dna	NN
cord-003403-ypefqm71	92	39	vaccine	vaccine	NN
cord-003403-ypefqm71	92	40	constructs	construct	VBZ
cord-003403-ypefqm71	92	41	[	[	-LRB-
cord-003403-ypefqm71	92	42	1	1	CD
cord-003403-ypefqm71	92	43	,	,	,
cord-003403-ypefqm71	92	44	2	2	CD
cord-003403-ypefqm71	92	45	,	,	,
cord-003403-ypefqm71	92	46	83	83	CD
cord-003403-ypefqm71	92	47	,	,	,
cord-003403-ypefqm71	92	48	84	84	CD
cord-003403-ypefqm71	92	49	]	]	-RRB-
cord-003403-ypefqm71	92	50	.	.	.
cord-003403-ypefqm71	93	1	These	these	DT
cord-003403-ypefqm71	93	2	assays	assay	NNS
cord-003403-ypefqm71	93	3	performed	perform	VBD
cord-003403-ypefqm71	93	4	consistently	consistently	RB
cord-003403-ypefqm71	93	5	on	on	IN
cord-003403-ypefqm71	93	6	a	a	DT
cord-003403-ypefqm71	93	7	pre	pre	JJ
cord-003403-ypefqm71	93	8	-	-	JJ
cord-003403-ypefqm71	93	9	clinical	clinical	JJ
cord-003403-ypefqm71	93	10	scale	scale	NN
cord-003403-ypefqm71	93	11	and	and	CC
cord-003403-ypefqm71	93	12	we	-PRON-	PRP
cord-003403-ypefqm71	93	13	were	be	VBD
cord-003403-ypefqm71	93	14	able	able	JJ
cord-003403-ypefqm71	93	15	to	to	TO
cord-003403-ypefqm71	93	16	quickly	quickly	RB
cord-003403-ypefqm71	93	17	expand	expand	VB
cord-003403-ypefqm71	93	18	their	-PRON-	PRP$
cord-003403-ypefqm71	93	19	use	use	NN
cord-003403-ypefqm71	93	20	to	to	TO
cord-003403-ypefqm71	93	21	support	support	VB
cord-003403-ypefqm71	93	22	our	-PRON-	PRP$
cord-003403-ypefqm71	93	23	two	two	CD
cord-003403-ypefqm71	93	24	Phase	phase	NN
cord-003403-ypefqm71	93	25	1	1	CD
cord-003403-ypefqm71	93	26	GLS-5700	GLS-5700	NNP
cord-003403-ypefqm71	93	27	vaccine	vaccine	NN
cord-003403-ypefqm71	93	28	clinical	clinical	JJ
cord-003403-ypefqm71	93	29	trials	trial	NNS
cord-003403-ypefqm71	93	30	.	.	.
cord-003403-ypefqm71	94	1	A	a	DT
cord-003403-ypefqm71	94	2	concern	concern	NN
cord-003403-ypefqm71	94	3	always	always	RB
cord-003403-ypefqm71	94	4	remains	remain	VBZ
cord-003403-ypefqm71	94	5	,	,	,
cord-003403-ypefqm71	94	6	however	however	RB
cord-003403-ypefqm71	94	7	,	,	,
cord-003403-ypefqm71	94	8	that	that	IN
cord-003403-ypefqm71	94	9	the	the	DT
cord-003403-ypefqm71	94	10	lack	lack	NN
cord-003403-ypefqm71	94	11	of	of	IN
cord-003403-ypefqm71	94	12	highly	highly	RB
cord-003403-ypefqm71	94	13	-	-	HYPH
cord-003403-ypefqm71	94	14	characterized	characterize	VBN
cord-003403-ypefqm71	94	15	reagents	reagent	NNS
cord-003403-ypefqm71	94	16	and	and	CC
cord-003403-ypefqm71	94	17	controls	control	NNS
cord-003403-ypefqm71	94	18	in	in	IN
cord-003403-ypefqm71	94	19	early	early	JJ
cord-003403-ypefqm71	94	20	versions	version	NNS
cord-003403-ypefqm71	94	21	of	of	IN
cord-003403-ypefqm71	94	22	vaccine	vaccine	NN
cord-003403-ypefqm71	94	23	clinical	clinical	JJ
cord-003403-ypefqm71	94	24	assays	assay	NNS
cord-003403-ypefqm71	94	25	will	will	MD
cord-003403-ypefqm71	94	26	result	result	VB
cord-003403-ypefqm71	94	27	in	in	IN
cord-003403-ypefqm71	94	28	difficulties	difficulty	NNS
cord-003403-ypefqm71	94	29	in	in	IN
cord-003403-ypefqm71	94	30	the	the	DT
cord-003403-ypefqm71	94	31	maintenance	maintenance	NN
cord-003403-ypefqm71	94	32	of	of	IN
cord-003403-ypefqm71	94	33	the	the	DT
cord-003403-ypefqm71	94	34	assays	assay	NNS
cord-003403-ypefqm71	94	35	through	through	IN
cord-003403-ypefqm71	94	36	its	-PRON-	PRP$
cord-003403-ypefqm71	94	37	full	full	JJ
cord-003403-ypefqm71	94	38	life	life	NN
cord-003403-ypefqm71	94	39	cycle	cycle	NN
cord-003403-ypefqm71	94	40	.	.	.
cord-003403-ypefqm71	95	1	Sourcing	sourcing	NN
cord-003403-ypefqm71	95	2	,	,	,
cord-003403-ypefqm71	95	3	batch	batch	NN
cord-003403-ypefqm71	95	4	-	-	HYPH
cord-003403-ypefqm71	95	5	to	to	IN
cord-003403-ypefqm71	95	6	-	-	HYPH
cord-003403-ypefqm71	95	7	batch	batch	NN
cord-003403-ypefqm71	95	8	variability	variability	NN
cord-003403-ypefqm71	95	9	and	and	CC
cord-003403-ypefqm71	95	10	overall	overall	JJ
cord-003403-ypefqm71	95	11	quality	quality	NN
cord-003403-ypefqm71	95	12	of	of	IN
cord-003403-ypefqm71	95	13	critical	critical	JJ
cord-003403-ypefqm71	95	14	reagents	reagent	NNS
cord-003403-ypefqm71	95	15	,	,	,
cord-003403-ypefqm71	95	16	standards	standard	NNS
cord-003403-ypefqm71	95	17	and	and	CC
cord-003403-ypefqm71	95	18	controls	control	NNS
cord-003403-ypefqm71	95	19	can	can	MD
cord-003403-ypefqm71	95	20	become	become	VB
cord-003403-ypefqm71	95	21	an	an	DT
cord-003403-ypefqm71	95	22	issue	issue	NN
cord-003403-ypefqm71	95	23	over	over	IN
cord-003403-ypefqm71	95	24	time	time	NN
cord-003403-ypefqm71	95	25	.	.	.
cord-003403-ypefqm71	96	1	Lack	lack	NN
cord-003403-ypefqm71	96	2	of	of	IN
cord-003403-ypefqm71	96	3	standardization	standardization	NN
cord-003403-ypefqm71	96	4	across	across	IN
cord-003403-ypefqm71	96	5	the	the	DT
cord-003403-ypefqm71	96	6	scientific	scientific	JJ
cord-003403-ypefqm71	96	7	field	field	NN
cord-003403-ypefqm71	96	8	can	can	MD
cord-003403-ypefqm71	96	9	be	be	VB
cord-003403-ypefqm71	96	10	confounding	confound	VBG
cord-003403-ypefqm71	96	11	in	in	IN
cord-003403-ypefqm71	96	12	that	that	DT
cord-003403-ypefqm71	96	13	interpretation	interpretation	NN
cord-003403-ypefqm71	96	14	of	of	IN
cord-003403-ypefqm71	96	15	results	result	NNS
cord-003403-ypefqm71	96	16	from	from	IN
cord-003403-ypefqm71	96	17	multiple	multiple	JJ
cord-003403-ypefqm71	96	18	"	"	``
cord-003403-ypefqm71	96	19	home	home	NN
cord-003403-ypefqm71	96	20	brew	brew	NN
cord-003403-ypefqm71	96	21	"	"	''
cord-003403-ypefqm71	96	22	assays	assays	RB
cord-003403-ypefqm71	96	23	across	across	IN
cord-003403-ypefqm71	96	24	labs	lab	NNS
cord-003403-ypefqm71	96	25	are	be	VBP
cord-003403-ypefqm71	96	26	not	not	RB
cord-003403-ypefqm71	96	27	directly	directly	RB
cord-003403-ypefqm71	96	28	comparable	comparable	JJ
cord-003403-ypefqm71	96	29	in	in	IN
cord-003403-ypefqm71	96	30	the	the	DT
cord-003403-ypefqm71	96	31	absence	absence	NN
cord-003403-ypefqm71	96	32	of	of	IN
cord-003403-ypefqm71	96	33	an	an	DT
cord-003403-ypefqm71	96	34	accepted	accepted	JJ
cord-003403-ypefqm71	96	35	international	international	JJ
cord-003403-ypefqm71	96	36	standard	standard	NN
cord-003403-ypefqm71	96	37	or	or	CC
cord-003403-ypefqm71	96	38	a	a	DT
cord-003403-ypefqm71	96	39	proficiency	proficiency	NN
cord-003403-ypefqm71	96	40	panel	panel	NN
cord-003403-ypefqm71	96	41	of	of	IN
cord-003403-ypefqm71	96	42	samples	sample	NNS
cord-003403-ypefqm71	96	43	[	[	-LRB-
cord-003403-ypefqm71	96	44	4	4	CD
cord-003403-ypefqm71	96	45	]	]	-RRB-
cord-003403-ypefqm71	96	46	.	.	.
cord-003403-ypefqm71	97	1	The	the	DT
cord-003403-ypefqm71	97	2	main	main	JJ
cord-003403-ypefqm71	97	3	methodologies	methodology	NNS
cord-003403-ypefqm71	97	4	used	use	VBD
cord-003403-ypefqm71	97	5	to	to	TO
cord-003403-ypefqm71	97	6	detect	detect	VB
cord-003403-ypefqm71	97	7	incident	incident	NN
cord-003403-ypefqm71	97	8	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	97	9	infection	infection	NN
cord-003403-ypefqm71	97	10	are	be	VBP
cord-003403-ypefqm71	97	11	currently	currently	RB
cord-003403-ypefqm71	97	12	molecular	molecular	JJ
cord-003403-ypefqm71	97	13	-	-	HYPH
cord-003403-ypefqm71	97	14	based	base	VBN
cord-003403-ypefqm71	97	15	,	,	,
cord-003403-ypefqm71	97	16	mainly	mainly	RB
cord-003403-ypefqm71	97	17	reverse	reverse	VB
cord-003403-ypefqm71	97	18	transcriptase	transcriptase	NN
cord-003403-ypefqm71	97	19	polymerase	polymerase	NN
cord-003403-ypefqm71	97	20	chain	chain	NN
cord-003403-ypefqm71	97	21	reaction	reaction	NN
cord-003403-ypefqm71	97	22	(	(	-LRB-
cord-003403-ypefqm71	97	23	RT	RT	NNP
cord-003403-ypefqm71	97	24	-	-	HYPH
cord-003403-ypefqm71	97	25	PCR	PCR	NNP
cord-003403-ypefqm71	97	26	)	)	-RRB-
cord-003403-ypefqm71	97	27	[	[	-LRB-
cord-003403-ypefqm71	97	28	36	36	CD
cord-003403-ypefqm71	97	29	,	,	,
cord-003403-ypefqm71	97	30	41	41	CD
cord-003403-ypefqm71	97	31	,	,	,
cord-003403-ypefqm71	97	32	43	43	CD
cord-003403-ypefqm71	97	33	,	,	,
cord-003403-ypefqm71	97	34	50	50	CD
cord-003403-ypefqm71	97	35	,	,	,
cord-003403-ypefqm71	97	36	52	52	CD
cord-003403-ypefqm71	97	37	,	,	,
cord-003403-ypefqm71	97	38	54	54	CD
cord-003403-ypefqm71	97	39	,	,	,
cord-003403-ypefqm71	97	40	56	56	CD
cord-003403-ypefqm71	97	41	,	,	,
cord-003403-ypefqm71	97	42	70	70	CD
cord-003403-ypefqm71	97	43	,	,	,
cord-003403-ypefqm71	97	44	85	85	CD
cord-003403-ypefqm71	97	45	]	]	-RRB-
cord-003403-ypefqm71	97	46	or	or	CC
cord-003403-ypefqm71	97	47	varieties	variety	NNS
cord-003403-ypefqm71	97	48	thereof	thereof	IN
cord-003403-ypefqm71	97	49	[	[	-LRB-
cord-003403-ypefqm71	97	50	55	55	CD
cord-003403-ypefqm71	97	51	,	,	,
cord-003403-ypefqm71	97	52	86	86	CD
cord-003403-ypefqm71	97	53	,	,	,
cord-003403-ypefqm71	97	54	87	87	CD
cord-003403-ypefqm71	97	55	]	]	-RRB-
cord-003403-ypefqm71	97	56	,	,	,
cord-003403-ypefqm71	97	57	since	since	IN
cord-003403-ypefqm71	97	58	culture	culture	NN
cord-003403-ypefqm71	97	59	methods	method	NNS
cord-003403-ypefqm71	97	60	can	can	MD
cord-003403-ypefqm71	97	61	be	be	VB
cord-003403-ypefqm71	97	62	both	both	DT
cord-003403-ypefqm71	97	63	difficult	difficult	JJ
cord-003403-ypefqm71	97	64	and	and	CC
cord-003403-ypefqm71	97	65	laborious	laborious	JJ
cord-003403-ypefqm71	97	66	[	[	-LRB-
cord-003403-ypefqm71	97	67	88	88	CD
cord-003403-ypefqm71	97	68	]	]	-RRB-
cord-003403-ypefqm71	97	69	[	[	-LRB-
cord-003403-ypefqm71	97	70	89	89	CD
cord-003403-ypefqm71	97	71	]	]	-RRB-
cord-003403-ypefqm71	97	72	[	[	-LRB-
cord-003403-ypefqm71	97	73	90	90	CD
cord-003403-ypefqm71	97	74	]	]	-RRB-
cord-003403-ypefqm71	97	75	.	.	.
cord-003403-ypefqm71	98	1	Those	those	DT
cord-003403-ypefqm71	98	2	viral	viral	JJ
cord-003403-ypefqm71	98	3	detection	detection	NN
cord-003403-ypefqm71	98	4	systems	system	NNS
cord-003403-ypefqm71	98	5	with	with	IN
cord-003403-ypefqm71	98	6	EUA	EUA	NNP
cord-003403-ypefqm71	98	7	approval	approval	NN
cord-003403-ypefqm71	98	8	are	be	VBP
cord-003403-ypefqm71	98	9	shown	show	VBN
cord-003403-ypefqm71	98	10	in	in	IN
cord-003403-ypefqm71	98	11	Table	Table	NNP
cord-003403-ypefqm71	98	12	2	2	CD
cord-003403-ypefqm71	98	13	.	.	.
cord-003403-ypefqm71	99	1	In	in	IN
cord-003403-ypefqm71	99	2	clinical	clinical	JJ
cord-003403-ypefqm71	99	3	trials	trial	NNS
cord-003403-ypefqm71	99	4	,	,	,
cord-003403-ypefqm71	99	5	identification	identification	NN
cord-003403-ypefqm71	99	6	of	of	IN
cord-003403-ypefqm71	99	7	newly	newly	RB
cord-003403-ypefqm71	99	8	infected	infect	VBN
cord-003403-ypefqm71	99	9	subjects	subject	NNS
cord-003403-ypefqm71	99	10	over	over	IN
cord-003403-ypefqm71	99	11	the	the	DT
cord-003403-ypefqm71	99	12	treatment	treatment	NN
cord-003403-ypefqm71	99	13	and	and	CC
cord-003403-ypefqm71	99	14	follow	follow	NN
cord-003403-ypefqm71	99	15	-	-	HYPH
cord-003403-ypefqm71	99	16	up	up	NN
cord-003403-ypefqm71	99	17	periods	period	NNS
cord-003403-ypefqm71	99	18	are	be	VBP
cord-003403-ypefqm71	99	19	necessary	necessary	JJ
cord-003403-ypefqm71	99	20	to	to	TO
cord-003403-ypefqm71	99	21	determine	determine	VB
cord-003403-ypefqm71	99	22	vaccine	vaccine	NN
cord-003403-ypefqm71	99	23	efficacy	efficacy	NN
cord-003403-ypefqm71	99	24	.	.	.
cord-003403-ypefqm71	100	1	As	as	IN
cord-003403-ypefqm71	100	2	discussed	discuss	VBN
cord-003403-ypefqm71	100	3	earlier	early	RBR
cord-003403-ypefqm71	100	4	,	,	,
cord-003403-ypefqm71	100	5	for	for	IN
cord-003403-ypefqm71	100	6	most	most	JJS
cord-003403-ypefqm71	100	7	individuals	individual	NNS
cord-003403-ypefqm71	100	8	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	100	9	infection	infection	NN
cord-003403-ypefqm71	100	10	is	be	VBZ
cord-003403-ypefqm71	100	11	minimally	minimally	RB
cord-003403-ypefqm71	100	12	symptomatic	symptomatic	JJ
cord-003403-ypefqm71	100	13	such	such	JJ
cord-003403-ypefqm71	100	14	that	that	IN
cord-003403-ypefqm71	100	15	few	few	JJ
cord-003403-ypefqm71	100	16	present	present	JJ
cord-003403-ypefqm71	100	17	to	to	IN
cord-003403-ypefqm71	100	18	clinical	clinical	JJ
cord-003403-ypefqm71	100	19	care	care	NN
cord-003403-ypefqm71	100	20	.	.	.
cord-003403-ypefqm71	101	1	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	101	2	is	be	VBZ
cord-003403-ypefqm71	101	3	detectable	detectable	JJ
cord-003403-ypefqm71	101	4	in	in	IN
cord-003403-ypefqm71	101	5	serum	serum	NN
cord-003403-ypefqm71	101	6	by	by	IN
cord-003403-ypefqm71	101	7	RT	RT	NNP
cord-003403-ypefqm71	101	8	-	-	HYPH
cord-003403-ypefqm71	101	9	PCR	PCR	NNP
cord-003403-ypefqm71	101	10	for	for	IN
cord-003403-ypefqm71	101	11	only	only	RB
cord-003403-ypefqm71	101	12	a	a	DT
cord-003403-ypefqm71	101	13	short	short	JJ
cord-003403-ypefqm71	101	14	interval	interval	NN
cord-003403-ypefqm71	101	15	following	follow	VBG
cord-003403-ypefqm71	101	16	the	the	DT
cord-003403-ypefqm71	101	17	onset	onset	NN
cord-003403-ypefqm71	101	18	of	of	IN
cord-003403-ypefqm71	101	19	symptoms	symptom	NNS
cord-003403-ypefqm71	101	20	,	,	,
cord-003403-ypefqm71	101	21	typically	typically	RB
cord-003403-ypefqm71	101	22	for	for	IN
cord-003403-ypefqm71	101	23	only	only	RB
cord-003403-ypefqm71	101	24	seven	seven	CD
cord-003403-ypefqm71	101	25	days	day	NNS
cord-003403-ypefqm71	101	26	to	to	IN
cord-003403-ypefqm71	101	27	a	a	DT
cord-003403-ypefqm71	101	28	maximum	maximum	NN
cord-003403-ypefqm71	101	29	of	of	IN
cord-003403-ypefqm71	101	30	14	14	CD
cord-003403-ypefqm71	101	31	days	day	NNS
cord-003403-ypefqm71	101	32	[	[	-LRB-
cord-003403-ypefqm71	101	33	42	42	CD
cord-003403-ypefqm71	101	34	,	,	,
cord-003403-ypefqm71	101	35	43	43	CD
cord-003403-ypefqm71	101	36	]	]	-RRB-
cord-003403-ypefqm71	101	37	,	,	,
cord-003403-ypefqm71	101	38	though	though	IN
cord-003403-ypefqm71	101	39	longer	long	JJR
cord-003403-ypefqm71	101	40	periods	period	NNS
cord-003403-ypefqm71	101	41	of	of	IN
cord-003403-ypefqm71	101	42	RT	RT	NNP
cord-003403-ypefqm71	101	43	-	-	HYPH
cord-003403-ypefqm71	101	44	PCR	PCR	NNP
cord-003403-ypefqm71	101	45	detection	detection	NN
cord-003403-ypefqm71	101	46	(	(	-LRB-
cord-003403-ypefqm71	101	47	up	up	IN
cord-003403-ypefqm71	101	48	to	to	TO
cord-003403-ypefqm71	101	49	53	53	CD
cord-003403-ypefqm71	101	50	days	day	NNS
cord-003403-ypefqm71	101	51	)	)	-RRB-
cord-003403-ypefqm71	101	52	have	have	VBP
cord-003403-ypefqm71	101	53	been	be	VBN
cord-003403-ypefqm71	101	54	observed	observe	VBN
cord-003403-ypefqm71	101	55	in	in	IN
cord-003403-ypefqm71	101	56	serum	serum	NN
cord-003403-ypefqm71	101	57	of	of	IN
cord-003403-ypefqm71	101	58	pregnant	pregnant	JJ
cord-003403-ypefqm71	101	59	women	woman	NNS
cord-003403-ypefqm71	101	60	[	[	-LRB-
cord-003403-ypefqm71	101	61	53	53	CD
cord-003403-ypefqm71	101	62	]	]	-RRB-
cord-003403-ypefqm71	101	63	,	,	,
cord-003403-ypefqm71	101	64	which	which	WDT
cord-003403-ypefqm71	101	65	may	may	MD
cord-003403-ypefqm71	101	66	contribute	contribute	VB
cord-003403-ypefqm71	101	67	to	to	IN
cord-003403-ypefqm71	101	68	the	the	DT
cord-003403-ypefqm71	101	69	incidence	incidence	NN
cord-003403-ypefqm71	101	70	of	of	IN
cord-003403-ypefqm71	101	71	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	101	72	-	-	HYPH
cord-003403-ypefqm71	101	73	related	relate	VBN
cord-003403-ypefqm71	101	74	birth	birth	NN
cord-003403-ypefqm71	101	75	defects	defect	NNS
cord-003403-ypefqm71	101	76	.	.	.
cord-003403-ypefqm71	102	1	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	102	2	is	be	VBZ
cord-003403-ypefqm71	102	3	excreted	excrete	VBN
cord-003403-ypefqm71	102	4	into	into	IN
cord-003403-ypefqm71	102	5	the	the	DT
cord-003403-ypefqm71	102	6	urine	urine	NN
cord-003403-ypefqm71	102	7	for	for	IN
cord-003403-ypefqm71	102	8	approximately	approximately	RB
cord-003403-ypefqm71	102	9	four	four	CD
cord-003403-ypefqm71	102	10	weeks	week	NNS
cord-003403-ypefqm71	102	11	in	in	IN
cord-003403-ypefqm71	102	12	most	most	JJS
cord-003403-ypefqm71	102	13	individuals	individual	NNS
cord-003403-ypefqm71	102	14	,	,	,
cord-003403-ypefqm71	102	15	though	though	IN
cord-003403-ypefqm71	102	16	this	this	DT
cord-003403-ypefqm71	102	17	observation	observation	NN
cord-003403-ypefqm71	102	18	was	be	VBD
cord-003403-ypefqm71	102	19	not	not	RB
cord-003403-ypefqm71	102	20	documented	document	VBN
cord-003403-ypefqm71	102	21	until	until	IN
cord-003403-ypefqm71	102	22	over	over	IN
cord-003403-ypefqm71	102	23	a	a	DT
cord-003403-ypefqm71	102	24	year	year	NN
cord-003403-ypefqm71	102	25	into	into	IN
cord-003403-ypefqm71	102	26	the	the	DT
cord-003403-ypefqm71	102	27	epidemic	epidemic	NN
cord-003403-ypefqm71	102	28	[	[	-LRB-
cord-003403-ypefqm71	102	29	42	42	CD
cord-003403-ypefqm71	102	30	,	,	,
cord-003403-ypefqm71	102	31	43	43	CD
cord-003403-ypefqm71	102	32	,	,	,
cord-003403-ypefqm71	102	33	91	91	CD
cord-003403-ypefqm71	102	34	,	,	,
cord-003403-ypefqm71	102	35	92	92	CD
cord-003403-ypefqm71	102	36	]	]	-RRB-
cord-003403-ypefqm71	102	37	.	.	.
cord-003403-ypefqm71	103	1	Because	because	IN
cord-003403-ypefqm71	103	2	of	of	IN
cord-003403-ypefqm71	103	3	this	this	DT
cord-003403-ypefqm71	103	4	,	,	,
cord-003403-ypefqm71	103	5	RT	RT	NNP
cord-003403-ypefqm71	103	6	-	-	HYPH
cord-003403-ypefqm71	103	7	PCR	PCR	NNP
cord-003403-ypefqm71	103	8	-	-	HYPH
cord-003403-ypefqm71	103	9	based	base	VBN
cord-003403-ypefqm71	103	10	diagnosis	diagnosis	NN
cord-003403-ypefqm71	103	11	of	of	IN
cord-003403-ypefqm71	103	12	incident	incident	NN
cord-003403-ypefqm71	103	13	infections	infection	NNS
cord-003403-ypefqm71	103	14	in	in	IN
cord-003403-ypefqm71	103	15	a	a	DT
cord-003403-ypefqm71	103	16	vaccine	vaccine	NN
cord-003403-ypefqm71	103	17	clinical	clinical	JJ
cord-003403-ypefqm71	103	18	trial	trial	NN
cord-003403-ypefqm71	103	19	would	would	MD
cord-003403-ypefqm71	103	20	require	require	VB
cord-003403-ypefqm71	103	21	very	very	RB
cord-003403-ypefqm71	103	22	frequent	frequent	JJ
cord-003403-ypefqm71	103	23	sampling	sampling	NN
cord-003403-ypefqm71	103	24	.	.	.
cord-003403-ypefqm71	104	1	Other	other	JJ
cord-003403-ypefqm71	104	2	sample	sample	NN
cord-003403-ypefqm71	104	3	types	type	NNS
cord-003403-ypefqm71	104	4	have	have	VBP
cord-003403-ypefqm71	104	5	been	be	VBN
cord-003403-ypefqm71	104	6	evaluated	evaluate	VBN
cord-003403-ypefqm71	104	7	for	for	IN
cord-003403-ypefqm71	104	8	RT	RT	NNP
cord-003403-ypefqm71	104	9	-	-	HYPH
cord-003403-ypefqm71	104	10	PCR	pcr	NN
cord-003403-ypefqm71	104	11	detection	detection	NN
cord-003403-ypefqm71	104	12	including	include	VBG
cord-003403-ypefqm71	104	13	saliva	saliva	NN
cord-003403-ypefqm71	104	14	,	,	,
cord-003403-ypefqm71	104	15	whole	whole	JJ
cord-003403-ypefqm71	104	16	blood	blood	NN
cord-003403-ypefqm71	104	17	,	,	,
cord-003403-ypefqm71	104	18	plasma	plasma	NN
cord-003403-ypefqm71	104	19	,	,	,
cord-003403-ypefqm71	104	20	brain	brain	NN
cord-003403-ypefqm71	104	21	tissue	tissue	NN
cord-003403-ypefqm71	104	22	,	,	,
cord-003403-ypefqm71	104	23	amniotic	amniotic	NN
cord-003403-ypefqm71	104	24	fluid	fluid	NN
cord-003403-ypefqm71	104	25	and	and	CC
cord-003403-ypefqm71	104	26	vaginal	vaginal	JJ
cord-003403-ypefqm71	104	27	secretions	secretion	NNS
cord-003403-ypefqm71	104	28	[	[	-LRB-
cord-003403-ypefqm71	104	29	41	41	CD
cord-003403-ypefqm71	104	30	,	,	,
cord-003403-ypefqm71	104	31	43	43	CD
cord-003403-ypefqm71	104	32	,	,	,
cord-003403-ypefqm71	104	33	54	54	CD
cord-003403-ypefqm71	104	34	,	,	,
cord-003403-ypefqm71	104	35	90	90	CD
cord-003403-ypefqm71	104	36	,	,	,
cord-003403-ypefqm71	104	37	93	93	CD
cord-003403-ypefqm71	104	38	,	,	,
cord-003403-ypefqm71	104	39	94	94	CD
cord-003403-ypefqm71	104	40	]	]	-RRB-
cord-003403-ypefqm71	104	41	.	.	.
cord-003403-ypefqm71	105	1	A	a	DT
cord-003403-ypefqm71	105	2	key	key	JJ
cord-003403-ypefqm71	105	3	concern	concern	NN
cord-003403-ypefqm71	105	4	from	from	IN
cord-003403-ypefqm71	105	5	developers	developer	NNS
cord-003403-ypefqm71	105	6	of	of	IN
cord-003403-ypefqm71	105	7	both	both	DT
cord-003403-ypefqm71	105	8	diagnostics	diagnostic	NNS
cord-003403-ypefqm71	105	9	and	and	CC
cord-003403-ypefqm71	105	10	of	of	IN
cord-003403-ypefqm71	105	11	vaccines	vaccine	NNS
cord-003403-ypefqm71	105	12	or	or	CC
cord-003403-ypefqm71	105	13	therapeutics	therapeutic	NNS
cord-003403-ypefqm71	105	14	for	for	IN
cord-003403-ypefqm71	105	15	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	105	16	highlighted	highlight	VBN
cord-003403-ypefqm71	105	17	at	at	IN
cord-003403-ypefqm71	105	18	the	the	DT
cord-003403-ypefqm71	105	19	HHS	HHS	NNP
cord-003403-ypefqm71	105	20	Summit	Summit	NNP
cord-003403-ypefqm71	105	21	for	for	IN
cord-003403-ypefqm71	105	22	Diagnostics	Diagnostics	NNPS
cord-003403-ypefqm71	105	23	in	in	IN
cord-003403-ypefqm71	105	24	July	July	NNP
cord-003403-ypefqm71	105	25	2016	2016	CD
cord-003403-ypefqm71	105	26	was	be	VBD
cord-003403-ypefqm71	105	27	the	the	DT
cord-003403-ypefqm71	105	28	lack	lack	NN
cord-003403-ypefqm71	105	29	of	of	IN
cord-003403-ypefqm71	105	30	well	well	RB
cord-003403-ypefqm71	105	31	-	-	HYPH
cord-003403-ypefqm71	105	32	characterized	characterize	VBN
cord-003403-ypefqm71	105	33	human	human	JJ
cord-003403-ypefqm71	105	34	ZIKV	zikv	NN
cord-003403-ypefqm71	105	35	specimens	specimen	NNS
cord-003403-ypefqm71	105	36	which	which	WDT
cord-003403-ypefqm71	105	37	groups	group	NNS
cord-003403-ypefqm71	105	38	could	could	MD
cord-003403-ypefqm71	105	39	use	use	VB
cord-003403-ypefqm71	105	40	to	to	TO
cord-003403-ypefqm71	105	41	fully	fully	RB
cord-003403-ypefqm71	105	42	understand	understand	VB
cord-003403-ypefqm71	105	43	the	the	DT
cord-003403-ypefqm71	105	44	performance	performance	NN
cord-003403-ypefqm71	105	45	characteristics	characteristic	NNS
cord-003403-ypefqm71	105	46	of	of	IN
cord-003403-ypefqm71	105	47	the	the	DT
cord-003403-ypefqm71	105	48	assays	assay	NNS
cord-003403-ypefqm71	105	49	being	be	VBG
cord-003403-ypefqm71	105	50	developed	develop	VBN
cord-003403-ypefqm71	105	51	and	and	CC
cord-003403-ypefqm71	105	52	,	,	,
cord-003403-ypefqm71	105	53	eventually	eventually	RB
cord-003403-ypefqm71	105	54	,	,	,
cord-003403-ypefqm71	105	55	work	work	VB
cord-003403-ypefqm71	105	56	toward	toward	IN
cord-003403-ypefqm71	105	57	some	some	DT
cord-003403-ypefqm71	105	58	standardization	standardization	NN
cord-003403-ypefqm71	105	59	across	across	IN
cord-003403-ypefqm71	105	60	the	the	DT
cord-003403-ypefqm71	105	61	field	field	NN
cord-003403-ypefqm71	105	62	.	.	.
cord-003403-ypefqm71	106	1	The	the	DT
cord-003403-ypefqm71	106	2	WHO	who	WP
cord-003403-ypefqm71	106	3	has	have	VBZ
cord-003403-ypefqm71	106	4	initiated	initiate	VBN
cord-003403-ypefqm71	106	5	in	in	IN
cord-003403-ypefqm71	106	6	,	,	,
cord-003403-ypefqm71	106	7	July	July	NNP
cord-003403-ypefqm71	106	8	2016	2016	CD
cord-003403-ypefqm71	106	9	,	,	,
cord-003403-ypefqm71	106	10	a	a	DT
cord-003403-ypefqm71	106	11	collaborative	collaborative	JJ
cord-003403-ypefqm71	106	12	study	study	NN
cord-003403-ypefqm71	106	13	effort	effort	NN
cord-003403-ypefqm71	106	14	for	for	IN
cord-003403-ypefqm71	106	15	the	the	DT
cord-003403-ypefqm71	106	16	development	development	NN
cord-003403-ypefqm71	106	17	of	of	IN
cord-003403-ypefqm71	106	18	Nucleic	Nucleic	NNP
cord-003403-ypefqm71	106	19	Acid	Acid	NNP
cord-003403-ypefqm71	106	20	Testing	Testing	NNP
cord-003403-ypefqm71	106	21	International	International	NNP
cord-003403-ypefqm71	106	22	Standard	Standard	NNP
cord-003403-ypefqm71	106	23	for	for	IN
cord-003403-ypefqm71	106	24	Zika	Zika	NNP
cord-003403-ypefqm71	106	25	[	[	-LRB-
cord-003403-ypefqm71	106	26	95	95	CD
cord-003403-ypefqm71	106	27	]	]	-RRB-
cord-003403-ypefqm71	106	28	.	.	.
cord-003403-ypefqm71	107	1	Additionally	additionally	RB
cord-003403-ypefqm71	107	2	,	,	,
cord-003403-ypefqm71	107	3	in	in	IN
cord-003403-ypefqm71	107	4	July	July	NNP
cord-003403-ypefqm71	107	5	2017	2017	CD
cord-003403-ypefqm71	107	6	,	,	,
cord-003403-ypefqm71	107	7	a	a	DT
cord-003403-ypefqm71	107	8	plasma	plasma	NN
cord-003403-ypefqm71	107	9	sample	sample	NN
cord-003403-ypefqm71	107	10	panel	panel	NN
cord-003403-ypefqm71	107	11	became	become	VBD
cord-003403-ypefqm71	107	12	available	available	JJ
cord-003403-ypefqm71	107	13	through	through	IN
cord-003403-ypefqm71	107	14	the	the	DT
cord-003403-ypefqm71	107	15	US	US	NNP
cord-003403-ypefqm71	107	16	FDA	FDA	NNP
cord-003403-ypefqm71	107	17	for	for	IN
cord-003403-ypefqm71	107	18	use	use	NN
cord-003403-ypefqm71	107	19	in	in	IN
cord-003403-ypefqm71	107	20	evaluating	evaluate	VBG
cord-003403-ypefqm71	107	21	ZIKV	zikv	NN
cord-003403-ypefqm71	107	22	immunoassay	immunoassay	JJ
cord-003403-ypefqm71	107	23	performance	performance	NN
cord-003403-ypefqm71	107	24	[	[	-LRB-
cord-003403-ypefqm71	107	25	96	96	CD
cord-003403-ypefqm71	107	26	]	]	-RRB-
cord-003403-ypefqm71	107	27	.	.	.
cord-003403-ypefqm71	108	1	Reagents	reagent	NNS
cord-003403-ypefqm71	108	2	for	for	IN
cord-003403-ypefqm71	108	3	newly	newly	RB
cord-003403-ypefqm71	108	4	emergent	emergent	JJ
cord-003403-ypefqm71	108	5	infectious	infectious	JJ
cord-003403-ypefqm71	108	6	diseases	disease	NNS
cord-003403-ypefqm71	108	7	like	like	IN
cord-003403-ypefqm71	108	8	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	108	9	were	be	VBD
cord-003403-ypefqm71	108	10	not	not	RB
cord-003403-ypefqm71	108	11	readily	readily	RB
cord-003403-ypefqm71	108	12	available	available	JJ
cord-003403-ypefqm71	108	13	from	from	IN
cord-003403-ypefqm71	108	14	commercial	commercial	JJ
cord-003403-ypefqm71	108	15	vendors	vendor	NNS
cord-003403-ypefqm71	108	16	that	that	WDT
cord-003403-ypefqm71	108	17	had	have	VBD
cord-003403-ypefqm71	108	18	consistent	consistent	JJ
cord-003403-ypefqm71	108	19	production	production	NN
cord-003403-ypefqm71	108	20	methods	method	NNS
cord-003403-ypefqm71	108	21	and	and	CC
cord-003403-ypefqm71	108	22	quality	quality	NN
cord-003403-ypefqm71	108	23	controls	control	NNS
cord-003403-ypefqm71	108	24	in	in	IN
cord-003403-ypefqm71	108	25	place	place	NN
cord-003403-ypefqm71	108	26	,	,	,
cord-003403-ypefqm71	108	27	thus	thus	RB
cord-003403-ypefqm71	108	28	many	many	JJ
cord-003403-ypefqm71	108	29	reagents	reagent	NNS
cord-003403-ypefqm71	108	30	were	be	VBD
cord-003403-ypefqm71	108	31	not	not	RB
cord-003403-ypefqm71	108	32	well	well	RB
cord-003403-ypefqm71	108	33	characterized	characterize	VBN
cord-003403-ypefqm71	108	34	early	early	RB
cord-003403-ypefqm71	108	35	on	on	RB
cord-003403-ypefqm71	108	36	in	in	IN
cord-003403-ypefqm71	108	37	the	the	DT
cord-003403-ypefqm71	108	38	development	development	NN
cord-003403-ypefqm71	108	39	of	of	IN
cord-003403-ypefqm71	108	40	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	108	41	clinical	clinical	JJ
cord-003403-ypefqm71	108	42	assays	assay	NNS
cord-003403-ypefqm71	108	43	.	.	.
cord-003403-ypefqm71	109	1	Because	because	IN
cord-003403-ypefqm71	109	2	validated	validate	VBN
cord-003403-ypefqm71	109	3	assays	assay	NNS
cord-003403-ypefqm71	109	4	supporting	support	VBG
cord-003403-ypefqm71	109	5	vaccine	vaccine	NN
cord-003403-ypefqm71	109	6	efficacy	efficacy	NN
cord-003403-ypefqm71	109	7	endpoints	endpoint	NNS
cord-003403-ypefqm71	109	8	need	need	VBP
cord-003403-ypefqm71	109	9	to	to	TO
cord-003403-ypefqm71	109	10	support	support	VB
cord-003403-ypefqm71	109	11	clinical	clinical	JJ
cord-003403-ypefqm71	109	12	and	and	CC
cord-003403-ypefqm71	109	13	regulatory	regulatory	JJ
cord-003403-ypefqm71	109	14	expectations	expectation	NNS
cord-003403-ypefqm71	109	15	over	over	IN
cord-003403-ypefqm71	109	16	the	the	DT
cord-003403-ypefqm71	109	17	life	life	NN
cord-003403-ypefqm71	109	18	of	of	IN
cord-003403-ypefqm71	109	19	the	the	DT
cord-003403-ypefqm71	109	20	product	product	NN
cord-003403-ypefqm71	109	21	,	,	,
cord-003403-ypefqm71	109	22	it	-PRON-	PRP
cord-003403-ypefqm71	109	23	is	be	VBZ
cord-003403-ypefqm71	109	24	imperative	imperative	JJ
cord-003403-ypefqm71	109	25	that	that	IN
cord-003403-ypefqm71	109	26	a	a	DT
cord-003403-ypefqm71	109	27	line	line	NN
cord-003403-ypefqm71	109	28	-	-	HYPH
cord-003403-ypefqm71	109	29	of	of	IN
cord-003403-ypefqm71	109	30	-	-	HYPH
cord-003403-ypefqm71	109	31	sight	sight	NN
cord-003403-ypefqm71	109	32	is	be	VBZ
cord-003403-ypefqm71	109	33	maintained	maintain	VBN
cord-003403-ypefqm71	109	34	such	such	PDT
cord-003403-ypefqm71	109	35	that	that	IN
cord-003403-ypefqm71	109	36	reliable	reliable	JJ
cord-003403-ypefqm71	109	37	and	and	CC
cord-003403-ypefqm71	109	38	qualified	qualified	JJ
cord-003403-ypefqm71	109	39	materials	material	NNS
cord-003403-ypefqm71	109	40	in	in	IN
cord-003403-ypefqm71	109	41	appropriate	appropriate	JJ
cord-003403-ypefqm71	109	42	quantity	quantity	NN
cord-003403-ypefqm71	109	43	are	be	VBP
cord-003403-ypefqm71	109	44	available	available	JJ
cord-003403-ypefqm71	109	45	for	for	IN
cord-003403-ypefqm71	109	46	resolving	resolve	VBG
cord-003403-ypefqm71	109	47	issues	issue	NNS
cord-003403-ypefqm71	109	48	that	that	WDT
cord-003403-ypefqm71	109	49	arise	arise	VBP
cord-003403-ypefqm71	109	50	.	.	.
cord-003403-ypefqm71	110	1	Assays	assay	NNS
cord-003403-ypefqm71	110	2	typically	typically	RB
cord-003403-ypefqm71	110	3	require	require	VBP
cord-003403-ypefqm71	110	4	some	some	DT
cord-003403-ypefqm71	110	5	troubleshooting	troubleshooting	NN
cord-003403-ypefqm71	110	6	over	over	IN
cord-003403-ypefqm71	110	7	time	time	NN
cord-003403-ypefqm71	110	8	,	,	,
cord-003403-ypefqm71	110	9	changes	change	NNS
cord-003403-ypefqm71	110	10	to	to	IN
cord-003403-ypefqm71	110	11	reagent	reagent	NN
cord-003403-ypefqm71	110	12	lots	lot	NNS
cord-003403-ypefqm71	110	13	or	or	CC
cord-003403-ypefqm71	110	14	instruments	instrument	NNS
cord-003403-ypefqm71	110	15	,	,	,
cord-003403-ypefqm71	110	16	potential	potential	NN
cord-003403-ypefqm71	110	17	for	for	IN
cord-003403-ypefqm71	110	18	multiplexing	multiplexing	NN
cord-003403-ypefqm71	110	19	,	,	,
cord-003403-ypefqm71	110	20	platform	platform	NN
cord-003403-ypefqm71	110	21	changes	change	NNS
cord-003403-ypefqm71	110	22	to	to	TO
cord-003403-ypefqm71	110	23	increase	increase	VB
cord-003403-ypefqm71	110	24	testing	testing	NN
cord-003403-ypefqm71	110	25	throughput	throughput	NN
cord-003403-ypefqm71	110	26	,	,	,
cord-003403-ypefqm71	110	27	or	or	CC
cord-003403-ypefqm71	110	28	a	a	DT
cord-003403-ypefqm71	110	29	desire	desire	NN
cord-003403-ypefqm71	110	30	to	to	TO
cord-003403-ypefqm71	110	31	bridge	bridge	VB
cord-003403-ypefqm71	110	32	to	to	IN
cord-003403-ypefqm71	110	33	a	a	DT
cord-003403-ypefqm71	110	34	new	new	JJ
cord-003403-ypefqm71	110	35	technology	technology	NN
cord-003403-ypefqm71	110	36	[	[	-LRB-
cord-003403-ypefqm71	110	37	4	4	CD
cord-003403-ypefqm71	110	38	]	]	-RRB-
cord-003403-ypefqm71	110	39	.	.	.
cord-003403-ypefqm71	111	1	The	the	DT
cord-003403-ypefqm71	111	2	development	development	NN
cord-003403-ypefqm71	111	3	,	,	,
cord-003403-ypefqm71	111	4	qualification	qualification	NN
cord-003403-ypefqm71	111	5	,	,	,
cord-003403-ypefqm71	111	6	validation	validation	NN
cord-003403-ypefqm71	111	7	and	and	CC
cord-003403-ypefqm71	111	8	maintenance	maintenance	NN
cord-003403-ypefqm71	111	9	of	of	IN
cord-003403-ypefqm71	111	10	vaccine	vaccine	NN
cord-003403-ypefqm71	111	11	clinical	clinical	JJ
cord-003403-ypefqm71	111	12	assays	assay	NNS
cord-003403-ypefqm71	111	13	should	should	MD
cord-003403-ypefqm71	111	14	be	be	VB
cord-003403-ypefqm71	111	15	done	do	VBN
cord-003403-ypefqm71	111	16	in	in	IN
cord-003403-ypefqm71	111	17	close	close	JJ
cord-003403-ypefqm71	111	18	consultation	consultation	NN
cord-003403-ypefqm71	111	19	with	with	IN
cord-003403-ypefqm71	111	20	biostatisticians	biostatistician	NNS
cord-003403-ypefqm71	111	21	and	and	CC
cord-003403-ypefqm71	111	22	bench	bench	NN
cord-003403-ypefqm71	111	23	scientists	scientist	NNS
cord-003403-ypefqm71	111	24	to	to	TO
cord-003403-ypefqm71	111	25	ensure	ensure	VB
cord-003403-ypefqm71	111	26	the	the	DT
cord-003403-ypefqm71	111	27	optimal	optimal	JJ
cord-003403-ypefqm71	111	28	assay	assay	NN
cord-003403-ypefqm71	111	29	design	design	NN
cord-003403-ypefqm71	111	30	,	,	,
cord-003403-ypefqm71	111	31	control	control	NN
cord-003403-ypefqm71	111	32	parameters	parameter	NNS
cord-003403-ypefqm71	111	33	and	and	CC
cord-003403-ypefqm71	111	34	performance	performance	NN
cord-003403-ypefqm71	111	35	characteristics	characteristic	NNS
cord-003403-ypefqm71	111	36	for	for	IN
cord-003403-ypefqm71	111	37	the	the	DT
cord-003403-ypefqm71	111	38	needs	need	NNS
cord-003403-ypefqm71	111	39	of	of	IN
cord-003403-ypefqm71	111	40	the	the	DT
cord-003403-ypefqm71	111	41	vaccine	vaccine	NN
cord-003403-ypefqm71	111	42	program	program	NN
cord-003403-ypefqm71	111	43	from	from	IN
cord-003403-ypefqm71	111	44	beginning	begin	VBG
cord-003403-ypefqm71	111	45	to	to	IN
cord-003403-ypefqm71	111	46	end	end	VB
cord-003403-ypefqm71	111	47	.	.	.
cord-003403-ypefqm71	112	1	It	-PRON-	PRP
cord-003403-ypefqm71	112	2	should	should	MD
cord-003403-ypefqm71	112	3	be	be	VB
cord-003403-ypefqm71	112	4	noted	note	VBN
cord-003403-ypefqm71	112	5	that	that	IN
cord-003403-ypefqm71	112	6	vaccine	vaccine	NN
cord-003403-ypefqm71	112	7	assay	assay	NN
cord-003403-ypefqm71	112	8	quality	quality	NN
cord-003403-ypefqm71	112	9	is	be	VBZ
cord-003403-ypefqm71	112	10	highly	highly	RB
cord-003403-ypefqm71	112	11	dependent	dependent	JJ
cord-003403-ypefqm71	112	12	upon	upon	IN
cord-003403-ypefqm71	112	13	clinical	clinical	JJ
cord-003403-ypefqm71	112	14	study	study	NN
cord-003403-ypefqm71	112	15	execution	execution	NN
cord-003403-ypefqm71	112	16	from	from	IN
cord-003403-ypefqm71	112	17	collection	collection	NN
cord-003403-ypefqm71	112	18	through	through	IN
cord-003403-ypefqm71	112	19	final	final	JJ
cord-003403-ypefqm71	112	20	data	datum	NNS
cord-003403-ypefqm71	112	21	reporting	reporting	NN
cord-003403-ypefqm71	112	22	.	.	.
cord-003403-ypefqm71	113	1	Sample	sample	NN
cord-003403-ypefqm71	113	2	collection	collection	NN
cord-003403-ypefqm71	113	3	&	&	CC
cord-003403-ypefqm71	113	4	handling	handling	NN
cord-003403-ypefqm71	113	5	are	be	VBP
cord-003403-ypefqm71	113	6	critical	critical	JJ
cord-003403-ypefqm71	113	7	to	to	IN
cord-003403-ypefqm71	113	8	the	the	DT
cord-003403-ypefqm71	113	9	quality	quality	NN
cord-003403-ypefqm71	113	10	of	of	IN
cord-003403-ypefqm71	113	11	the	the	DT
cord-003403-ypefqm71	113	12	specimen	specimen	NN
cord-003403-ypefqm71	113	13	and	and	CC
cord-003403-ypefqm71	113	14	its	-PRON-	PRP$
cord-003403-ypefqm71	113	15	ability	ability	NN
cord-003403-ypefqm71	113	16	to	to	TO
cord-003403-ypefqm71	113	17	be	be	VB
cord-003403-ypefqm71	113	18	used	use	VBN
cord-003403-ypefqm71	113	19	in	in	IN
cord-003403-ypefqm71	113	20	an	an	DT
cord-003403-ypefqm71	113	21	assay	assay	NN
cord-003403-ypefqm71	113	22	.	.	.
cord-003403-ypefqm71	114	1	Implementing	implementing	NN
cord-003403-ypefqm71	114	2	methods	method	NNS
cord-003403-ypefqm71	114	3	to	to	TO
cord-003403-ypefqm71	114	4	assure	assure	VB
cord-003403-ypefqm71	114	5	the	the	DT
cord-003403-ypefqm71	114	6	following	follow	VBG
cord-003403-ypefqm71	114	7	are	be	VBP
cord-003403-ypefqm71	114	8	keys	key	NNS
cord-003403-ypefqm71	114	9	to	to	IN
cord-003403-ypefqm71	114	10	successful	successful	JJ
cord-003403-ypefqm71	114	11	vaccine	vaccine	NN
cord-003403-ypefqm71	114	12	clinical	clinical	JJ
cord-003403-ypefqm71	114	13	trials	trial	NNS
cord-003403-ypefqm71	114	14	:	:	:
cord-003403-ypefqm71	114	15	proper	proper	JJ
cord-003403-ypefqm71	114	16	sample	sample	NN
cord-003403-ypefqm71	114	17	storage	storage	NN
cord-003403-ypefqm71	114	18	and	and	CC
cord-003403-ypefqm71	114	19	shipping	shipping	NN
cord-003403-ypefqm71	114	20	conditions	condition	NNS
cord-003403-ypefqm71	114	21	,	,	,
cord-003403-ypefqm71	114	22	processing	processing	NN
cord-003403-ypefqm71	114	23	and	and	CC
cord-003403-ypefqm71	114	24	aliquotting	aliquotting	NN
cord-003403-ypefqm71	114	25	with	with	IN
cord-003403-ypefqm71	114	26	methods	method	NNS
cord-003403-ypefqm71	114	27	for	for	IN
cord-003403-ypefqm71	114	28	contamination	contamination	NN
cord-003403-ypefqm71	114	29	control	control	NN
cord-003403-ypefqm71	114	30	,	,	,
cord-003403-ypefqm71	114	31	proper	proper	JJ
cord-003403-ypefqm71	114	32	training	training	NN
cord-003403-ypefqm71	114	33	of	of	IN
cord-003403-ypefqm71	114	34	site	site	NN
cord-003403-ypefqm71	114	35	and	and	CC
cord-003403-ypefqm71	114	36	clinical	clinical	JJ
cord-003403-ypefqm71	114	37	research	research	NN
cord-003403-ypefqm71	114	38	organization	organization	NN
cord-003403-ypefqm71	114	39	lab	lab	NN
cord-003403-ypefqm71	114	40	personnel	personnel	NNS
cord-003403-ypefqm71	114	41	,	,	,
cord-003403-ypefqm71	114	42	chain	chain	NN
cord-003403-ypefqm71	114	43	of	of	IN
cord-003403-ypefqm71	114	44	custody	custody	NN
cord-003403-ypefqm71	114	45	verification	verification	NN
cord-003403-ypefqm71	114	46	of	of	IN
cord-003403-ypefqm71	114	47	samples	sample	NNS
cord-003403-ypefqm71	114	48	from	from	IN
cord-003403-ypefqm71	114	49	collection	collection	NN
cord-003403-ypefqm71	114	50	to	to	IN
cord-003403-ypefqm71	114	51	final	final	JJ
cord-003403-ypefqm71	114	52	valid	valid	JJ
cord-003403-ypefqm71	114	53	test	test	NN
cord-003403-ypefqm71	114	54	result	result	NN
cord-003403-ypefqm71	114	55	,	,	,
cord-003403-ypefqm71	114	56	quality	quality	NN
cord-003403-ypefqm71	114	57	control	control	NN
cord-003403-ypefqm71	114	58	checks	check	NNS
cord-003403-ypefqm71	114	59	and	and	CC
cord-003403-ypefqm71	114	60	good	good	JJ
cord-003403-ypefqm71	114	61	data	datum	NNS
cord-003403-ypefqm71	114	62	management	management	NN
cord-003403-ypefqm71	114	63	.	.	.
cord-003403-ypefqm71	115	1	In	in	IN
cord-003403-ypefqm71	115	2	the	the	DT
cord-003403-ypefqm71	115	3	execution	execution	NN
cord-003403-ypefqm71	115	4	of	of	IN
cord-003403-ypefqm71	115	5	vaccine	vaccine	NN
cord-003403-ypefqm71	115	6	clinical	clinical	JJ
cord-003403-ypefqm71	115	7	trials	trial	NNS
cord-003403-ypefqm71	115	8	,	,	,
cord-003403-ypefqm71	115	9	there	there	EX
cord-003403-ypefqm71	115	10	is	be	VBZ
cord-003403-ypefqm71	115	11	the	the	DT
cord-003403-ypefqm71	115	12	need	need	NN
cord-003403-ypefqm71	115	13	for	for	IN
cord-003403-ypefqm71	115	14	testing	testing	NN
cord-003403-ypefqm71	115	15	methodology	methodology	NN
cord-003403-ypefqm71	115	16	to	to	TO
cord-003403-ypefqm71	115	17	be	be	VB
cord-003403-ypefqm71	115	18	reliable	reliable	JJ
cord-003403-ypefqm71	115	19	,	,	,
cord-003403-ypefqm71	115	20	reproducible	reproducible	JJ
cord-003403-ypefqm71	115	21	(	(	-LRB-
cord-003403-ypefqm71	115	22	accuracy	accuracy	NN
cord-003403-ypefqm71	115	23	,	,	,
cord-003403-ypefqm71	115	24	specificity	specificity	NN
cord-003403-ypefqm71	115	25	,	,	,
cord-003403-ypefqm71	115	26	robustness	robustness	NN
cord-003403-ypefqm71	115	27	)	)	-RRB-
cord-003403-ypefqm71	115	28	,	,	,
cord-003403-ypefqm71	115	29	and	and	CC
cord-003403-ypefqm71	115	30	occasionally	occasionally	RB
cord-003403-ypefqm71	115	31	to	to	TO
cord-003403-ypefqm71	115	32	provide	provide	VB
cord-003403-ypefqm71	115	33	rapid	rapid	JJ
cord-003403-ypefqm71	115	34	diagnosis	diagnosis	NN
cord-003403-ypefqm71	115	35	(	(	-LRB-
cord-003403-ypefqm71	115	36	on	on	IN
cord-003403-ypefqm71	115	37	-	-	HYPH
cord-003403-ypefqm71	115	38	site	site	NN
cord-003403-ypefqm71	115	39	or	or	CC
cord-003403-ypefqm71	115	40	point	point	NN
cord-003403-ypefqm71	115	41	-	-	HYPH
cord-003403-ypefqm71	115	42	of	of	IN
cord-003403-ypefqm71	115	43	-	-	HYPH
cord-003403-ypefqm71	115	44	care	care	NN
cord-003403-ypefqm71	115	45	testing	testing	NN
cord-003403-ypefqm71	115	46	,	,	,
cord-003403-ypefqm71	115	47	if	if	IN
cord-003403-ypefqm71	115	48	needed	need	VBN
cord-003403-ypefqm71	115	49	)	)	-RRB-
cord-003403-ypefqm71	115	50	,	,	,
cord-003403-ypefqm71	115	51	which	which	WDT
cord-003403-ypefqm71	115	52	contributes	contribute	VBZ
cord-003403-ypefqm71	115	53	to	to	IN
cord-003403-ypefqm71	115	54	patient	patient	JJ
cord-003403-ypefqm71	115	55	care	care	NN
cord-003403-ypefqm71	115	56	as	as	RB
cord-003403-ypefqm71	115	57	well	well	RB
cord-003403-ypefqm71	115	58	as	as	IN
cord-003403-ypefqm71	115	59	to	to	IN
cord-003403-ypefqm71	115	60	the	the	DT
cord-003403-ypefqm71	115	61	understanding	understanding	NN
cord-003403-ypefqm71	115	62	of	of	IN
cord-003403-ypefqm71	115	63	vaccine	vaccine	NN
cord-003403-ypefqm71	115	64	efficacy	efficacy	NN
cord-003403-ypefqm71	115	65	or	or	CC
cord-003403-ypefqm71	115	66	disease	disease	NN
cord-003403-ypefqm71	115	67	epidemiology	epidemiology	NN
cord-003403-ypefqm71	115	68	.	.	.
cord-003403-ypefqm71	116	1	The	the	DT
cord-003403-ypefqm71	116	2	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	116	3	assay	assay	NN
cord-003403-ypefqm71	116	4	development	development	NN
cord-003403-ypefqm71	116	5	response	response	NN
cord-003403-ypefqm71	116	6	to	to	IN
cord-003403-ypefqm71	116	7	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	116	8	was	be	VBD
cord-003403-ypefqm71	116	9	quite	quite	RB
cord-003403-ypefqm71	116	10	rapid	rapid	JJ
cord-003403-ypefqm71	116	11	with	with	IN
cord-003403-ypefqm71	116	12	the	the	DT
cord-003403-ypefqm71	116	13	EUA	EUA	NNP
cord-003403-ypefqm71	116	14	approval	approval	NN
cord-003403-ypefqm71	116	15	of	of	IN
cord-003403-ypefqm71	116	16	14	14	CD
cord-003403-ypefqm71	116	17	different	different	JJ
cord-003403-ypefqm71	116	18	molecular	molecular	JJ
cord-003403-ypefqm71	116	19	detection	detection	NN
cord-003403-ypefqm71	116	20	assays	assay	NNS
cord-003403-ypefqm71	116	21	and	and	CC
cord-003403-ypefqm71	116	22	five	five	CD
cord-003403-ypefqm71	116	23	serological	serological	JJ
cord-003403-ypefqm71	116	24	assays	assay	NNS
cord-003403-ypefqm71	116	25	in	in	IN
cord-003403-ypefqm71	116	26	roughly	roughly	RB
cord-003403-ypefqm71	116	27	18	18	CD
cord-003403-ypefqm71	116	28	months	month	NNS
cord-003403-ypefqm71	116	29	'	'	POS
cord-003403-ypefqm71	116	30	time	time	NN
cord-003403-ypefqm71	116	31	(	(	-LRB-
cord-003403-ypefqm71	116	32	Tables	table	NNS
cord-003403-ypefqm71	116	33	1	1	CD
cord-003403-ypefqm71	116	34	and	and	CC
cord-003403-ypefqm71	116	35	2	2	CD
cord-003403-ypefqm71	116	36	)	)	-RRB-
cord-003403-ypefqm71	116	37	and	and	CC
cord-003403-ypefqm71	116	38	the	the	DT
cord-003403-ypefqm71	116	39	initiation	initiation	NN
cord-003403-ypefqm71	116	40	of	of	IN
cord-003403-ypefqm71	116	41	efforts	effort	NNS
cord-003403-ypefqm71	116	42	to	to	TO
cord-003403-ypefqm71	116	43	build	build	VB
cord-003403-ypefqm71	116	44	international	international	JJ
cord-003403-ypefqm71	116	45	reference	reference	NN
cord-003403-ypefqm71	116	46	standards	standard	NNS
cord-003403-ypefqm71	116	47	for	for	IN
cord-003403-ypefqm71	116	48	both	both	DT
cord-003403-ypefqm71	116	49	assay	assay	NN
cord-003403-ypefqm71	116	50	types	type	NNS
cord-003403-ypefqm71	116	51	.	.	.
cord-003403-ypefqm71	117	1	However	however	RB
cord-003403-ypefqm71	117	2	,	,	,
cord-003403-ypefqm71	117	3	at	at	IN
cord-003403-ypefqm71	117	4	the	the	DT
cord-003403-ypefqm71	117	5	time	time	NN
cord-003403-ypefqm71	117	6	of	of	IN
cord-003403-ypefqm71	117	7	writing	writing	NN
cord-003403-ypefqm71	117	8	,	,	,
cord-003403-ypefqm71	117	9	there	there	EX
cord-003403-ypefqm71	117	10	are	be	VBP
cord-003403-ypefqm71	117	11	still	still	RB
cord-003403-ypefqm71	117	12	no	no	RB
cord-003403-ypefqm71	117	13	fully	fully	RB
cord-003403-ypefqm71	117	14	approved	approve	VBN
cord-003403-ypefqm71	117	15	diagnostics	diagnostic	NNS
cord-003403-ypefqm71	117	16	,	,	,
cord-003403-ypefqm71	117	17	no	no	DT
cord-003403-ypefqm71	117	18	established	establish	VBN
cord-003403-ypefqm71	117	19	"	"	``
cord-003403-ypefqm71	117	20	gold	gold	JJ
cord-003403-ypefqm71	117	21	standard	standard	NN
cord-003403-ypefqm71	117	22	"	"	''
cord-003403-ypefqm71	117	23	detection	detection	NN
cord-003403-ypefqm71	117	24	methods	method	NNS
cord-003403-ypefqm71	117	25	nor	nor	CC
cord-003403-ypefqm71	117	26	any	any	DT
cord-003403-ypefqm71	117	27	fully	fully	RB
cord-003403-ypefqm71	117	28	characterized	characterize	VBN
cord-003403-ypefqm71	117	29	and	and	CC
cord-003403-ypefqm71	117	30	accepted	accept	VBN
cord-003403-ypefqm71	117	31	international	international	JJ
cord-003403-ypefqm71	117	32	reference	reference	NN
cord-003403-ypefqm71	117	33	standards	standard	NNS
cord-003403-ypefqm71	117	34	for	for	IN
cord-003403-ypefqm71	117	35	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	117	36	.	.	.
cord-003403-ypefqm71	118	1	While	while	IN
cord-003403-ypefqm71	118	2	our	-PRON-	PRP$
cord-003403-ypefqm71	118	3	understanding	understanding	NN
cord-003403-ypefqm71	118	4	of	of	IN
cord-003403-ypefqm71	118	5	the	the	DT
cord-003403-ypefqm71	118	6	immune	immune	JJ
cord-003403-ypefqm71	118	7	response	response	NN
cord-003403-ypefqm71	118	8	to	to	IN
cord-003403-ypefqm71	118	9	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	118	10	has	have	VBZ
cord-003403-ypefqm71	118	11	greatly	greatly	RB
cord-003403-ypefqm71	118	12	expanded	expand	VBN
cord-003403-ypefqm71	118	13	since	since	IN
cord-003403-ypefqm71	118	14	the	the	DT
cord-003403-ypefqm71	118	15	start	start	NN
cord-003403-ypefqm71	118	16	of	of	IN
cord-003403-ypefqm71	118	17	the	the	DT
cord-003403-ypefqm71	118	18	most	most	RBS
cord-003403-ypefqm71	118	19	recent	recent	JJ
cord-003403-ypefqm71	118	20	outbreak	outbreak	NN
cord-003403-ypefqm71	118	21	and	and	CC
cord-003403-ypefqm71	118	22	leverages	leverage	VBZ
cord-003403-ypefqm71	118	23	the	the	DT
cord-003403-ypefqm71	118	24	years	year	NNS
cord-003403-ypefqm71	118	25	of	of	IN
cord-003403-ypefqm71	118	26	vaccine	vaccine	NN
cord-003403-ypefqm71	118	27	research	research	NN
cord-003403-ypefqm71	118	28	for	for	IN
cord-003403-ypefqm71	118	29	other	other	JJ
cord-003403-ypefqm71	118	30	flaviviruses	flavivirus	NNS
cord-003403-ypefqm71	118	31	,	,	,
cord-003403-ypefqm71	118	32	such	such	JJ
cord-003403-ypefqm71	118	33	as	as	IN
cord-003403-ypefqm71	118	34	dengue	dengue	NN
cord-003403-ypefqm71	118	35	,	,	,
cord-003403-ypefqm71	118	36	there	there	EX
cord-003403-ypefqm71	118	37	is	be	VBZ
cord-003403-ypefqm71	118	38	still	still	RB
cord-003403-ypefqm71	118	39	no	no	DT
cord-003403-ypefqm71	118	40	established	establish	VBN
cord-003403-ypefqm71	118	41	immune	immune	JJ
cord-003403-ypefqm71	118	42	correlate	correlate	NN
cord-003403-ypefqm71	118	43	of	of	IN
cord-003403-ypefqm71	118	44	protection	protection	NN
cord-003403-ypefqm71	118	45	.	.	.
cord-003403-ypefqm71	119	1	Other	other	JJ
cord-003403-ypefqm71	119	2	flavivirus	flavivirus	NNP
cord-003403-ypefqm71	120	1	vaccines	vaccine	NNS
cord-003403-ypefqm71	120	2	have	have	VBP
cord-003403-ypefqm71	120	3	established	establish	VBN
cord-003403-ypefqm71	120	4	immune	immune	JJ
cord-003403-ypefqm71	120	5	correlates	correlate	NNS
cord-003403-ypefqm71	120	6	that	that	WDT
cord-003403-ypefqm71	120	7	are	be	VBP
cord-003403-ypefqm71	120	8	based	base	VBN
cord-003403-ypefqm71	120	9	on	on	IN
cord-003403-ypefqm71	120	10	neutralization	neutralization	NN
cord-003403-ypefqm71	120	11	titers	titer	NNS
cord-003403-ypefqm71	120	12	and	and	CC
cord-003403-ypefqm71	120	13	it	-PRON-	PRP
cord-003403-ypefqm71	120	14	has	have	VBZ
cord-003403-ypefqm71	120	15	been	be	VBN
cord-003403-ypefqm71	120	16	assumed	assume	VBN
cord-003403-ypefqm71	120	17	that	that	IN
cord-003403-ypefqm71	120	18	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	120	19	will	will	MD
cord-003403-ypefqm71	120	20	,	,	,
cord-003403-ypefqm71	120	21	as	as	RB
cord-003403-ypefqm71	120	22	well	well	RB
cord-003403-ypefqm71	120	23	[	[	-LRB-
cord-003403-ypefqm71	120	24	97	97	CD
cord-003403-ypefqm71	120	25	]	]	-RRB-
cord-003403-ypefqm71	120	26	.	.	.
cord-003403-ypefqm71	121	1	Post	post	JJ
cord-003403-ypefqm71	121	2	-	-	JJ
cord-003403-ypefqm71	121	3	vaccination	vaccination	JJ
cord-003403-ypefqm71	121	4	serum	serum	NN
cord-003403-ypefqm71	121	5	from	from	IN
cord-003403-ypefqm71	121	6	participants	participant	NNS
cord-003403-ypefqm71	121	7	enrolled	enrol	VBN
cord-003403-ypefqm71	121	8	in	in	IN
cord-003403-ypefqm71	122	1	our	-PRON-	PRP$
cord-003403-ypefqm71	122	2	group	group	NN
cord-003403-ypefqm71	122	3	's	's	POS
cord-003403-ypefqm71	122	4	GLS-5700	GLS-5700	NNP
cord-003403-ypefqm71	122	5	Zika	Zika	NNP
cord-003403-ypefqm71	122	6	DNA	DNA	NNP
cord-003403-ypefqm71	122	7	vaccine	vaccine	NN
cord-003403-ypefqm71	122	8	phase	phase	NN
cord-003403-ypefqm71	122	9	1	1	CD
cord-003403-ypefqm71	122	10	trial	trial	NN
cord-003403-ypefqm71	122	11	protected	protect	VBD
cord-003403-ypefqm71	122	12	92	92	CD
cord-003403-ypefqm71	122	13	%	%	NN
cord-003403-ypefqm71	122	14	of	of	IN
cord-003403-ypefqm71	122	15	interferon	interferon	NN
cord-003403-ypefqm71	122	16	α	α	NNP
cord-003403-ypefqm71	122	17	/	/	SYM
cord-003403-ypefqm71	122	18	β	β	NNP
cord-003403-ypefqm71	122	19	receptor	receptor	NN
cord-003403-ypefqm71	122	20	knockout	knockout	NN
cord-003403-ypefqm71	122	21	mice	mouse	NNS
cord-003403-ypefqm71	122	22	(	(	-LRB-
cord-003403-ypefqm71	122	23	IFNAR	IFNAR	NNP
cord-003403-ypefqm71	122	24	)	)	-RRB-
cord-003403-ypefqm71	122	25	in	in	IN
cord-003403-ypefqm71	122	26	a	a	DT
cord-003403-ypefqm71	122	27	lethal	lethal	JJ
cord-003403-ypefqm71	122	28	-	-	HYPH
cord-003403-ypefqm71	122	29	challenge	challenge	NN
cord-003403-ypefqm71	122	30	model	model	NN
cord-003403-ypefqm71	122	31	of	of	IN
cord-003403-ypefqm71	122	32	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	122	33	infection	infection	NN
cord-003403-ypefqm71	122	34	,	,	,
cord-003403-ypefqm71	122	35	however	however	RB
cord-003403-ypefqm71	122	36	this	this	DT
cord-003403-ypefqm71	122	37	protection	protection	NN
cord-003403-ypefqm71	122	38	was	be	VBD
cord-003403-ypefqm71	122	39	not	not	RB
cord-003403-ypefqm71	122	40	dependent	dependent	JJ
cord-003403-ypefqm71	122	41	upon	upon	IN
cord-003403-ypefqm71	122	42	neutralizing	neutralize	VBG
cord-003403-ypefqm71	122	43	antibody	antibody	NN
cord-003403-ypefqm71	122	44	titers	titer	NNS
cord-003403-ypefqm71	122	45	.	.	.
cord-003403-ypefqm71	123	1	Other	other	JJ
cord-003403-ypefqm71	123	2	vaccines	vaccine	NNS
cord-003403-ypefqm71	123	3	in	in	IN
cord-003403-ypefqm71	123	4	clinical	clinical	JJ
cord-003403-ypefqm71	123	5	development	development	NN
cord-003403-ypefqm71	123	6	have	have	VBP
cord-003403-ypefqm71	123	7	achieved	achieve	VBN
cord-003403-ypefqm71	123	8	neutralizing	neutralize	VBG
cord-003403-ypefqm71	123	9	antibody	antibody	NN
cord-003403-ypefqm71	123	10	titers	titer	NNS
cord-003403-ypefqm71	123	11	in	in	IN
cord-003403-ypefqm71	123	12	humans	human	NNS
cord-003403-ypefqm71	123	13	which	which	WDT
cord-003403-ypefqm71	123	14	were	be	VBD
cord-003403-ypefqm71	123	15	similar	similar	JJ
cord-003403-ypefqm71	123	16	to	to	IN
cord-003403-ypefqm71	123	17	the	the	DT
cord-003403-ypefqm71	123	18	titers	titer	NNS
cord-003403-ypefqm71	123	19	conferring	confer	VBG
cord-003403-ypefqm71	123	20	protection	protection	NN
cord-003403-ypefqm71	123	21	in	in	IN
cord-003403-ypefqm71	123	22	pre	pre	JJ
cord-003403-ypefqm71	123	23	-	-	JJ
cord-003403-ypefqm71	123	24	clinical	clinical	JJ
cord-003403-ypefqm71	123	25	studies	study	NNS
cord-003403-ypefqm71	123	26	of	of	IN
cord-003403-ypefqm71	123	27	the	the	DT
cord-003403-ypefqm71	123	28	vaccines	vaccine	NNS
cord-003403-ypefqm71	123	29	[	[	-LRB-
cord-003403-ypefqm71	123	30	98	98	CD
cord-003403-ypefqm71	123	31	,	,	,
cord-003403-ypefqm71	123	32	99	99	CD
cord-003403-ypefqm71	123	33	]	]	-RRB-
cord-003403-ypefqm71	123	34	.	.	.
cord-003403-ypefqm71	124	1	Serum	serum	NN
cord-003403-ypefqm71	124	2	from	from	IN
cord-003403-ypefqm71	124	3	participants	participant	NNS
cord-003403-ypefqm71	124	4	in	in	IN
cord-003403-ypefqm71	124	5	a	a	DT
cord-003403-ypefqm71	124	6	phase	phase	NN
cord-003403-ypefqm71	124	7	1	1	CD
cord-003403-ypefqm71	124	8	clinical	clinical	JJ
cord-003403-ypefqm71	124	9	study	study	NN
cord-003403-ypefqm71	124	10	receiving	receive	VBG
cord-003403-ypefqm71	124	11	a	a	DT
cord-003403-ypefqm71	124	12	purified	purify	VBN
cord-003403-ypefqm71	124	13	inactivated	inactivate	VBN
cord-003403-ypefqm71	124	14	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	124	15	vaccine	vaccine	NN
cord-003403-ypefqm71	124	16	was	be	VBD
cord-003403-ypefqm71	124	17	also	also	RB
cord-003403-ypefqm71	124	18	able	able	JJ
cord-003403-ypefqm71	124	19	to	to	TO
cord-003403-ypefqm71	124	20	protect	protect	VB
cord-003403-ypefqm71	124	21	mice	mouse	NNS
cord-003403-ypefqm71	124	22	in	in	IN
cord-003403-ypefqm71	124	23	a	a	DT
cord-003403-ypefqm71	124	24	passive	passive	JJ
cord-003403-ypefqm71	124	25	transfer	transfer	NN
cord-003403-ypefqm71	124	26	mouse	mouse	NN
cord-003403-ypefqm71	124	27	model	model	NN
cord-003403-ypefqm71	124	28	[	[	-LRB-
cord-003403-ypefqm71	124	29	98	98	CD
cord-003403-ypefqm71	124	30	]	]	-RRB-
cord-003403-ypefqm71	124	31	.	.	.
cord-003403-ypefqm71	125	1	The	the	DT
cord-003403-ypefqm71	125	2	development	development	NN
cord-003403-ypefqm71	125	3	and	and	CC
cord-003403-ypefqm71	125	4	validation	validation	NN
cord-003403-ypefqm71	125	5	of	of	IN
cord-003403-ypefqm71	125	6	sensitive	sensitive	JJ
cord-003403-ypefqm71	125	7	,	,	,
cord-003403-ypefqm71	125	8	specific	specific	JJ
cord-003403-ypefqm71	125	9	and	and	CC
cord-003403-ypefqm71	125	10	standardized	standardized	JJ
cord-003403-ypefqm71	125	11	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	125	12	immunoassays	immunoassay	NNS
cord-003403-ypefqm71	125	13	to	to	TO
cord-003403-ypefqm71	125	14	better	better	RB
cord-003403-ypefqm71	125	15	characterize	characterize	VB
cord-003403-ypefqm71	125	16	the	the	DT
cord-003403-ypefqm71	125	17	immune	immune	JJ
cord-003403-ypefqm71	125	18	response	response	NN
cord-003403-ypefqm71	125	19	to	to	IN
cord-003403-ypefqm71	125	20	vaccination	vaccination	NN
cord-003403-ypefqm71	125	21	are	be	VBP
cord-003403-ypefqm71	125	22	necessary	necessary	JJ
cord-003403-ypefqm71	125	23	to	to	TO
cord-003403-ypefqm71	125	24	work	work	VB
cord-003403-ypefqm71	125	25	toward	toward	IN
cord-003403-ypefqm71	125	26	the	the	DT
cord-003403-ypefqm71	125	27	establishment	establishment	NN
cord-003403-ypefqm71	125	28	of	of	IN
cord-003403-ypefqm71	125	29	an	an	DT
cord-003403-ypefqm71	125	30	immune	immune	JJ
cord-003403-ypefqm71	125	31	correlate	correlate	NN
cord-003403-ypefqm71	125	32	of	of	IN
cord-003403-ypefqm71	125	33	protection	protection	NN
cord-003403-ypefqm71	125	34	in	in	IN
cord-003403-ypefqm71	125	35	humans	human	NNS
cord-003403-ypefqm71	125	36	.	.	.
cord-003403-ypefqm71	126	1	Efforts	effort	NNS
cord-003403-ypefqm71	126	2	are	be	VBP
cord-003403-ypefqm71	126	3	being	be	VBG
cord-003403-ypefqm71	126	4	made	make	VBN
cord-003403-ypefqm71	126	5	through	through	IN
cord-003403-ypefqm71	126	6	the	the	DT
cord-003403-ypefqm71	126	7	work	work	NN
cord-003403-ypefqm71	126	8	of	of	IN
cord-003403-ypefqm71	126	9	the	the	DT
cord-003403-ypefqm71	126	10	Coalition	Coalition	NNP
cord-003403-ypefqm71	126	11	for	for	IN
cord-003403-ypefqm71	126	12	Epidemic	Epidemic	NNP
cord-003403-ypefqm71	126	13	Preparedness	Preparedness	NNP
cord-003403-ypefqm71	126	14	Innovations	Innovations	NNPS
cord-003403-ypefqm71	126	15	(	(	-LRB-
cord-003403-ypefqm71	126	16	CEPI	CEPI	NNP
cord-003403-ypefqm71	126	17	)	)	-RRB-
cord-003403-ypefqm71	126	18	and	and	CC
cord-003403-ypefqm71	126	19	others	other	NNS
cord-003403-ypefqm71	126	20	to	to	TO
cord-003403-ypefqm71	126	21	ensure	ensure	VB
cord-003403-ypefqm71	126	22	that	that	IN
cord-003403-ypefqm71	126	23	rapid	rapid	JJ
cord-003403-ypefqm71	126	24	response	response	NN
cord-003403-ypefqm71	126	25	mechanisms	mechanism	NNS
cord-003403-ypefqm71	126	26	are	be	VBP
cord-003403-ypefqm71	126	27	in	in	IN
cord-003403-ypefqm71	126	28	place	place	NN
cord-003403-ypefqm71	126	29	to	to	TO
cord-003403-ypefqm71	126	30	address	address	VB
cord-003403-ypefqm71	126	31	emerging	emerge	VBG
cord-003403-ypefqm71	126	32	infectious	infectious	JJ
cord-003403-ypefqm71	126	33	diseases	disease	NNS
cord-003403-ypefqm71	126	34	.	.	.
cord-003403-ypefqm71	127	1	Well	well	RB
cord-003403-ypefqm71	127	2	-	-	HYPH
cord-003403-ypefqm71	127	3	seasoned	season	VBN
cord-003403-ypefqm71	127	4	development	development	NN
cord-003403-ypefqm71	127	5	teams	team	NNS
cord-003403-ypefqm71	127	6	have	have	VBP
cord-003403-ypefqm71	127	7	accepted	accept	VBN
cord-003403-ypefqm71	127	8	the	the	DT
cord-003403-ypefqm71	127	9	challenges	challenge	NNS
cord-003403-ypefqm71	127	10	and	and	CC
cord-003403-ypefqm71	127	11	funding	funding	NN
cord-003403-ypefqm71	127	12	to	to	TO
cord-003403-ypefqm71	127	13	support	support	VB
cord-003403-ypefqm71	127	14	building	build	VBG
cord-003403-ypefqm71	127	15	the	the	DT
cord-003403-ypefqm71	127	16	vaccine	vaccine	NN
cord-003403-ypefqm71	127	17	design	design	NN
cord-003403-ypefqm71	127	18	,	,	,
cord-003403-ypefqm71	127	19	manufacture	manufacture	NN
cord-003403-ypefqm71	127	20	and	and	CC
cord-003403-ypefqm71	127	21	clinical	clinical	JJ
cord-003403-ypefqm71	127	22	assessment	assessment	NN
cord-003403-ypefqm71	127	23	infrastructure	infrastructure	NN
cord-003403-ypefqm71	127	24	needed	need	VBN
cord-003403-ypefqm71	127	25	to	to	TO
cord-003403-ypefqm71	127	26	save	save	VB
cord-003403-ypefqm71	127	27	lives	life	NNS
cord-003403-ypefqm71	127	28	in	in	IN
cord-003403-ypefqm71	127	29	outbreak	outbreak	NN
cord-003403-ypefqm71	127	30	situations	situation	NNS
cord-003403-ypefqm71	127	31	.	.	.
cord-003403-ypefqm71	128	1	Scientific	scientific	JJ
cord-003403-ypefqm71	128	2	and	and	CC
cord-003403-ypefqm71	128	3	quality	quality	NN
cord-003403-ypefqm71	128	4	principles	principle	NNS
cord-003403-ypefqm71	128	5	must	must	MD
cord-003403-ypefqm71	128	6	still	still	RB
cord-003403-ypefqm71	128	7	apply	apply	VB
cord-003403-ypefqm71	128	8	although	although	IN
cord-003403-ypefqm71	128	9	speed	speed	NN
cord-003403-ypefqm71	128	10	may	may	MD
cord-003403-ypefqm71	128	11	be	be	VB
cord-003403-ypefqm71	128	12	required	require	VBN
cord-003403-ypefqm71	128	13	when	when	WRB
cord-003403-ypefqm71	128	14	developing	develop	VBG
cord-003403-ypefqm71	128	15	vaccine	vaccine	NN
cord-003403-ypefqm71	128	16	or	or	CC
cord-003403-ypefqm71	128	17	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	128	18	assays	assay	NNS
cord-003403-ypefqm71	128	19	during	during	IN
cord-003403-ypefqm71	128	20	an	an	DT
cord-003403-ypefqm71	128	21	outbreak	outbreak	NN
cord-003403-ypefqm71	128	22	of	of	IN
cord-003403-ypefqm71	128	23	a	a	DT
cord-003403-ypefqm71	128	24	new	new	JJ
cord-003403-ypefqm71	128	25	emerging	emerge	VBG
cord-003403-ypefqm71	128	26	infectious	infectious	JJ
cord-003403-ypefqm71	128	27	disease	disease	NN
cord-003403-ypefqm71	128	28	.	.	.
cord-003403-ypefqm71	129	1	EID	EID	NNP
cord-003403-ypefqm71	129	2	public	public	JJ
cord-003403-ypefqm71	129	3	health	health	NN
cord-003403-ypefqm71	129	4	and	and	CC
cord-003403-ypefqm71	129	5	countermeasure	countermeasure	NN
cord-003403-ypefqm71	129	6	programs	program	NNS
cord-003403-ypefqm71	129	7	often	often	RB
cord-003403-ypefqm71	129	8	have	have	VBP
cord-003403-ypefqm71	129	9	unique	unique	JJ
cord-003403-ypefqm71	129	10	challenges	challenge	NNS
cord-003403-ypefqm71	129	11	for	for	IN
cord-003403-ypefqm71	129	12	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	129	13	and	and	CC
cord-003403-ypefqm71	129	14	vaccine	vaccine	NN
cord-003403-ypefqm71	129	15	clinical	clinical	JJ
cord-003403-ypefqm71	129	16	assay	assay	NN
cord-003403-ypefqm71	129	17	development	development	NN
cord-003403-ypefqm71	129	18	purposes	purpose	NNS
cord-003403-ypefqm71	129	19	including	include	VBG
cord-003403-ypefqm71	129	20	:	:	:
cord-003403-ypefqm71	129	21	1	1	CD
cord-003403-ypefqm71	129	22	.	.	.
cord-003403-ypefqm71	130	1	Incomplete	incomplete	JJ
cord-003403-ypefqm71	130	2	understanding	understanding	NN
cord-003403-ypefqm71	130	3	of	of	IN
cord-003403-ypefqm71	130	4	biology	biology	NN
cord-003403-ypefqm71	130	5	or	or	CC
cord-003403-ypefqm71	130	6	epidemiology	epidemiology	NN
cord-003403-ypefqm71	130	7	for	for	IN
cord-003403-ypefqm71	130	8	appropriate	appropriate	JJ
cord-003403-ypefqm71	130	9	target	target	NN
cord-003403-ypefqm71	130	10	selection	selection	NN
cord-003403-ypefqm71	130	11	.	.	.
cord-003403-ypefqm71	131	1	Lack	lack	NN
cord-003403-ypefqm71	131	2	of	of	IN
cord-003403-ypefqm71	131	3	available	available	JJ
cord-003403-ypefqm71	131	4	reagent	reagent	NN
cord-003403-ypefqm71	131	5	sources	source	NNS
cord-003403-ypefqm71	131	6	;	;	:
cord-003403-ypefqm71	131	7	inconsistency	inconsistency	NN
cord-003403-ypefqm71	131	8	in	in	IN
cord-003403-ypefqm71	131	9	quantity	quantity	NN
cord-003403-ypefqm71	131	10	and/or	and/or	CC
cord-003403-ypefqm71	131	11	quality	quality	NN
cord-003403-ypefqm71	131	12	of	of	IN
cord-003403-ypefqm71	131	13	those	those	DT
cord-003403-ypefqm71	131	14	available	available	JJ
cord-003403-ypefqm71	131	15	.	.	.
cord-003403-ypefqm71	132	1	Difficulty	difficulty	NN
cord-003403-ypefqm71	132	2	in	in	IN
cord-003403-ypefqm71	132	3	obtaining	obtain	VBG
cord-003403-ypefqm71	132	4	relevant	relevant	JJ
cord-003403-ypefqm71	132	5	human	human	JJ
cord-003403-ypefqm71	132	6	sample	sample	NN
cord-003403-ypefqm71	132	7	panels	panel	NNS
cord-003403-ypefqm71	132	8	for	for	IN
cord-003403-ypefqm71	132	9	the	the	DT
cord-003403-ypefqm71	132	10	evaluation	evaluation	NN
cord-003403-ypefqm71	132	11	of	of	IN
cord-003403-ypefqm71	132	12	test	test	NN
cord-003403-ypefqm71	132	13	methods	method	NNS
cord-003403-ypefqm71	132	14	.	.	.
cord-003403-ypefqm71	133	1	Challenges	challenge	NNS
cord-003403-ypefqm71	133	2	to	to	TO
cord-003403-ypefqm71	133	3	produce	produce	VB
cord-003403-ypefqm71	133	4	clear	clear	JJ
cord-003403-ypefqm71	133	5	line	line	NN
cord-003403-ypefqm71	133	6	of	of	IN
cord-003403-ypefqm71	133	7	sight	sight	NN
cord-003403-ypefqm71	133	8	sourcing	sourcing	NN
cord-003403-ypefqm71	133	9	and	and	CC
cord-003403-ypefqm71	133	10	quality	quality	NN
cord-003403-ypefqm71	133	11	from	from	IN
cord-003403-ypefqm71	133	12	early	early	JJ
cord-003403-ypefqm71	133	13	vaccine	vaccine	NN
cord-003403-ypefqm71	133	14	development	development	NN
cord-003403-ypefqm71	133	15	through	through	IN
cord-003403-ypefqm71	133	16	licensure	licensure	NN
cord-003403-ypefqm71	133	17	.	.	.
cord-003403-ypefqm71	134	1	Although	although	IN
cord-003403-ypefqm71	134	2	the	the	DT
cord-003403-ypefqm71	134	3	speed	speed	NN
cord-003403-ypefqm71	134	4	at	at	IN
cord-003403-ypefqm71	134	5	which	which	WDT
cord-003403-ypefqm71	134	6	the	the	DT
cord-003403-ypefqm71	134	7	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	134	8	or	or	CC
cord-003403-ypefqm71	134	9	vaccine	vaccine	NN
cord-003403-ypefqm71	134	10	development	development	NN
cord-003403-ypefqm71	134	11	field	field	NN
cord-003403-ypefqm71	134	12	needs	need	VBZ
cord-003403-ypefqm71	134	13	to	to	TO
cord-003403-ypefqm71	134	14	move	move	VB
cord-003403-ypefqm71	134	15	will	will	MD
cord-003403-ypefqm71	134	16	be	be	VB
cord-003403-ypefqm71	134	17	dependent	dependent	JJ
cord-003403-ypefqm71	134	18	upon	upon	IN
cord-003403-ypefqm71	134	19	the	the	DT
cord-003403-ypefqm71	134	20	urgency	urgency	NN
cord-003403-ypefqm71	134	21	of	of	IN
cord-003403-ypefqm71	134	22	the	the	DT
cord-003403-ypefqm71	134	23	emerging	emerge	VBG
cord-003403-ypefqm71	134	24	infectious	infectious	JJ
cord-003403-ypefqm71	134	25	pathogen	pathogen	NN
cord-003403-ypefqm71	134	26	and	and	CC
cord-003403-ypefqm71	134	27	its	-PRON-	PRP$
cord-003403-ypefqm71	134	28	impact	impact	NN
cord-003403-ypefqm71	134	29	on	on	IN
cord-003403-ypefqm71	134	30	human	human	JJ
cord-003403-ypefqm71	134	31	life	life	NN
cord-003403-ypefqm71	134	32	,	,	,
cord-003403-ypefqm71	134	33	biological	biological	JJ
cord-003403-ypefqm71	134	34	assay	assay	NN
cord-003403-ypefqm71	134	35	standardization	standardization	NN
cord-003403-ypefqm71	134	36	is	be	VBZ
cord-003403-ypefqm71	134	37	a	a	DT
cord-003403-ypefqm71	134	38	critical	critical	JJ
cord-003403-ypefqm71	134	39	component	component	NN
cord-003403-ypefqm71	134	40	and	and	CC
cord-003403-ypefqm71	134	41	requires	require	VBZ
cord-003403-ypefqm71	134	42	three	three	CD
cord-003403-ypefqm71	134	43	separate	separate	JJ
cord-003403-ypefqm71	134	44	activities	activity	NNS
cord-003403-ypefqm71	134	45	:	:	:
cord-003403-ypefqm71	135	1	•	•	NNP
cord-003403-ypefqm71	135	2	Development	Development	NNP
cord-003403-ypefqm71	135	3	of	of	IN
cord-003403-ypefqm71	135	4	relevant	relevant	JJ
cord-003403-ypefqm71	135	5	,	,	,
cord-003403-ypefqm71	135	6	sensitive	sensitive	JJ
cord-003403-ypefqm71	135	7	,	,	,
cord-003403-ypefqm71	135	8	specific	specific	JJ
cord-003403-ypefqm71	135	9	and	and	CC
cord-003403-ypefqm71	135	10	preferably	preferably	RB
cord-003403-ypefqm71	135	11	quantitative	quantitative	JJ
cord-003403-ypefqm71	135	12	biological	biological	JJ
cord-003403-ypefqm71	135	13	assays	assay	NNS
cord-003403-ypefqm71	135	14	.	.	.
cord-003403-ypefqm71	136	1	Use	use	NN
cord-003403-ypefqm71	136	2	of	of	IN
cord-003403-ypefqm71	136	3	biostatistics	biostatistic	NNS
cord-003403-ypefqm71	136	4	to	to	TO
cord-003403-ypefqm71	136	5	analyze	analyze	VB
cord-003403-ypefqm71	136	6	assay	assay	NN
cord-003403-ypefqm71	136	7	performance	performance	NN
cord-003403-ypefqm71	136	8	data	datum	NNS
cord-003403-ypefqm71	136	9	from	from	IN
cord-003403-ypefqm71	136	10	development	development	NN
cord-003403-ypefqm71	136	11	to	to	IN
cord-003403-ypefqm71	136	12	validation	validation	NN
cord-003403-ypefqm71	136	13	to	to	IN
cord-003403-ypefqm71	136	14	life	life	NN
cord-003403-ypefqm71	136	15	cycle	cycle	NN
cord-003403-ypefqm71	136	16	performance	performance	NN
cord-003403-ypefqm71	136	17	management	management	NN
cord-003403-ypefqm71	136	18	.	.	.
cord-003403-ypefqm71	137	1	•	•	NFP
cord-003403-ypefqm71	137	2	Ability	ability	NN
cord-003403-ypefqm71	137	3	to	to	TO
cord-003403-ypefqm71	137	4	prepare	prepare	VB
cord-003403-ypefqm71	137	5	stable	stable	JJ
cord-003403-ypefqm71	137	6	and	and	CC
cord-003403-ypefqm71	137	7	reproducible	reproducible	JJ
cord-003403-ypefqm71	137	8	results	result	NNS
cord-003403-ypefqm71	137	9	over	over	IN
cord-003403-ypefqm71	137	10	time	time	NN
cord-003403-ypefqm71	137	11	to	to	TO
cord-003403-ypefqm71	137	12	support	support	VB
cord-003403-ypefqm71	137	13	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	137	14	or	or	CC
cord-003403-ypefqm71	137	15	vaccine	vaccine	NN
cord-003403-ypefqm71	137	16	program	program	NN
cord-003403-ypefqm71	137	17	needs	need	NNS
cord-003403-ypefqm71	137	18	.	.	.
cord-003403-ypefqm71	138	1	If	if	IN
cord-003403-ypefqm71	138	2	assay	assay	NN
cord-003403-ypefqm71	138	3	performance	performance	NN
cord-003403-ypefqm71	138	4	consistency	consistency	NN
cord-003403-ypefqm71	138	5	and	and	CC
cord-003403-ypefqm71	138	6	quality	quality	NN
cord-003403-ypefqm71	138	7	is	be	VBZ
cord-003403-ypefqm71	138	8	not	not	RB
cord-003403-ypefqm71	138	9	demonstrated	demonstrate	VBN
cord-003403-ypefqm71	138	10	,	,	,
cord-003403-ypefqm71	138	11	the	the	DT
cord-003403-ypefqm71	138	12	validity	validity	NN
cord-003403-ypefqm71	138	13	of	of	IN
cord-003403-ypefqm71	138	14	clinical	clinical	JJ
cord-003403-ypefqm71	138	15	study	study	NN
cord-003403-ypefqm71	138	16	results	result	NNS
cord-003403-ypefqm71	138	17	may	may	MD
cord-003403-ypefqm71	138	18	be	be	VB
cord-003403-ypefqm71	138	19	questioned	question	VBN
cord-003403-ypefqm71	138	20	.	.	.
cord-003403-ypefqm71	139	1	Assay	assay	NN
cord-003403-ypefqm71	139	2	standardization	standardization	NN
cord-003403-ypefqm71	139	3	for	for	IN
cord-003403-ypefqm71	139	4	any	any	DT
cord-003403-ypefqm71	139	5	newly	newly	RB
cord-003403-ypefqm71	139	6	emergent	emergent	JJ
cord-003403-ypefqm71	139	7	infectious	infectious	JJ
cord-003403-ypefqm71	139	8	disease	disease	NN
cord-003403-ypefqm71	139	9	will	will	MD
cord-003403-ypefqm71	139	10	be	be	VB
cord-003403-ypefqm71	139	11	challenging	challenging	JJ
cord-003403-ypefqm71	139	12	and	and	CC
cord-003403-ypefqm71	139	13	will	will	MD
cord-003403-ypefqm71	139	14	:	:	:
cord-003403-ypefqm71	139	15	(	(	-LRB-
cord-003403-ypefqm71	139	16	i	i	NN
cord-003403-ypefqm71	139	17	)	)	-RRB-
cord-003403-ypefqm71	139	18	take	take	VB
cord-003403-ypefqm71	139	19	time	time	NN
cord-003403-ypefqm71	139	20	to	to	TO
cord-003403-ypefqm71	139	21	develop	develop	VB
cord-003403-ypefqm71	139	22	,	,	,
cord-003403-ypefqm71	139	23	collect	collect	VB
cord-003403-ypefqm71	139	24	and	and	CC
cord-003403-ypefqm71	139	25	characterize	characterize	VB
cord-003403-ypefqm71	139	26	quality	quality	NN
cord-003403-ypefqm71	139	27	reagents	reagent	NNS
cord-003403-ypefqm71	139	28	,	,	,
cord-003403-ypefqm71	139	29	(	(	-LRB-
cord-003403-ypefqm71	139	30	ii	ii	NN
cord-003403-ypefqm71	139	31	)	)	-RRB-
cord-003403-ypefqm71	139	32	to	to	TO
cord-003403-ypefqm71	139	33	achieve	achieve	VB
cord-003403-ypefqm71	139	34	sufficient	sufficient	JJ
cord-003403-ypefqm71	139	35	sources	source	NNS
cord-003403-ypefqm71	139	36	of	of	IN
cord-003403-ypefqm71	139	37	confirmed	confirm	VBN
cord-003403-ypefqm71	139	38	positive	positive	JJ
cord-003403-ypefqm71	139	39	samples	sample	NNS
cord-003403-ypefqm71	139	40	for	for	IN
cord-003403-ypefqm71	139	41	establishment	establishment	NN
cord-003403-ypefqm71	139	42	of	of	IN
cord-003403-ypefqm71	139	43	serological	serological	JJ
cord-003403-ypefqm71	139	44	standards	standard	NNS
cord-003403-ypefqm71	139	45	,	,	,
cord-003403-ypefqm71	139	46	and	and	CC
cord-003403-ypefqm71	139	47	(	(	-LRB-
cord-003403-ypefqm71	139	48	iii	iii	NN
cord-003403-ypefqm71	139	49	)	)	-RRB-
cord-003403-ypefqm71	139	50	to	to	TO
cord-003403-ypefqm71	139	51	confirm	confirm	VB
cord-003403-ypefqm71	139	52	new	new	JJ
cord-003403-ypefqm71	139	53	molecular	molecular	JJ
cord-003403-ypefqm71	139	54	standards	standard	NNS
cord-003403-ypefqm71	139	55	,	,	,
cord-003403-ypefqm71	139	56	though	though	IN
cord-003403-ypefqm71	139	57	this	this	DT
cord-003403-ypefqm71	139	58	is	be	VBZ
cord-003403-ypefqm71	139	59	more	more	RBR
cord-003403-ypefqm71	139	60	straightforward	straightforward	JJ
cord-003403-ypefqm71	139	61	for	for	IN
cord-003403-ypefqm71	139	62	molecular	molecular	JJ
cord-003403-ypefqm71	139	63	assays	assay	NNS
cord-003403-ypefqm71	139	64	than	than	IN
cord-003403-ypefqm71	139	65	serology	serology	NN
cord-003403-ypefqm71	139	66	.	.	.
cord-003403-ypefqm71	140	1	Any	any	DT
cord-003403-ypefqm71	140	2	efforts	effort	NNS
cord-003403-ypefqm71	140	3	to	to	TO
cord-003403-ypefqm71	140	4	prepare	prepare	VB
cord-003403-ypefqm71	140	5	reagents	reagent	NNS
cord-003403-ypefqm71	140	6	,	,	,
cord-003403-ypefqm71	140	7	collect	collect	VB
cord-003403-ypefqm71	140	8	characterized	characterize	VBN
cord-003403-ypefqm71	140	9	samples	sample	NNS
cord-003403-ypefqm71	140	10	,	,	,
cord-003403-ypefqm71	140	11	develop	develop	VB
cord-003403-ypefqm71	140	12	research	research	NN
cord-003403-ypefqm71	140	13	materials	material	NNS
cord-003403-ypefqm71	140	14	and	and	CC
cord-003403-ypefqm71	140	15	international	international	JJ
cord-003403-ypefqm71	140	16	standards	standard	NNS
cord-003403-ypefqm71	140	17	in	in	IN
cord-003403-ypefqm71	140	18	advance	advance	NN
cord-003403-ypefqm71	140	19	for	for	IN
cord-003403-ypefqm71	140	20	EIDs	eid	NNS
cord-003403-ypefqm71	140	21	for	for	IN
cord-003403-ypefqm71	140	22	whom	whom	WP
cord-003403-ypefqm71	140	23	alerts	alert	VBZ
cord-003403-ypefqm71	140	24	have	have	VBP
cord-003403-ypefqm71	140	25	already	already	RB
cord-003403-ypefqm71	140	26	been	be	VBN
cord-003403-ypefqm71	140	27	raised	raise	VBN
cord-003403-ypefqm71	140	28	will	will	MD
cord-003403-ypefqm71	140	29	leave	leave	VB
cord-003403-ypefqm71	140	30	the	the	DT
cord-003403-ypefqm71	140	31	field	field	NN
cord-003403-ypefqm71	140	32	better	better	RB
cord-003403-ypefqm71	140	33	suited	suited	JJ
cord-003403-ypefqm71	140	34	to	to	TO
cord-003403-ypefqm71	140	35	respond	respond	VB
cord-003403-ypefqm71	140	36	in	in	IN
cord-003403-ypefqm71	140	37	case	case	NN
cord-003403-ypefqm71	140	38	of	of	IN
cord-003403-ypefqm71	140	39	emergency	emergency	NN
cord-003403-ypefqm71	140	40	.	.	.
cord-003403-ypefqm71	140	41	 	 	_SP
cord-003403-ypefqm71	141	1	Rapid	rapid	JJ
cord-003403-ypefqm71	141	2	response	response	NN
cord-003403-ypefqm71	141	3	to	to	IN
cord-003403-ypefqm71	141	4	an	an	DT
cord-003403-ypefqm71	141	5	emerging	emerge	VBG
cord-003403-ypefqm71	141	6	infectious	infectious	JJ
cord-003403-ypefqm71	141	7	disease	disease	NN
cord-003403-ypefqm71	141	8	-	-	HYPH
cord-003403-ypefqm71	141	9	lessons	lesson	NNS
cord-003403-ypefqm71	141	10	learned	learn	VBN
cord-003403-ypefqm71	141	11	from	from	IN
cord-003403-ypefqm71	141	12	development	development	NN
cord-003403-ypefqm71	141	13	of	of	IN
cord-003403-ypefqm71	141	14	a	a	DT
cord-003403-ypefqm71	141	15	synthetic	synthetic	JJ
cord-003403-ypefqm71	141	16	DNA	dna	NN
cord-003403-ypefqm71	141	17	vaccine	vaccine	NN
cord-003403-ypefqm71	141	18	targeting	target	VBG
cord-003403-ypefqm71	141	19	Zika	Zika	NNP
cord-003403-ypefqm71	141	20	virus	virus	NN
cord-003403-ypefqm71	141	21	Safety	safety	NN
cord-003403-ypefqm71	141	22	and	and	CC
cord-003403-ypefqm71	141	23	immunogenicity	immunogenicity	NN
cord-003403-ypefqm71	141	24	of	of	IN
cord-003403-ypefqm71	141	25	an	an	DT
cord-003403-ypefqm71	141	26	anti	anti	JJ
cord-003403-ypefqm71	141	27	-	-	JJ
cord-003403-ypefqm71	141	28	zika	zika	JJ
cord-003403-ypefqm71	141	29	virus	virus	NN
cord-003403-ypefqm71	141	30	DNA	DNA	NNP
cord-003403-ypefqm71	141	31	vaccine	vaccine	NN
cord-003403-ypefqm71	141	32	-	-	HYPH
cord-003403-ypefqm71	141	33	Preliminary	preliminary	JJ
cord-003403-ypefqm71	141	34	report	report	NN
cord-003403-ypefqm71	141	35	Vaccines	vaccine	NNS
cord-003403-ypefqm71	141	36	for	for	IN
cord-003403-ypefqm71	141	37	emerging	emerge	VBG
cord-003403-ypefqm71	141	38	infectious	infectious	JJ
cord-003403-ypefqm71	141	39	diseases	disease	NNS
cord-003403-ypefqm71	141	40	:	:	:
cord-003403-ypefqm71	142	1	Lessons	lesson	NNS
cord-003403-ypefqm71	142	2	from	from	IN
cord-003403-ypefqm71	142	3	MERS	MERS	NNP
cord-003403-ypefqm71	142	4	coronavirus	coronavirus	NN
cord-003403-ypefqm71	142	5	and	and	CC
cord-003403-ypefqm71	142	6	Zika	Zika	NNP
cord-003403-ypefqm71	142	7	virus	virus	NN
cord-003403-ypefqm71	142	8	Utilization	utilization	NN
cord-003403-ypefqm71	142	9	of	of	IN
cord-003403-ypefqm71	142	10	serologic	serologic	JJ
cord-003403-ypefqm71	142	11	assays	assay	NNS
cord-003403-ypefqm71	142	12	to	to	TO
cord-003403-ypefqm71	142	13	support	support	VB
cord-003403-ypefqm71	142	14	efficacy	efficacy	NN
cord-003403-ypefqm71	142	15	of	of	IN
cord-003403-ypefqm71	142	16	vaccines	vaccine	NNS
cord-003403-ypefqm71	142	17	in	in	IN
cord-003403-ypefqm71	142	18	nonclinical	nonclinical	JJ
cord-003403-ypefqm71	142	19	and	and	CC
cord-003403-ypefqm71	142	20	clinical	clinical	JJ
cord-003403-ypefqm71	142	21	trials	trial	NNS
cord-003403-ypefqm71	142	22	:	:	:
cord-003403-ypefqm71	142	23	Meeting	meet	VBG
cord-003403-ypefqm71	142	24	at	at	IN
cord-003403-ypefqm71	142	25	the	the	DT
cord-003403-ypefqm71	142	26	crossroads	crossroad	NNS
cord-003403-ypefqm71	142	27	.	.	.
cord-003403-ypefqm71	143	1	Vaccine	vaccine	NN
cord-003403-ypefqm71	143	2	Nomenclature	Nomenclature	NNP
cord-003403-ypefqm71	143	3	for	for	IN
cord-003403-ypefqm71	143	4	immune	immune	JJ
cord-003403-ypefqm71	143	5	correlates	correlate	NNS
cord-003403-ypefqm71	143	6	of	of	IN
cord-003403-ypefqm71	143	7	protection	protection	NN
cord-003403-ypefqm71	143	8	after	after	IN
cord-003403-ypefqm71	143	9	vaccination	vaccination	NN
cord-003403-ypefqm71	143	10	Zika	Zika	NNP
cord-003403-ypefqm71	143	11	virus	virus	NN
cord-003403-ypefqm71	143	12	outbreak	outbreak	NN
cord-003403-ypefqm71	143	13	on	on	IN
cord-003403-ypefqm71	143	14	Yap	Yap	NNP
cord-003403-ypefqm71	143	15	Island	Island	NNP
cord-003403-ypefqm71	143	16	,	,	,
cord-003403-ypefqm71	143	17	Federated	Federated	NNP
cord-003403-ypefqm71	143	18	States	States	NNP
cord-003403-ypefqm71	143	19	of	of	IN
cord-003403-ypefqm71	143	20	Micronesia	Micronesia	NNP
cord-003403-ypefqm71	143	21	Zika	Zika	NNP
cord-003403-ypefqm71	143	22	virus	virus	NN
cord-003403-ypefqm71	143	23	,	,	,
cord-003403-ypefqm71	143	24	French	French	NNP
cord-003403-ypefqm71	143	25	polynesia	polynesia	NNP
cord-003403-ypefqm71	143	26	,	,	,
cord-003403-ypefqm71	144	1	South	South	NNP
cord-003403-ypefqm71	144	2	pacific	pacific	NNP
cord-003403-ypefqm71	144	3	Zika	Zika	NNP
cord-003403-ypefqm71	144	4	virus	virus	NN
cord-003403-ypefqm71	144	5	:	:	:
cord-003403-ypefqm71	144	6	History	history	NN
cord-003403-ypefqm71	144	7	,	,	,
cord-003403-ypefqm71	144	8	epidemiology	epidemiology	NN
cord-003403-ypefqm71	144	9	,	,	,
cord-003403-ypefqm71	144	10	transmission	transmission	NN
cord-003403-ypefqm71	144	11	,	,	,
cord-003403-ypefqm71	144	12	and	and	CC
cord-003403-ypefqm71	144	13	clinical	clinical	JJ
cord-003403-ypefqm71	144	14	presentation	presentation	NN
cord-003403-ypefqm71	144	15	Guillain	Guillain	NNP
cord-003403-ypefqm71	144	16	-	-	HYPH
cord-003403-ypefqm71	144	17	Barre	Barre	NNP
cord-003403-ypefqm71	144	18	Syndrome	Syndrome	NNP
cord-003403-ypefqm71	144	19	outbreak	outbreak	NN
cord-003403-ypefqm71	144	20	associated	associate	VBN
cord-003403-ypefqm71	144	21	with	with	IN
cord-003403-ypefqm71	144	22	Zika	Zika	NNP
cord-003403-ypefqm71	144	23	virus	virus	NN
cord-003403-ypefqm71	144	24	infection	infection	NN
cord-003403-ypefqm71	144	25	in	in	IN
cord-003403-ypefqm71	144	26	French	French	NNP
cord-003403-ypefqm71	144	27	Polynesia	Polynesia	NNP
cord-003403-ypefqm71	144	28	:	:	:
cord-003403-ypefqm71	144	29	A	a	DT
cord-003403-ypefqm71	144	30	case	case	NN
cord-003403-ypefqm71	144	31	-	-	HYPH
cord-003403-ypefqm71	144	32	control	control	NN
cord-003403-ypefqm71	144	33	study	study	NN
cord-003403-ypefqm71	144	34	Teratogenic	teratogenic	JJ
cord-003403-ypefqm71	144	35	effects	effect	NNS
cord-003403-ypefqm71	144	36	of	of	IN
cord-003403-ypefqm71	144	37	the	the	DT
cord-003403-ypefqm71	144	38	Zika	Zika	NNP
cord-003403-ypefqm71	144	39	virus	virus	NN
cord-003403-ypefqm71	144	40	and	and	CC
cord-003403-ypefqm71	144	41	the	the	DT
cord-003403-ypefqm71	144	42	role	role	NN
cord-003403-ypefqm71	144	43	of	of	IN
cord-003403-ypefqm71	144	44	the	the	DT
cord-003403-ypefqm71	144	45	placenta	placenta	NN
cord-003403-ypefqm71	144	46	Zika	Zika	NNP
cord-003403-ypefqm71	144	47	Virus	Virus	NNP
cord-003403-ypefqm71	144	48	targets	target	VBZ
cord-003403-ypefqm71	144	49	different	different	JJ
cord-003403-ypefqm71	144	50	primary	primary	JJ
cord-003403-ypefqm71	144	51	human	human	JJ
cord-003403-ypefqm71	144	52	placental	placental	NN
cord-003403-ypefqm71	144	53	cells	cell	NNS
cord-003403-ypefqm71	144	54	,	,	,
cord-003403-ypefqm71	144	55	suggesting	suggest	VBG
cord-003403-ypefqm71	144	56	two	two	CD
cord-003403-ypefqm71	144	57	routes	route	NNS
cord-003403-ypefqm71	144	58	for	for	IN
cord-003403-ypefqm71	144	59	vertical	vertical	JJ
cord-003403-ypefqm71	144	60	transmission	transmission	NN
cord-003403-ypefqm71	144	61	Zika	Zika	NNP
cord-003403-ypefqm71	144	62	Virus	Virus	NNP
cord-003403-ypefqm71	144	63	on	on	IN
cord-003403-ypefqm71	144	64	a	a	DT
cord-003403-ypefqm71	144	65	spreading	spread	VBG
cord-003403-ypefqm71	144	66	spree	spree	NN
cord-003403-ypefqm71	144	67	:	:	:
cord-003403-ypefqm71	144	68	What	what	WP
cord-003403-ypefqm71	144	69	we	-PRON-	PRP
cord-003403-ypefqm71	144	70	now	now	RB
cord-003403-ypefqm71	144	71	know	know	VBP
cord-003403-ypefqm71	144	72	that	that	DT
cord-003403-ypefqm71	144	73	was	be	VBD
cord-003403-ypefqm71	144	74	unknown	unknown	JJ
cord-003403-ypefqm71	144	75	in	in	IN
cord-003403-ypefqm71	144	76	the	the	DT
cord-003403-ypefqm71	144	77	1950	1950	CD
cord-003403-ypefqm71	144	78	's	's	POS
cord-003403-ypefqm71	144	79	Miscarriage	miscarriage	NN
cord-003403-ypefqm71	144	80	associated	associate	VBN
cord-003403-ypefqm71	144	81	with	with	IN
cord-003403-ypefqm71	144	82	Zika	Zika	NNP
cord-003403-ypefqm71	144	83	Virus	Virus	NNP
cord-003403-ypefqm71	144	84	infection	infection	NN
cord-003403-ypefqm71	144	85	Zika	Zika	NNP
cord-003403-ypefqm71	144	86	virus	virus	NN
cord-003403-ypefqm71	144	87	epidemic	epidemic	NN
cord-003403-ypefqm71	144	88	in	in	IN
cord-003403-ypefqm71	144	89	Brazil	Brazil	NNP
cord-003403-ypefqm71	144	90	.	.	.
cord-003403-ypefqm71	145	1	I.	I.	NNP
cord-003403-ypefqm71	145	2	Fatal	fatal	JJ
cord-003403-ypefqm71	145	3	disease	disease	NN
cord-003403-ypefqm71	145	4	in	in	IN
cord-003403-ypefqm71	145	5	adults	adult	NNS
cord-003403-ypefqm71	145	6	:	:	:
cord-003403-ypefqm71	146	1	Clinical	clinical	JJ
cord-003403-ypefqm71	146	2	and	and	CC
cord-003403-ypefqm71	146	3	laboratorial	laboratorial	JJ
cord-003403-ypefqm71	146	4	aspects	aspect	NNS
cord-003403-ypefqm71	147	1	Zika	Zika	NNP
cord-003403-ypefqm71	147	2	virus	virus	NN
cord-003403-ypefqm71	147	3	associated	associate	VBD
cord-003403-ypefqm71	147	4	deaths	death	NNS
cord-003403-ypefqm71	147	5	in	in	IN
cord-003403-ypefqm71	147	6	Colombia	Colombia	NNP
cord-003403-ypefqm71	147	7	Evaluation	Evaluation	NNP
cord-003403-ypefqm71	147	8	of	of	IN
cord-003403-ypefqm71	147	9	a	a	DT
cord-003403-ypefqm71	147	10	prototype	prototype	NN
cord-003403-ypefqm71	147	11	dengue-1	dengue-1	NNP
cord-003403-ypefqm71	147	12	DNA	DNA	NNP
cord-003403-ypefqm71	147	13	vaccine	vaccine	NN
cord-003403-ypefqm71	147	14	in	in	IN
cord-003403-ypefqm71	147	15	a	a	DT
cord-003403-ypefqm71	147	16	Phase	phase	NN
cord-003403-ypefqm71	147	17	1	1	CD
cord-003403-ypefqm71	147	18	clinical	clinical	JJ
cord-003403-ypefqm71	147	19	trial	trial	NN
cord-003403-ypefqm71	147	20	Development	Development	NNP
cord-003403-ypefqm71	147	21	of	of	IN
cord-003403-ypefqm71	147	22	a	a	DT
cord-003403-ypefqm71	147	23	novel	novel	JJ
cord-003403-ypefqm71	147	24	DNA	dna	NN
cord-003403-ypefqm71	147	25	SynCon	SynCon	NNP
cord-003403-ypefqm71	147	26	tetravalent	tetravalent	NN
cord-003403-ypefqm71	147	27	dengue	dengue	NN
cord-003403-ypefqm71	147	28	vaccine	vaccine	NN
cord-003403-ypefqm71	147	29	that	that	WDT
cord-003403-ypefqm71	147	30	elicits	elicit	VBZ
cord-003403-ypefqm71	147	31	immune	immune	JJ
cord-003403-ypefqm71	147	32	responses	response	NNS
cord-003403-ypefqm71	147	33	against	against	IN
cord-003403-ypefqm71	147	34	four	four	CD
cord-003403-ypefqm71	147	35	serotypes	serotype	NNS
cord-003403-ypefqm71	147	36	A	a	DT
cord-003403-ypefqm71	147	37	West	West	NNP
cord-003403-ypefqm71	147	38	Nile	Nile	NNP
cord-003403-ypefqm71	147	39	virus	virus	NN
cord-003403-ypefqm71	147	40	DNA	dna	NN
cord-003403-ypefqm71	147	41	vaccine	vaccine	NN
cord-003403-ypefqm71	147	42	utilizing	utilize	VBG
cord-003403-ypefqm71	147	43	a	a	DT
cord-003403-ypefqm71	147	44	modified	modify	VBN
cord-003403-ypefqm71	147	45	promoter	promoter	NN
cord-003403-ypefqm71	147	46	induces	induce	VBZ
cord-003403-ypefqm71	147	47	neutralizing	neutralize	VBG
cord-003403-ypefqm71	147	48	antibody	antibody	NN
cord-003403-ypefqm71	147	49	in	in	IN
cord-003403-ypefqm71	147	50	younger	young	JJR
cord-003403-ypefqm71	147	51	and	and	CC
cord-003403-ypefqm71	147	52	older	old	JJR
cord-003403-ypefqm71	147	53	healthy	healthy	JJ
cord-003403-ypefqm71	147	54	adults	adult	NNS
cord-003403-ypefqm71	147	55	in	in	IN
cord-003403-ypefqm71	147	56	a	a	DT
cord-003403-ypefqm71	147	57	phase	phase	NN
cord-003403-ypefqm71	147	58	I.	i.	NN
cord-003403-ypefqm71	147	59	clinical	clinical	JJ
cord-003403-ypefqm71	147	60	trial	trial	NN
cord-003403-ypefqm71	148	1	A	a	DT
cord-003403-ypefqm71	148	2	West	West	NNP
cord-003403-ypefqm71	148	3	Nile	Nile	NNP
cord-003403-ypefqm71	148	4	virus	virus	NN
cord-003403-ypefqm71	148	5	DNA	dna	NN
cord-003403-ypefqm71	148	6	vaccine	vaccine	NN
cord-003403-ypefqm71	148	7	induces	induce	VBZ
cord-003403-ypefqm71	148	8	neutralizing	neutralize	VBG
cord-003403-ypefqm71	148	9	antibody	antibody	NN
cord-003403-ypefqm71	148	10	in	in	IN
cord-003403-ypefqm71	148	11	healthy	healthy	JJ
cord-003403-ypefqm71	148	12	adults	adult	NNS
cord-003403-ypefqm71	148	13	during	during	IN
cord-003403-ypefqm71	148	14	a	a	DT
cord-003403-ypefqm71	148	15	phase	phase	NN
cord-003403-ypefqm71	148	16	1	1	CD
cord-003403-ypefqm71	148	17	clinical	clinical	JJ
cord-003403-ypefqm71	148	18	trial	trial	NN
cord-003403-ypefqm71	148	19	Coimmunization	Coimmunization	NNP
cord-003403-ypefqm71	148	20	with	with	IN
cord-003403-ypefqm71	148	21	an	an	DT
cord-003403-ypefqm71	148	22	optimized	optimize	VBN
cord-003403-ypefqm71	148	23	IL15	IL15	NNP
cord-003403-ypefqm71	148	24	plasmid	plasmid	NN
cord-003403-ypefqm71	148	25	adjuvant	adjuvant	NN
cord-003403-ypefqm71	148	26	enhances	enhance	VBZ
cord-003403-ypefqm71	148	27	humoral	humoral	JJ
cord-003403-ypefqm71	148	28	immunity	immunity	NN
cord-003403-ypefqm71	148	29	via	via	IN
cord-003403-ypefqm71	148	30	stimulating	stimulate	VBG
cord-003403-ypefqm71	148	31	B	b	NN
cord-003403-ypefqm71	148	32	cells	cell	NNS
cord-003403-ypefqm71	148	33	induced	induce	VBN
cord-003403-ypefqm71	148	34	by	by	IN
cord-003403-ypefqm71	148	35	genetically	genetically	RB
cord-003403-ypefqm71	148	36	engineered	engineer	VBN
cord-003403-ypefqm71	148	37	DNA	dna	NN
cord-003403-ypefqm71	148	38	vaccines	vaccine	NNS
cord-003403-ypefqm71	148	39	expressing	express	VBG
cord-003403-ypefqm71	148	40	consensus	consensus	NN
cord-003403-ypefqm71	148	41	JEV	JEV	NNP
cord-003403-ypefqm71	148	42	and	and	CC
cord-003403-ypefqm71	148	43	WNV	WNV	NNP
cord-003403-ypefqm71	148	44	E	E	NNP
cord-003403-ypefqm71	148	45	DIII	DIII	NNP
cord-003403-ypefqm71	148	46	Induction	Induction	NNP
cord-003403-ypefqm71	148	47	of	of	IN
cord-003403-ypefqm71	148	48	potent	potent	JJ
cord-003403-ypefqm71	148	49	Th1-type	Th1-type	NNP
cord-003403-ypefqm71	148	50	immune	immune	JJ
cord-003403-ypefqm71	148	51	responses	response	NNS
cord-003403-ypefqm71	148	52	from	from	IN
cord-003403-ypefqm71	148	53	a	a	DT
cord-003403-ypefqm71	148	54	novel	novel	JJ
cord-003403-ypefqm71	148	55	DNA	dna	NN
cord-003403-ypefqm71	148	56	vaccine	vaccine	NN
cord-003403-ypefqm71	148	57	for	for	IN
cord-003403-ypefqm71	148	58	west	west	NNP
cord-003403-ypefqm71	148	59	nile	nile	NNP
cord-003403-ypefqm71	148	60	virus	virus	NN
cord-003403-ypefqm71	148	61	New	New	NNP
cord-003403-ypefqm71	148	62	York	York	NNP
cord-003403-ypefqm71	148	63	isolate	isolate	NN
cord-003403-ypefqm71	148	64	(	(	-LRB-
cord-003403-ypefqm71	148	65	WNV	WNV	NNP
cord-003403-ypefqm71	148	66	-	-	HYPH
cord-003403-ypefqm71	148	67	NY1999	NY1999	NNP
cord-003403-ypefqm71	148	68	)	)	-RRB-
cord-003403-ypefqm71	148	69	Development	Development	NNP
cord-003403-ypefqm71	148	70	of	of	IN
cord-003403-ypefqm71	148	71	vaccines	vaccine	NNS
cord-003403-ypefqm71	148	72	against	against	IN
cord-003403-ypefqm71	148	73	Zika	Zika	NNP
cord-003403-ypefqm71	148	74	virus	virus	NN
cord-003403-ypefqm71	148	75	Zika	Zika	NNP
cord-003403-ypefqm71	148	76	virus	virus	NN
cord-003403-ypefqm71	148	77	structural	structural	JJ
cord-003403-ypefqm71	148	78	biology	biology	NN
cord-003403-ypefqm71	148	79	and	and	CC
cord-003403-ypefqm71	148	80	progress	progress	NN
cord-003403-ypefqm71	148	81	in	in	IN
cord-003403-ypefqm71	148	82	vaccine	vaccine	NN
cord-003403-ypefqm71	148	83	development	development	NN
cord-003403-ypefqm71	148	84	Role	role	NN
cord-003403-ypefqm71	148	85	of	of	IN
cord-003403-ypefqm71	148	86	Zika	Zika	NNP
cord-003403-ypefqm71	148	87	Virus	Virus	NNP
cord-003403-ypefqm71	148	88	prM	prm	JJ
cord-003403-ypefqm71	148	89	protein	protein	NN
cord-003403-ypefqm71	148	90	in	in	IN
cord-003403-ypefqm71	148	91	viral	viral	JJ
cord-003403-ypefqm71	148	92	pathogenicity	pathogenicity	NN
cord-003403-ypefqm71	148	93	and	and	CC
cord-003403-ypefqm71	148	94	use	use	NN
cord-003403-ypefqm71	148	95	in	in	IN
cord-003403-ypefqm71	148	96	vaccine	vaccine	NN
cord-003403-ypefqm71	148	97	development	development	NN
cord-003403-ypefqm71	148	98	Zika	Zika	NNP
cord-003403-ypefqm71	148	99	virus	virus	NN
cord-003403-ypefqm71	148	100	emergence	emergence	NN
cord-003403-ypefqm71	148	101	in	in	IN
cord-003403-ypefqm71	148	102	mosquitos	mosquitos	NN
cord-003403-ypefqm71	148	103	in	in	IN
cord-003403-ypefqm71	148	104	Southeastern	Southeastern	NNP
cord-003403-ypefqm71	148	105	Senegal	Senegal	NNP
cord-003403-ypefqm71	148	106	Evolutionary	evolutionary	JJ
cord-003403-ypefqm71	148	107	enhancement	enhancement	NN
cord-003403-ypefqm71	148	108	of	of	IN
cord-003403-ypefqm71	148	109	Zika	Zika	NNP
cord-003403-ypefqm71	148	110	virus	virus	NN
cord-003403-ypefqm71	148	111	infectivity	infectivity	NN
cord-003403-ypefqm71	148	112	in	in	IN
cord-003403-ypefqm71	148	113	Aedes	Aedes	NNP
cord-003403-ypefqm71	148	114	aegypti	aegypti	NN
cord-003403-ypefqm71	148	115	mosquitoes	mosquito	NNS
cord-003403-ypefqm71	148	116	Assessing	assess	VBG
cord-003403-ypefqm71	148	117	Seasonal	seasonal	JJ
cord-003403-ypefqm71	148	118	risks	risk	NNS
cord-003403-ypefqm71	148	119	for	for	IN
cord-003403-ypefqm71	148	120	the	the	DT
cord-003403-ypefqm71	148	121	introduction	introduction	NN
cord-003403-ypefqm71	148	122	and	and	CC
cord-003403-ypefqm71	148	123	mosquito	mosquito	NN
cord-003403-ypefqm71	148	124	-	-	HYPH
cord-003403-ypefqm71	148	125	borne	bear	VBN
cord-003403-ypefqm71	148	126	spread	spread	NN
cord-003403-ypefqm71	148	127	of	of	IN
cord-003403-ypefqm71	148	128	Zika	Zika	NNP
cord-003403-ypefqm71	148	129	virus	virus	NN
cord-003403-ypefqm71	148	130	in	in	IN
cord-003403-ypefqm71	148	131	Europe	Europe	NNP
cord-003403-ypefqm71	148	132	Zika	Zika	NNP
cord-003403-ypefqm71	148	133	virus	virus	NN
cord-003403-ypefqm71	148	134	vector	vector	NN
cord-003403-ypefqm71	148	135	competency	competency	NN
cord-003403-ypefqm71	148	136	of	of	IN
cord-003403-ypefqm71	148	137	mosquitoes	mosquito	NNS
cord-003403-ypefqm71	148	138	Aedes	Aedes	NNP
cord-003403-ypefqm71	148	139	hensilli	hensilli	NNP
cord-003403-ypefqm71	148	140	as	as	IN
cord-003403-ypefqm71	148	141	a	a	DT
cord-003403-ypefqm71	148	142	potential	potential	JJ
cord-003403-ypefqm71	148	143	vector	vector	NN
cord-003403-ypefqm71	148	144	of	of	IN
cord-003403-ypefqm71	148	145	Chikungunya	Chikungunya	NNP
cord-003403-ypefqm71	148	146	and	and	CC
cord-003403-ypefqm71	148	147	Zika	Zika	NNP
cord-003403-ypefqm71	148	148	viruses	virus	NNS
cord-003403-ypefqm71	148	149	Outbreak	outbreak	NN
cord-003403-ypefqm71	148	150	of	of	IN
cord-003403-ypefqm71	148	151	Zika	Zika	NNP
cord-003403-ypefqm71	148	152	virus	virus	NN
cord-003403-ypefqm71	148	153	infection	infection	NN
cord-003403-ypefqm71	148	154	,	,	,
cord-003403-ypefqm71	148	155	Chiapas	Chiapas	NNP
cord-003403-ypefqm71	148	156	State	State	NNP
cord-003403-ypefqm71	148	157	,	,	,
cord-003403-ypefqm71	148	158	Mexico	Mexico	NNP
cord-003403-ypefqm71	148	159	,	,	,
cord-003403-ypefqm71	148	160	2015	2015	CD
cord-003403-ypefqm71	148	161	,	,	,
cord-003403-ypefqm71	148	162	and	and	CC
cord-003403-ypefqm71	148	163	first	first	RB
cord-003403-ypefqm71	148	164	confirmed	confirmed	JJ
cord-003403-ypefqm71	148	165	transmission	transmission	NN
cord-003403-ypefqm71	148	166	by	by	IN
cord-003403-ypefqm71	148	167	aedes	aedes	NNP
cord-003403-ypefqm71	148	168	aegypti	aegypti	NNP
cord-003403-ypefqm71	148	169	mosquitoes	mosquito	NNS
cord-003403-ypefqm71	148	170	in	in	IN
cord-003403-ypefqm71	148	171	the	the	DT
cord-003403-ypefqm71	148	172	Americas	Americas	NNP
cord-003403-ypefqm71	148	173	Autophagy	Autophagy	NNP
cord-003403-ypefqm71	148	174	and	and	CC
cord-003403-ypefqm71	148	175	viral	viral	JJ
cord-003403-ypefqm71	148	176	diseases	disease	NNS
cord-003403-ypefqm71	148	177	transmitted	transmit	VBN
cord-003403-ypefqm71	148	178	by	by	IN
cord-003403-ypefqm71	148	179	Aedes	Aedes	NNP
cord-003403-ypefqm71	148	180	aegypti	aegypti	NN
cord-003403-ypefqm71	148	181	and	and	CC
cord-003403-ypefqm71	148	182	Aedes	Aedes	NNP
cord-003403-ypefqm71	148	183	albopictus	albopictus	NN
cord-003403-ypefqm71	148	184	Zika	Zika	NNP
cord-003403-ypefqm71	148	185	virus	virus	NN
cord-003403-ypefqm71	148	186	:	:	:
cord-003403-ypefqm71	148	187	Following	follow	VBG
cord-003403-ypefqm71	148	188	the	the	DT
cord-003403-ypefqm71	148	189	path	path	NN
cord-003403-ypefqm71	148	190	of	of	IN
cord-003403-ypefqm71	148	191	dengue	dengue	NN
cord-003403-ypefqm71	148	192	and	and	CC
cord-003403-ypefqm71	148	193	chikungunya	chikungunya	NN
cord-003403-ypefqm71	148	194	?	?	.
cord-003403-ypefqm71	149	1	Lancet	Lancet	NNP
cord-003403-ypefqm71	149	2	Spatio	Spatio	NNP
cord-003403-ypefqm71	149	3	-	-	HYPH
cord-003403-ypefqm71	149	4	temporal	temporal	JJ
cord-003403-ypefqm71	149	5	coherence	coherence	NN
cord-003403-ypefqm71	149	6	of	of	IN
cord-003403-ypefqm71	149	7	dengue	dengue	NN
cord-003403-ypefqm71	149	8	,	,	,
cord-003403-ypefqm71	149	9	chikungunya	chikungunya	NN
cord-003403-ypefqm71	149	10	and	and	CC
cord-003403-ypefqm71	149	11	Zika	Zika	NNP
cord-003403-ypefqm71	149	12	outbreaks	outbreak	NNS
cord-003403-ypefqm71	149	13	in	in	IN
cord-003403-ypefqm71	149	14	Merida	Merida	NNP
cord-003403-ypefqm71	149	15	Zika	Zika	NNP
cord-003403-ypefqm71	149	16	might	may	MD
cord-003403-ypefqm71	149	17	not	not	RB
cord-003403-ypefqm71	149	18	be	be	VB
cord-003403-ypefqm71	149	19	acting	act	VBG
cord-003403-ypefqm71	149	20	alone	alone	RB
cord-003403-ypefqm71	149	21	:	:	:
cord-003403-ypefqm71	149	22	Using	use	VBG
cord-003403-ypefqm71	149	23	an	an	DT
cord-003403-ypefqm71	149	24	ecological	ecological	JJ
cord-003403-ypefqm71	149	25	study	study	NN
cord-003403-ypefqm71	149	26	approach	approach	NN
cord-003403-ypefqm71	149	27	to	to	TO
cord-003403-ypefqm71	149	28	investigate	investigate	VB
cord-003403-ypefqm71	149	29	potential	potential	JJ
cord-003403-ypefqm71	149	30	co	co	JJ
cord-003403-ypefqm71	149	31	-	-	JJ
cord-003403-ypefqm71	149	32	acting	acting	JJ
cord-003403-ypefqm71	149	33	risk	risk	NN
cord-003403-ypefqm71	149	34	factors	factor	NNS
cord-003403-ypefqm71	149	35	for	for	IN
cord-003403-ypefqm71	149	36	an	an	DT
cord-003403-ypefqm71	149	37	unusual	unusual	JJ
cord-003403-ypefqm71	149	38	pattern	pattern	NN
cord-003403-ypefqm71	149	39	of	of	IN
cord-003403-ypefqm71	149	40	microcephaly	microcephaly	NNS
cord-003403-ypefqm71	149	41	in	in	IN
cord-003403-ypefqm71	149	42	Brazil	Brazil	NNP
cord-003403-ypefqm71	149	43	Viremia	Viremia	NNP
cord-003403-ypefqm71	149	44	and	and	CC
cord-003403-ypefqm71	149	45	clinical	clinical	JJ
cord-003403-ypefqm71	149	46	presentation	presentation	NN
cord-003403-ypefqm71	149	47	in	in	IN
cord-003403-ypefqm71	149	48	nicaraguan	nicaraguan	JJ
cord-003403-ypefqm71	149	49	patients	patient	NNS
cord-003403-ypefqm71	149	50	infected	infect	VBN
cord-003403-ypefqm71	149	51	with	with	IN
cord-003403-ypefqm71	149	52	Zika	Zika	NNP
cord-003403-ypefqm71	149	53	Virus	Virus	NNP
cord-003403-ypefqm71	149	54	,	,	,
cord-003403-ypefqm71	149	55	Chikungunya	Chikungunya	NNP
cord-003403-ypefqm71	149	56	Virus	Virus	NNP
cord-003403-ypefqm71	149	57	,	,	,
cord-003403-ypefqm71	149	58	and	and	CC
cord-003403-ypefqm71	149	59	Dengue	Dengue	NNP
cord-003403-ypefqm71	149	60	Virus	Virus	NNP
cord-003403-ypefqm71	149	61	Evidence	evidence	NN
cord-003403-ypefqm71	149	62	of	of	IN
cord-003403-ypefqm71	149	63	perinatal	perinatal	JJ
cord-003403-ypefqm71	149	64	transmission	transmission	NN
cord-003403-ypefqm71	149	65	of	of	IN
cord-003403-ypefqm71	149	66	Zika	Zika	NNP
cord-003403-ypefqm71	149	67	virus	virus	NN
cord-003403-ypefqm71	149	68	Complete	complete	NN
cord-003403-ypefqm71	149	69	Genome	Genome	NNP
cord-003403-ypefqm71	149	70	Sequence	sequence	NN
cord-003403-ypefqm71	149	71	of	of	IN
cord-003403-ypefqm71	149	72	Zika	Zika	NNP
cord-003403-ypefqm71	149	73	Virus	Virus	NNP
cord-003403-ypefqm71	149	74	Isolated	isolate	VBN
cord-003403-ypefqm71	149	75	from	from	IN
cord-003403-ypefqm71	149	76	Semen	semen	NN
cord-003403-ypefqm71	149	77	Probable	probable	JJ
cord-003403-ypefqm71	149	78	non	non	JJ
cord-003403-ypefqm71	149	79	-	-	JJ
cord-003403-ypefqm71	149	80	vector	vector	NN
cord-003403-ypefqm71	149	81	-	-	HYPH
cord-003403-ypefqm71	149	82	borne	bear	VBN
cord-003403-ypefqm71	149	83	transmission	transmission	NN
cord-003403-ypefqm71	149	84	of	of	IN
cord-003403-ypefqm71	149	85	Zika	Zika	NNP
cord-003403-ypefqm71	149	86	virus	virus	NN
cord-003403-ypefqm71	149	87	Potential	potential	JJ
cord-003403-ypefqm71	149	88	sexual	sexual	JJ
cord-003403-ypefqm71	149	89	transmission	transmission	NN
cord-003403-ypefqm71	149	90	of	of	IN
cord-003403-ypefqm71	149	91	Zika	Zika	NNP
cord-003403-ypefqm71	149	92	virus	virus	NN
cord-003403-ypefqm71	149	93	Detection	detection	NN
cord-003403-ypefqm71	149	94	of	of	IN
cord-003403-ypefqm71	149	95	Zika	Zika	NNP
cord-003403-ypefqm71	149	96	virus	virus	NN
cord-003403-ypefqm71	149	97	in	in	IN
cord-003403-ypefqm71	149	98	saliva	saliva	NN
cord-003403-ypefqm71	149	99	Persistence	persistence	NN
cord-003403-ypefqm71	149	100	of	of	IN
cord-003403-ypefqm71	149	101	Zika	Zika	NNP
cord-003403-ypefqm71	149	102	Virus	Virus	NNP
cord-003403-ypefqm71	149	103	in	in	IN
cord-003403-ypefqm71	149	104	body	body	NN
cord-003403-ypefqm71	149	105	fluids	fluid	NNS
cord-003403-ypefqm71	149	106	-	-	:
cord-003403-ypefqm71	149	107	preliminary	preliminary	JJ
cord-003403-ypefqm71	149	108	report	report	NN
cord-003403-ypefqm71	150	1	Comparison	comparison	NN
cord-003403-ypefqm71	150	2	of	of	IN
cord-003403-ypefqm71	150	3	test	test	NN
cord-003403-ypefqm71	150	4	results	result	NNS
cord-003403-ypefqm71	150	5	for	for	IN
cord-003403-ypefqm71	150	6	Zika	Zika	NNP
cord-003403-ypefqm71	150	7	Virus	Virus	NNP
cord-003403-ypefqm71	150	8	RNA	RNA	NNP
cord-003403-ypefqm71	150	9	in	in	IN
cord-003403-ypefqm71	150	10	urine	urine	NN
cord-003403-ypefqm71	150	11	,	,	,
cord-003403-ypefqm71	150	12	serum	serum	NN
cord-003403-ypefqm71	150	13	,	,	,
cord-003403-ypefqm71	150	14	and	and	CC
cord-003403-ypefqm71	150	15	saliva	saliva	NN
cord-003403-ypefqm71	150	16	specimens	specimen	NNS
cord-003403-ypefqm71	150	17	from	from	IN
cord-003403-ypefqm71	150	18	persons	person	NNS
cord-003403-ypefqm71	150	19	with	with	IN
cord-003403-ypefqm71	150	20	travel	travel	NN
cord-003403-ypefqm71	150	21	-	-	HYPH
cord-003403-ypefqm71	150	22	associated	associate	VBN
cord-003403-ypefqm71	150	23	Zika	Zika	NNP
cord-003403-ypefqm71	150	24	Virus	Virus	NNP
cord-003403-ypefqm71	150	25	disease	disease	NN
cord-003403-ypefqm71	150	26	-	-	:
cord-003403-ypefqm71	150	27	Florida	Florida	NNP
cord-003403-ypefqm71	150	28	Potential	potential	JJ
cord-003403-ypefqm71	150	29	use	use	NN
cord-003403-ypefqm71	150	30	of	of	IN
cord-003403-ypefqm71	150	31	saliva	saliva	NN
cord-003403-ypefqm71	150	32	samples	sample	NNS
cord-003403-ypefqm71	150	33	to	to	TO
cord-003403-ypefqm71	150	34	diagnose	diagnose	VB
cord-003403-ypefqm71	150	35	Zika	Zika	NNP
cord-003403-ypefqm71	150	36	virus	virus	NN
cord-003403-ypefqm71	150	37	infection	infection	NN
cord-003403-ypefqm71	150	38	Use	use	NN
cord-003403-ypefqm71	150	39	of	of	IN
cord-003403-ypefqm71	150	40	blood	blood	NN
cord-003403-ypefqm71	150	41	donor	donor	NN
cord-003403-ypefqm71	150	42	screening	screening	NN
cord-003403-ypefqm71	150	43	data	datum	NNS
cord-003403-ypefqm71	150	44	to	to	TO
cord-003403-ypefqm71	150	45	estimate	estimate	VB
cord-003403-ypefqm71	150	46	Zika	Zika	NNP
cord-003403-ypefqm71	150	47	Virus	Virus	NNP
cord-003403-ypefqm71	150	48	incidence	incidence	NN
cord-003403-ypefqm71	150	49	,	,	,
cord-003403-ypefqm71	150	50	puerto	puerto	NNP
cord-003403-ypefqm71	150	51	rico	rico	NNP
cord-003403-ypefqm71	150	52	Zika	Zika	NNP
cord-003403-ypefqm71	150	53	virus	virus	NN
cord-003403-ypefqm71	150	54	outbreak	outbreak	NN
cord-003403-ypefqm71	150	55	and	and	CC
cord-003403-ypefqm71	150	56	the	the	DT
cord-003403-ypefqm71	150	57	case	case	NN
cord-003403-ypefqm71	150	58	for	for	IN
cord-003403-ypefqm71	150	59	building	build	VBG
cord-003403-ypefqm71	150	60	effective	effective	JJ
cord-003403-ypefqm71	150	61	and	and	CC
cord-003403-ypefqm71	150	62	sustainable	sustainable	JJ
cord-003403-ypefqm71	150	63	rapid	rapid	JJ
cord-003403-ypefqm71	150	64	diagnostics	diagnostic	NNS
cord-003403-ypefqm71	150	65	laboratory	laboratory	NN
cord-003403-ypefqm71	150	66	capacity	capacity	NN
cord-003403-ypefqm71	150	67	globally	globally	RB
cord-003403-ypefqm71	150	68	Comparison	comparison	NN
cord-003403-ypefqm71	150	69	of	of	IN
cord-003403-ypefqm71	150	70	four	four	CD
cord-003403-ypefqm71	150	71	serological	serological	JJ
cord-003403-ypefqm71	150	72	methods	method	NNS
cord-003403-ypefqm71	150	73	and	and	CC
cord-003403-ypefqm71	150	74	two	two	CD
cord-003403-ypefqm71	150	75	reverse	reverse	JJ
cord-003403-ypefqm71	150	76	transcription	transcription	NN
cord-003403-ypefqm71	150	77	-	-	HYPH
cord-003403-ypefqm71	150	78	PCR	PCR	NNP
cord-003403-ypefqm71	150	79	Assays	Assays	NNPS
cord-003403-ypefqm71	150	80	for	for	IN
cord-003403-ypefqm71	150	81	diagnosis	diagnosis	NN
cord-003403-ypefqm71	150	82	and	and	CC
cord-003403-ypefqm71	150	83	surveillance	surveillance	NN
cord-003403-ypefqm71	150	84	of	of	IN
cord-003403-ypefqm71	150	85	Zika	Zika	NNP
cord-003403-ypefqm71	150	86	Virus	Virus	NNP
cord-003403-ypefqm71	150	87	infection	infection	NN
cord-003403-ypefqm71	150	88	Seroprevalence	Seroprevalence	NNP
cord-003403-ypefqm71	150	89	of	of	IN
cord-003403-ypefqm71	150	90	arboviruses	arbovirus	NNS
cord-003403-ypefqm71	150	91	among	among	IN
cord-003403-ypefqm71	150	92	blood	blood	NN
cord-003403-ypefqm71	150	93	donors	donor	NNS
cord-003403-ypefqm71	150	94	in	in	IN
cord-003403-ypefqm71	150	95	French	French	NNP
cord-003403-ypefqm71	150	96	Polynesia	Polynesia	NNP
cord-003403-ypefqm71	150	97	Unexpected	unexpected	JJ
cord-003403-ypefqm71	150	98	outbreaks	outbreak	NNS
cord-003403-ypefqm71	150	99	of	of	IN
cord-003403-ypefqm71	150	100	arbovirus	arbovirus	NN
cord-003403-ypefqm71	150	101	infections	infection	NNS
cord-003403-ypefqm71	150	102	:	:	:
cord-003403-ypefqm71	151	1	Lessons	lesson	NNS
cord-003403-ypefqm71	151	2	learned	learn	VBD
cord-003403-ypefqm71	151	3	from	from	IN
cord-003403-ypefqm71	151	4	the	the	DT
cord-003403-ypefqm71	151	5	Pacific	Pacific	NNP
cord-003403-ypefqm71	151	6	and	and	CC
cord-003403-ypefqm71	151	7	tropical	tropical	JJ
cord-003403-ypefqm71	151	8	America	America	NNP
cord-003403-ypefqm71	151	9	Evaluation	Evaluation	NNP
cord-003403-ypefqm71	151	10	of	of	IN
cord-003403-ypefqm71	151	11	Altona	Altona	NNP
cord-003403-ypefqm71	151	12	Diagnostics	Diagnostics	NNPS
cord-003403-ypefqm71	151	13	RealStar	RealStar	NNP
cord-003403-ypefqm71	151	14	Zika	Zika	NNP
cord-003403-ypefqm71	152	1	Virus	Virus	NNP
cord-003403-ypefqm71	152	2	Reverse	Reverse	NNP
cord-003403-ypefqm71	152	3	Transcription	Transcription	NNP
cord-003403-ypefqm71	152	4	-	-	HYPH
cord-003403-ypefqm71	152	5	PCR	PCR	NNP
cord-003403-ypefqm71	152	6	Test	test	NN
cord-003403-ypefqm71	152	7	Kit	kit	NN
cord-003403-ypefqm71	152	8	for	for	IN
cord-003403-ypefqm71	152	9	Zika	Zika	NNP
cord-003403-ypefqm71	152	10	Virus	Virus	NNP
cord-003403-ypefqm71	152	11	PCR	PCR	NNP
cord-003403-ypefqm71	152	12	Testing	Testing	NNP
cord-003403-ypefqm71	152	13	Molecular	molecular	JJ
cord-003403-ypefqm71	152	14	and	and	CC
cord-003403-ypefqm71	152	15	serological	serological	JJ
cord-003403-ypefqm71	152	16	techniques	technique	NNS
cord-003403-ypefqm71	152	17	to	to	TO
cord-003403-ypefqm71	152	18	detect	detect	VB
cord-003403-ypefqm71	152	19	co	co	NN
cord-003403-ypefqm71	152	20	-	-	NN
cord-003403-ypefqm71	152	21	circulation	circulation	NN
cord-003403-ypefqm71	152	22	of	of	IN
cord-003403-ypefqm71	152	23	DENV	DENV	NNP
cord-003403-ypefqm71	152	24	,	,	,
cord-003403-ypefqm71	152	25	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	152	26	and	and	CC
cord-003403-ypefqm71	152	27	CHIKV	CHIKV	NNP
cord-003403-ypefqm71	152	28	in	in	IN
cord-003403-ypefqm71	152	29	suspected	suspect	VBN
cord-003403-ypefqm71	152	30	dengue	dengue	NN
cord-003403-ypefqm71	152	31	-	-	HYPH
cord-003403-ypefqm71	152	32	like	like	JJ
cord-003403-ypefqm71	152	33	syndrome	syndrome	NN
cord-003403-ypefqm71	152	34	patients	patient	NNS
cord-003403-ypefqm71	152	35	Assay	Assay	NNP
cord-003403-ypefqm71	152	36	optimization	optimization	NN
cord-003403-ypefqm71	152	37	for	for	IN
cord-003403-ypefqm71	152	38	molecular	molecular	JJ
cord-003403-ypefqm71	152	39	detection	detection	NN
cord-003403-ypefqm71	152	40	of	of	IN
cord-003403-ypefqm71	152	41	Zika	Zika	NNP
cord-003403-ypefqm71	152	42	virus	virus	NN
cord-003403-ypefqm71	152	43	Prolonged	prolong	VBN
cord-003403-ypefqm71	152	44	detection	detection	NN
cord-003403-ypefqm71	152	45	of	of	IN
cord-003403-ypefqm71	152	46	Zika	Zika	NNP
cord-003403-ypefqm71	152	47	Virus	Virus	NNP
cord-003403-ypefqm71	152	48	RNA	RNA	NNP
cord-003403-ypefqm71	152	49	in	in	IN
cord-003403-ypefqm71	152	50	pregnant	pregnant	JJ
cord-003403-ypefqm71	152	51	women	woman	NNS
cord-003403-ypefqm71	152	52	Simultaneous	simultaneous	JJ
cord-003403-ypefqm71	152	53	detection	detection	NN
cord-003403-ypefqm71	152	54	of	of	IN
cord-003403-ypefqm71	152	55	Zika	Zika	NNP
cord-003403-ypefqm71	152	56	,	,	,
cord-003403-ypefqm71	152	57	Chikungunya	chikungunya	NN
cord-003403-ypefqm71	152	58	and	and	CC
cord-003403-ypefqm71	152	59	Dengue	dengue	NN
cord-003403-ypefqm71	152	60	viruses	virus	NNS
cord-003403-ypefqm71	152	61	by	by	IN
cord-003403-ypefqm71	152	62	a	a	DT
cord-003403-ypefqm71	152	63	multiplex	multiplex	JJ
cord-003403-ypefqm71	152	64	real	real	JJ
cord-003403-ypefqm71	152	65	-	-	HYPH
cord-003403-ypefqm71	152	66	time	time	NN
cord-003403-ypefqm71	152	67	RT	RT	NNP
cord-003403-ypefqm71	152	68	-	-	HYPH
cord-003403-ypefqm71	152	69	PCR	PCR	NNP
cord-003403-ypefqm71	152	70	assay	assay	NN
cord-003403-ypefqm71	152	71	Attomolar	Attomolar	NNP
cord-003403-ypefqm71	152	72	Zika	Zika	NNP
cord-003403-ypefqm71	152	73	virus	virus	NN
cord-003403-ypefqm71	152	74	oligonucleotide	oligonucleotide	IN
cord-003403-ypefqm71	152	75	detection	detection	NN
cord-003403-ypefqm71	152	76	based	base	VBN
cord-003403-ypefqm71	152	77	on	on	IN
cord-003403-ypefqm71	152	78	loop	loop	NN
cord-003403-ypefqm71	152	79	-	-	HYPH
cord-003403-ypefqm71	152	80	mediated	mediate	VBN
cord-003403-ypefqm71	152	81	isothermal	isothermal	JJ
cord-003403-ypefqm71	152	82	amplification	amplification	NN
cord-003403-ypefqm71	152	83	and	and	CC
cord-003403-ypefqm71	152	84	AC	AC	NNP
cord-003403-ypefqm71	152	85	susceptometry	susceptometry	NN
cord-003403-ypefqm71	152	86	Single	single	JJ
cord-003403-ypefqm71	152	87	-	-	HYPH
cord-003403-ypefqm71	152	88	reaction	reaction	NN
cord-003403-ypefqm71	152	89	multiplex	multiplex	NN
cord-003403-ypefqm71	152	90	reverse	reverse	NN
cord-003403-ypefqm71	152	91	transcription	transcription	NN
cord-003403-ypefqm71	152	92	PCR	pcr	NN
cord-003403-ypefqm71	152	93	for	for	IN
cord-003403-ypefqm71	152	94	detection	detection	NN
cord-003403-ypefqm71	152	95	of	of	IN
cord-003403-ypefqm71	152	96	Zika	Zika	NNP
cord-003403-ypefqm71	152	97	,	,	,
cord-003403-ypefqm71	152	98	Chikungunya	Chikungunya	NNP
cord-003403-ypefqm71	152	99	,	,	,
cord-003403-ypefqm71	152	100	and	and	CC
cord-003403-ypefqm71	152	101	Dengue	dengue	NN
cord-003403-ypefqm71	152	102	viruses	virus	NNS
cord-003403-ypefqm71	152	103	Detection	detection	NN
cord-003403-ypefqm71	152	104	of	of	IN
cord-003403-ypefqm71	152	105	dengue	dengue	NN
cord-003403-ypefqm71	152	106	virus	virus	NN
cord-003403-ypefqm71	152	107	genome	genome	NN
cord-003403-ypefqm71	152	108	in	in	IN
cord-003403-ypefqm71	152	109	urine	urine	NN
cord-003403-ypefqm71	152	110	by	by	IN
cord-003403-ypefqm71	152	111	real	real	JJ
cord-003403-ypefqm71	152	112	-	-	HYPH
cord-003403-ypefqm71	152	113	time	time	NN
cord-003403-ypefqm71	152	114	reverse	reverse	NN
cord-003403-ypefqm71	152	115	transcriptase	transcriptase	NN
cord-003403-ypefqm71	152	116	PCR	pcr	NN
cord-003403-ypefqm71	152	117	:	:	:
cord-003403-ypefqm71	153	1	A	a	DT
cord-003403-ypefqm71	153	2	laboratory	laboratory	NN
cord-003403-ypefqm71	153	3	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	153	4	method	method	NN
cord-003403-ypefqm71	153	5	useful	useful	JJ
cord-003403-ypefqm71	153	6	after	after	IN
cord-003403-ypefqm71	153	7	disappearance	disappearance	NN
cord-003403-ypefqm71	153	8	of	of	IN
cord-003403-ypefqm71	153	9	the	the	DT
cord-003403-ypefqm71	153	10	genome	genome	NN
cord-003403-ypefqm71	153	11	in	in	IN
cord-003403-ypefqm71	153	12	serum	serum	NN
cord-003403-ypefqm71	153	13	Cryptic	cryptic	JJ
cord-003403-ypefqm71	153	14	properties	property	NNS
cord-003403-ypefqm71	153	15	of	of	IN
cord-003403-ypefqm71	153	16	a	a	DT
cord-003403-ypefqm71	153	17	cluster	cluster	NN
cord-003403-ypefqm71	153	18	of	of	IN
cord-003403-ypefqm71	153	19	dominant	dominant	JJ
cord-003403-ypefqm71	153	20	flavivirus	flavivirus	JJ
cord-003403-ypefqm71	153	21	cross	cross	JJ
cord-003403-ypefqm71	153	22	-	-	JJ
cord-003403-ypefqm71	153	23	reactive	reactive	JJ
cord-003403-ypefqm71	153	24	antigenic	antigenic	JJ
cord-003403-ypefqm71	153	25	sites	site	NNS
cord-003403-ypefqm71	153	26	Flavivirus	Flavivirus	NNP
cord-003403-ypefqm71	153	27	-	-	HYPH
cord-003403-ypefqm71	153	28	induced	induce	VBN
cord-003403-ypefqm71	153	29	antibody	antibody	NN
cord-003403-ypefqm71	153	30	cross	cross	NN
cord-003403-ypefqm71	153	31	-	-	NN
cord-003403-ypefqm71	153	32	reactivity	reactivity	NN
cord-003403-ypefqm71	154	1	A	a	DT
cord-003403-ypefqm71	154	2	multiplex	multiplex	JJ
cord-003403-ypefqm71	154	3	microsphere	microsphere	NN
cord-003403-ypefqm71	154	4	immunoassay	immunoassay	NN
cord-003403-ypefqm71	154	5	for	for	IN
cord-003403-ypefqm71	154	6	Zika	Zika	NNP
cord-003403-ypefqm71	154	7	Virus	Virus	NNP
cord-003403-ypefqm71	154	8	diagnosis	diagnosis	NN
cord-003403-ypefqm71	154	9	Serodiagnosis	Serodiagnosis	NNP
cord-003403-ypefqm71	154	10	of	of	IN
cord-003403-ypefqm71	154	11	Zika	Zika	NNP
cord-003403-ypefqm71	154	12	virus	virus	NN
cord-003403-ypefqm71	154	13	(	(	-LRB-
cord-003403-ypefqm71	154	14	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	154	15	)	)	-RRB-
cord-003403-ypefqm71	154	16	infections	infection	NNS
cord-003403-ypefqm71	154	17	by	by	IN
cord-003403-ypefqm71	154	18	a	a	DT
cord-003403-ypefqm71	154	19	novel	novel	JJ
cord-003403-ypefqm71	154	20	NS1-based	ns1-base	VBN
cord-003403-ypefqm71	154	21	ELISA	ELISA	NNP
cord-003403-ypefqm71	154	22	devoid	devoid	JJ
cord-003403-ypefqm71	154	23	of	of	IN
cord-003403-ypefqm71	154	24	cross	cross	NN
cord-003403-ypefqm71	154	25	-	-	NN
cord-003403-ypefqm71	154	26	reactivity	reactivity	NN
cord-003403-ypefqm71	154	27	with	with	IN
cord-003403-ypefqm71	154	28	dengue	dengue	NN
cord-003403-ypefqm71	154	29	virus	virus	NN
cord-003403-ypefqm71	154	30	antibodies	antibody	NNS
cord-003403-ypefqm71	154	31	:	:	:
cord-003403-ypefqm71	154	32	A	a	DT
cord-003403-ypefqm71	154	33	multicohort	multicohort	JJ
cord-003403-ypefqm71	154	34	study	study	NN
cord-003403-ypefqm71	154	35	of	of	IN
cord-003403-ypefqm71	154	36	assay	assay	NN
cord-003403-ypefqm71	154	37	performance	performance	NN
cord-003403-ypefqm71	154	38	Dengue	dengue	NN
cord-003403-ypefqm71	154	39	viruses	virus	NNS
cord-003403-ypefqm71	154	40	are	be	VBP
cord-003403-ypefqm71	154	41	enhanced	enhance	VBN
cord-003403-ypefqm71	154	42	by	by	IN
cord-003403-ypefqm71	154	43	distinct	distinct	JJ
cord-003403-ypefqm71	154	44	populations	population	NNS
cord-003403-ypefqm71	154	45	of	of	IN
cord-003403-ypefqm71	154	46	serotype	serotype	NN
cord-003403-ypefqm71	154	47	cross	cross	JJ
cord-003403-ypefqm71	154	48	-	-	JJ
cord-003403-ypefqm71	154	49	reactive	reactive	JJ
cord-003403-ypefqm71	154	50	antibodies	antibody	NNS
cord-003403-ypefqm71	154	51	in	in	IN
cord-003403-ypefqm71	154	52	human	human	JJ
cord-003403-ypefqm71	154	53	immune	immune	NN
cord-003403-ypefqm71	154	54	sera	sera	NNP
cord-003403-ypefqm71	155	1	A	a	DT
cord-003403-ypefqm71	155	2	broadly	broadly	RB
cord-003403-ypefqm71	155	3	flavivirus	flavivirus	JJ
cord-003403-ypefqm71	155	4	cross	cross	NN
cord-003403-ypefqm71	155	5	-	-	JJ
cord-003403-ypefqm71	155	6	neutralizing	neutralize	VBG
cord-003403-ypefqm71	155	7	monoclonal	monoclonal	JJ
cord-003403-ypefqm71	155	8	antibody	antibody	NN
cord-003403-ypefqm71	155	9	that	that	WDT
cord-003403-ypefqm71	155	10	recognizes	recognize	VBZ
cord-003403-ypefqm71	155	11	a	a	DT
cord-003403-ypefqm71	155	12	novel	novel	JJ
cord-003403-ypefqm71	155	13	epitope	epitope	NN
cord-003403-ypefqm71	155	14	within	within	IN
cord-003403-ypefqm71	155	15	the	the	DT
cord-003403-ypefqm71	155	16	fusion	fusion	NN
cord-003403-ypefqm71	155	17	loop	loop	NN
cord-003403-ypefqm71	155	18	of	of	IN
cord-003403-ypefqm71	155	19	E	e	NN
cord-003403-ypefqm71	155	20	protein	protein	NN
cord-003403-ypefqm71	155	21	Detection	detection	NN
cord-003403-ypefqm71	155	22	of	of	IN
cord-003403-ypefqm71	155	23	Virus	virus	NN
cord-003403-ypefqm71	155	24	-	-	HYPH
cord-003403-ypefqm71	155	25	specific	specific	JJ
cord-003403-ypefqm71	155	26	Antigen	antigen	NN
cord-003403-ypefqm71	155	27	in	in	IN
cord-003403-ypefqm71	155	28	the	the	DT
cord-003403-ypefqm71	155	29	Nuclei	Nuclei	NNP
cord-003403-ypefqm71	155	30	or	or	CC
cord-003403-ypefqm71	155	31	nucleoli	nucleoli	NN
cord-003403-ypefqm71	155	32	of	of	IN
cord-003403-ypefqm71	155	33	cells	cell	NNS
cord-003403-ypefqm71	155	34	infected	infect	VBN
cord-003403-ypefqm71	155	35	with	with	IN
cord-003403-ypefqm71	155	36	Zika	Zika	NNP
cord-003403-ypefqm71	155	37	or	or	CC
cord-003403-ypefqm71	155	38	Langat	Langat	NNP
cord-003403-ypefqm71	155	39	virus	virus	NN
cord-003403-ypefqm71	155	40	Detection	detection	NN
cord-003403-ypefqm71	155	41	of	of	IN
cord-003403-ypefqm71	155	42	anti	anti	JJ
cord-003403-ypefqm71	155	43	-	-	JJ
cord-003403-ypefqm71	155	44	arboviral	arboviral	JJ
cord-003403-ypefqm71	155	45	immunoglobulin	immunoglobulin	NN
cord-003403-ypefqm71	155	46	G	g	NN
cord-003403-ypefqm71	155	47	by	by	IN
cord-003403-ypefqm71	155	48	using	use	VBG
cord-003403-ypefqm71	155	49	a	a	DT
cord-003403-ypefqm71	155	50	monoclonal	monoclonal	JJ
cord-003403-ypefqm71	155	51	antibody	antibody	NN
cord-003403-ypefqm71	155	52	-	-	HYPH
cord-003403-ypefqm71	155	53	based	base	VBN
cord-003403-ypefqm71	155	54	capture	capture	NN
cord-003403-ypefqm71	155	55	enzyme	enzyme	NN
cord-003403-ypefqm71	155	56	-	-	HYPH
cord-003403-ypefqm71	155	57	linked	link	VBN
cord-003403-ypefqm71	155	58	immunosorbent	immunosorbent	JJ
cord-003403-ypefqm71	155	59	assay	assay	NN
cord-003403-ypefqm71	155	60	Standardization	Standardization	NNP
cord-003403-ypefqm71	155	61	of	of	IN
cord-003403-ypefqm71	155	62	immunoglobulin	immunoglobulin	NN
cord-003403-ypefqm71	155	63	m	m	NN
cord-003403-ypefqm71	155	64	capture	capture	NN
cord-003403-ypefqm71	155	65	enzyme	enzyme	NN
cord-003403-ypefqm71	155	66	-	-	HYPH
cord-003403-ypefqm71	155	67	linked	link	VBN
cord-003403-ypefqm71	155	68	immunosorbent	immunosorbent	JJ
cord-003403-ypefqm71	155	69	assays	assay	NNS
cord-003403-ypefqm71	155	70	for	for	IN
cord-003403-ypefqm71	155	71	routine	routine	JJ
cord-003403-ypefqm71	155	72	diagnosis	diagnosis	NN
cord-003403-ypefqm71	155	73	of	of	IN
cord-003403-ypefqm71	155	74	arboviral	arboviral	NNP
cord-003403-ypefqm71	155	75	infections	infection	NNS
cord-003403-ypefqm71	155	76	Evaluation	Evaluation	NNP
cord-003403-ypefqm71	155	77	of	of	IN
cord-003403-ypefqm71	155	78	diagnostic	diagnostic	JJ
cord-003403-ypefqm71	155	79	tests	test	NNS
cord-003403-ypefqm71	156	1	:	:	:
cord-003403-ypefqm71	156	2	Dengue	dengue	NN
cord-003403-ypefqm71	156	3	Approaches	approach	NNS
cord-003403-ypefqm71	156	4	for	for	IN
cord-003403-ypefqm71	156	5	the	the	DT
cord-003403-ypefqm71	156	6	development	development	NN
cord-003403-ypefqm71	156	7	of	of	IN
cord-003403-ypefqm71	156	8	rapid	rapid	JJ
cord-003403-ypefqm71	156	9	serological	serological	JJ
cord-003403-ypefqm71	156	10	assays	assay	NNS
cord-003403-ypefqm71	156	11	for	for	IN
cord-003403-ypefqm71	156	12	surveillance	surveillance	NN
cord-003403-ypefqm71	156	13	and	and	CC
cord-003403-ypefqm71	156	14	diagnosis	diagnosis	NN
cord-003403-ypefqm71	156	15	of	of	IN
cord-003403-ypefqm71	156	16	infections	infection	NNS
cord-003403-ypefqm71	156	17	caused	cause	VBN
cord-003403-ypefqm71	156	18	by	by	IN
cord-003403-ypefqm71	156	19	zoonotic	zoonotic	JJ
cord-003403-ypefqm71	156	20	flaviviruses	flavivirus	NNS
cord-003403-ypefqm71	156	21	of	of	IN
cord-003403-ypefqm71	156	22	the	the	DT
cord-003403-ypefqm71	156	23	Japanese	japanese	JJ
cord-003403-ypefqm71	156	24	encephalitis	encephalitis	RB
cord-003403-ypefqm71	156	25	virus	virus	NN
cord-003403-ypefqm71	156	26	serocomplex	serocomplex	NNP
cord-003403-ypefqm71	156	27	Flaviviruses	Flaviviruses	NNP
cord-003403-ypefqm71	156	28	in	in	IN
cord-003403-ypefqm71	156	29	Europe	Europe	NNP
cord-003403-ypefqm71	156	30	:	:	:
cord-003403-ypefqm71	157	1	Complex	complex	JJ
cord-003403-ypefqm71	157	2	circulation	circulation	NN
cord-003403-ypefqm71	157	3	patterns	pattern	NNS
cord-003403-ypefqm71	157	4	and	and	CC
cord-003403-ypefqm71	157	5	their	-PRON-	PRP$
cord-003403-ypefqm71	157	6	consequences	consequence	NNS
cord-003403-ypefqm71	157	7	for	for	IN
cord-003403-ypefqm71	157	8	the	the	DT
cord-003403-ypefqm71	157	9	diagnosis	diagnosis	NN
cord-003403-ypefqm71	157	10	and	and	CC
cord-003403-ypefqm71	157	11	control	control	NN
cord-003403-ypefqm71	157	12	of	of	IN
cord-003403-ypefqm71	157	13	West	West	NNP
cord-003403-ypefqm71	157	14	Nile	Nile	NNP
cord-003403-ypefqm71	157	15	disease	disease	NN
cord-003403-ypefqm71	157	16	Quantitative	quantitative	JJ
cord-003403-ypefqm71	157	17	real	real	JJ
cord-003403-ypefqm71	157	18	-	-	HYPH
cord-003403-ypefqm71	157	19	time	time	NN
cord-003403-ypefqm71	157	20	PCR	pcr	NN
cord-003403-ypefqm71	157	21	detection	detection	NN
cord-003403-ypefqm71	157	22	of	of	IN
cord-003403-ypefqm71	157	23	Zika	Zika	NNP
cord-003403-ypefqm71	157	24	virus	virus	NN
cord-003403-ypefqm71	157	25	and	and	CC
cord-003403-ypefqm71	157	26	evaluation	evaluation	NN
cord-003403-ypefqm71	157	27	with	with	IN
cord-003403-ypefqm71	157	28	field	field	NN
cord-003403-ypefqm71	157	29	-	-	HYPH
cord-003403-ypefqm71	157	30	caught	catch	VBN
cord-003403-ypefqm71	157	31	mosquitoes	mosquito	NNS
cord-003403-ypefqm71	158	1	Interpretation	interpretation	NN
cord-003403-ypefqm71	158	2	of	of	IN
cord-003403-ypefqm71	158	3	Nucleic	Nucleic	NNP
cord-003403-ypefqm71	158	4	Acid	Acid	NNP
cord-003403-ypefqm71	158	5	and	and	CC
cord-003403-ypefqm71	158	6	Immunoassay	Immunoassay	NNP
cord-003403-ypefqm71	158	7	test	test	NN
cord-003403-ypefqm71	158	8	results	result	NNS
cord-003403-ypefqm71	158	9	for	for	IN
cord-003403-ypefqm71	158	10	suspected	suspect	VBN
cord-003403-ypefqm71	158	11	Zika	Zika	NNP
cord-003403-ypefqm71	158	12	Infection	Infection	NNP
cord-003403-ypefqm71	158	13	CDC	CDC	NNP
cord-003403-ypefqm71	158	14	Zika	Zika	NNP
cord-003403-ypefqm71	158	15	Testing	Testing	NNP
cord-003403-ypefqm71	158	16	Guidance	guidance	NN
cord-003403-ypefqm71	158	17	for	for	IN
cord-003403-ypefqm71	159	1	Healthcare	Healthcare	NNP
cord-003403-ypefqm71	159	2	Providers	Providers	NNPS
cord-003403-ypefqm71	159	3	FDA	FDA	NNP
cord-003403-ypefqm71	159	4	Zika	Zika	NNP
cord-003403-ypefqm71	160	1	Emergency	emergency	NN
cord-003403-ypefqm71	160	2	Use	use	NN
cord-003403-ypefqm71	160	3	Authorizations	authorization	NNS
cord-003403-ypefqm71	160	4	Table	table	NN
cord-003403-ypefqm71	161	1	2	2	LS
cord-003403-ypefqm71	161	2	Summary	Summary	NNP
cord-003403-ypefqm71	161	3	Molecular	Molecular	NNP
cord-003403-ypefqm71	161	4	Assay	Assay	NNP
cord-003403-ypefqm71	161	5	Characteristics	Characteristics	NNP
cord-003403-ypefqm71	161	6	FDA	FDA	NNP
cord-003403-ypefqm71	162	1	Zika	Zika	NNP
cord-003403-ypefqm71	162	2	EUA	EUA	NNP
cord-003403-ypefqm71	162	3	Table	table	NN
cord-003403-ypefqm71	163	1	1	1	CD
cord-003403-ypefqm71	163	2	Molecular	Molecular	NNP
cord-003403-ypefqm71	163	3	Assay	Assay	NNP
cord-003403-ypefqm71	163	4	Performance	performance	NN
cord-003403-ypefqm71	163	5	Characteristics	characteristic	NNS
cord-003403-ypefqm71	163	6	FDA	FDA	NNP
cord-003403-ypefqm71	163	7	Zika	Zika	NNP
cord-003403-ypefqm71	164	1	Virus	Virus	NNP
cord-003403-ypefqm71	164	2	Diagnostic	Diagnostic	NNP
cord-003403-ypefqm71	164	3	Development	Development	NNP
cord-003403-ypefqm71	164	4	High	high	JJ
cord-003403-ypefqm71	164	5	specificity	specificity	NN
cord-003403-ypefqm71	164	6	of	of	IN
cord-003403-ypefqm71	164	7	a	a	DT
cord-003403-ypefqm71	164	8	novel	novel	JJ
cord-003403-ypefqm71	164	9	Zika	Zika	NNP
cord-003403-ypefqm71	164	10	virus	virus	NN
cord-003403-ypefqm71	164	11	ELISA	ELISA	NNP
cord-003403-ypefqm71	164	12	in	in	IN
cord-003403-ypefqm71	164	13	European	european	JJ
cord-003403-ypefqm71	164	14	patients	patient	NNS
cord-003403-ypefqm71	164	15	after	after	IN
cord-003403-ypefqm71	164	16	exposure	exposure	NN
cord-003403-ypefqm71	164	17	to	to	IN
cord-003403-ypefqm71	164	18	different	different	JJ
cord-003403-ypefqm71	164	19	flaviviruses	flavivirus	NNS
cord-003403-ypefqm71	164	20	Kinetics	Kinetics	NNP
cord-003403-ypefqm71	164	21	of	of	IN
cord-003403-ypefqm71	164	22	anti	anti	JJ
cord-003403-ypefqm71	164	23	-	-	JJ
cord-003403-ypefqm71	164	24	ZIKV	zikv	JJ
cord-003403-ypefqm71	164	25	antibodies	antibody	NNS
cord-003403-ypefqm71	164	26	after	after	IN
cord-003403-ypefqm71	164	27	Zika	Zika	NNP
cord-003403-ypefqm71	164	28	infection	infection	NN
cord-003403-ypefqm71	164	29	using	use	VBG
cord-003403-ypefqm71	164	30	two	two	CD
cord-003403-ypefqm71	164	31	commercial	commercial	JJ
cord-003403-ypefqm71	164	32	enzyme	enzyme	NN
cord-003403-ypefqm71	164	33	-	-	HYPH
cord-003403-ypefqm71	164	34	linked	link	VBN
cord-003403-ypefqm71	164	35	immunoassays	immunoassays	NNP
cord-003403-ypefqm71	164	36	Diagnostic	diagnostic	JJ
cord-003403-ypefqm71	164	37	performance	performance	NN
cord-003403-ypefqm71	164	38	of	of	IN
cord-003403-ypefqm71	164	39	commercial	commercial	JJ
cord-003403-ypefqm71	164	40	IgM	IgM	NNP
cord-003403-ypefqm71	164	41	and	and	CC
cord-003403-ypefqm71	164	42	IgG	IgG	NNP
cord-003403-ypefqm71	164	43	enzyme	enzyme	NNP
cord-003403-ypefqm71	164	44	-	-	HYPH
cord-003403-ypefqm71	164	45	linked	link	VBN
cord-003403-ypefqm71	164	46	immunoassays	immunoassay	NNS
cord-003403-ypefqm71	164	47	(	(	-LRB-
cord-003403-ypefqm71	164	48	ELISAs	elisa	NNS
cord-003403-ypefqm71	164	49	)	)	-RRB-
cord-003403-ypefqm71	164	50	for	for	IN
cord-003403-ypefqm71	164	51	diagnosis	diagnosis	NN
cord-003403-ypefqm71	164	52	of	of	IN
cord-003403-ypefqm71	164	53	Zika	Zika	NNP
cord-003403-ypefqm71	164	54	virus	virus	NN
cord-003403-ypefqm71	164	55	infection	infection	NN
cord-003403-ypefqm71	164	56	Evaluation	evaluation	NN
cord-003403-ypefqm71	164	57	of	of	IN
cord-003403-ypefqm71	164	58	5	5	CD
cord-003403-ypefqm71	164	59	commercially	commercially	RB
cord-003403-ypefqm71	164	60	available	available	JJ
cord-003403-ypefqm71	164	61	Zika	Zika	NNP
cord-003403-ypefqm71	164	62	virus	virus	NN
cord-003403-ypefqm71	164	63	immunoassays	immunoassay	VBZ
cord-003403-ypefqm71	164	64	Advances	advance	VBZ
cord-003403-ypefqm71	164	65	in	in	IN
cord-003403-ypefqm71	164	66	diagnosis	diagnosis	NN
cord-003403-ypefqm71	164	67	,	,	,
cord-003403-ypefqm71	164	68	surveillance	surveillance	NN
cord-003403-ypefqm71	164	69	,	,	,
cord-003403-ypefqm71	164	70	and	and	CC
cord-003403-ypefqm71	164	71	monitoring	monitoring	NN
cord-003403-ypefqm71	164	72	of	of	IN
cord-003403-ypefqm71	164	73	Zika	Zika	NNP
cord-003403-ypefqm71	164	74	virus	virus	NN
cord-003403-ypefqm71	165	1	:	:	:
cord-003403-ypefqm71	165	2	An	an	DT
cord-003403-ypefqm71	165	3	update	update	NN
cord-003403-ypefqm71	165	4	World	World	NNP
cord-003403-ypefqm71	165	5	Health	Health	NNP
cord-003403-ypefqm71	165	6	Organization	Organization	NNP
cord-003403-ypefqm71	165	7	Emergency	Emergency	NNP
cord-003403-ypefqm71	165	8	Use	Use	NNP
cord-003403-ypefqm71	165	9	and	and	CC
cord-003403-ypefqm71	165	10	Listings	Listings	NNP
cord-003403-ypefqm71	165	11	Procedures	Procedures	NNPS
cord-003403-ypefqm71	165	12	DNA	DNA	NNP
cord-003403-ypefqm71	165	13	vaccination	vaccination	NN
cord-003403-ypefqm71	165	14	protects	protect	VBZ
cord-003403-ypefqm71	165	15	mice	mouse	NNS
cord-003403-ypefqm71	165	16	against	against	IN
cord-003403-ypefqm71	165	17	Zika	Zika	NNP
cord-003403-ypefqm71	165	18	virus	virus	NN
cord-003403-ypefqm71	165	19	-	-	HYPH
cord-003403-ypefqm71	165	20	induced	induce	VBN
cord-003403-ypefqm71	165	21	damage	damage	NN
cord-003403-ypefqm71	165	22	to	to	IN
cord-003403-ypefqm71	165	23	the	the	DT
cord-003403-ypefqm71	165	24	testes	testis	NNS
cord-003403-ypefqm71	165	25	In	in	IN
cord-003403-ypefqm71	165	26	vivo	vivo	NN
cord-003403-ypefqm71	165	27	protection	protection	NN
cord-003403-ypefqm71	165	28	against	against	IN
cord-003403-ypefqm71	165	29	ZIKV	ZIKV	NNP
cord-003403-ypefqm71	165	30	infection	infection	NN
cord-003403-ypefqm71	165	31	and	and	CC
cord-003403-ypefqm71	165	32	pathogenesis	pathogenesis	NN
cord-003403-ypefqm71	165	33	through	through	IN
cord-003403-ypefqm71	165	34	passive	passive	JJ
cord-003403-ypefqm71	165	35	antibody	antibody	NN
cord-003403-ypefqm71	165	36	transfer	transfer	NN
cord-003403-ypefqm71	165	37	and	and	CC
cord-003403-ypefqm71	165	38	active	active	JJ
cord-003403-ypefqm71	165	39	immunisation	immunisation	NN
cord-003403-ypefqm71	165	40	with	with	IN
cord-003403-ypefqm71	165	41	a	a	DT
cord-003403-ypefqm71	165	42	prMEnv	prmenv	JJ
cord-003403-ypefqm71	165	43	DNA	dna	NN
cord-003403-ypefqm71	165	44	vaccine	vaccine	NN
cord-003403-ypefqm71	165	45	Genetic	genetic	JJ
cord-003403-ypefqm71	165	46	and	and	CC
cord-003403-ypefqm71	165	47	serologic	serologic	JJ
cord-003403-ypefqm71	165	48	properties	property	NNS
cord-003403-ypefqm71	165	49	of	of	IN
cord-003403-ypefqm71	165	50	Zika	Zika	NNP
cord-003403-ypefqm71	165	51	virus	virus	NN
cord-003403-ypefqm71	165	52	associated	associate	VBN
cord-003403-ypefqm71	165	53	with	with	IN
cord-003403-ypefqm71	165	54	an	an	DT
cord-003403-ypefqm71	165	55	epidemic	epidemic	NN
cord-003403-ypefqm71	165	56	,	,	,
cord-003403-ypefqm71	165	57	Yap	Yap	NNP
cord-003403-ypefqm71	165	58	State	State	NNP
cord-003403-ypefqm71	165	59	,	,	,
cord-003403-ypefqm71	165	60	Micronesia	Micronesia	NNP
cord-003403-ypefqm71	165	61	Future	future	JJ
cord-003403-ypefqm71	165	62	developments	development	NNS
cord-003403-ypefqm71	165	63	in	in	IN
cord-003403-ypefqm71	165	64	biosensors	biosensor	NNS
cord-003403-ypefqm71	165	65	for	for	IN
cord-003403-ypefqm71	165	66	field	field	NN
cord-003403-ypefqm71	165	67	-	-	HYPH
cord-003403-ypefqm71	165	68	ready	ready	JJ
cord-003403-ypefqm71	165	69	Zika	Zika	NNP
cord-003403-ypefqm71	165	70	virus	virus	NN
cord-003403-ypefqm71	165	71	diagnostics	diagnostic	NNS
cord-003403-ypefqm71	165	72	Electrochemical	electrochemical	JJ
cord-003403-ypefqm71	165	73	biosensors	biosensor	NNS
cord-003403-ypefqm71	165	74	for	for	IN
cord-003403-ypefqm71	165	75	early	early	JJ
cord-003403-ypefqm71	165	76	stage	stage	NN
cord-003403-ypefqm71	166	1	Zika	Zika	NNP
cord-003403-ypefqm71	166	2	diagnostics	diagnostic	NNS
cord-003403-ypefqm71	166	3	Role	role	NN
cord-003403-ypefqm71	166	4	of	of	IN
cord-003403-ypefqm71	166	5	cell	cell	NN
cord-003403-ypefqm71	166	6	culture	culture	NN
cord-003403-ypefqm71	166	7	for	for	IN
cord-003403-ypefqm71	166	8	virus	virus	NN
cord-003403-ypefqm71	166	9	detection	detection	NN
cord-003403-ypefqm71	166	10	in	in	IN
cord-003403-ypefqm71	166	11	the	the	DT
cord-003403-ypefqm71	166	12	age	age	NN
cord-003403-ypefqm71	166	13	of	of	IN
cord-003403-ypefqm71	166	14	technology	technology	NN
cord-003403-ypefqm71	166	15	Isolation	isolation	NN
cord-003403-ypefqm71	166	16	of	of	IN
cord-003403-ypefqm71	166	17	infective	infective	JJ
cord-003403-ypefqm71	166	18	Zika	Zika	NNP
cord-003403-ypefqm71	166	19	virus	virus	NN
cord-003403-ypefqm71	166	20	from	from	IN
cord-003403-ypefqm71	166	21	urine	urine	NN
cord-003403-ypefqm71	166	22	and	and	CC
cord-003403-ypefqm71	166	23	saliva	saliva	NN
cord-003403-ypefqm71	166	24	of	of	IN
cord-003403-ypefqm71	166	25	patients	patient	NNS
cord-003403-ypefqm71	166	26	in	in	IN
cord-003403-ypefqm71	166	27	Brazil	Brazil	NNP
cord-003403-ypefqm71	166	28	Prolonged	prolong	VBN
cord-003403-ypefqm71	166	29	detection	detection	NN
cord-003403-ypefqm71	166	30	of	of	IN
cord-003403-ypefqm71	166	31	Zika	Zika	NNP
cord-003403-ypefqm71	166	32	virus	virus	NN
cord-003403-ypefqm71	166	33	in	in	IN
cord-003403-ypefqm71	166	34	vaginal	vaginal	JJ
cord-003403-ypefqm71	166	35	secretions	secretion	NNS
cord-003403-ypefqm71	166	36	and	and	CC
cord-003403-ypefqm71	166	37	whole	whole	JJ
cord-003403-ypefqm71	166	38	blood	blood	NN
cord-003403-ypefqm71	166	39	Detection	detection	NN
cord-003403-ypefqm71	166	40	of	of	IN
cord-003403-ypefqm71	166	41	Zika	Zika	NNP
cord-003403-ypefqm71	166	42	Virus	Virus	NNP
cord-003403-ypefqm71	166	43	in	in	IN
cord-003403-ypefqm71	166	44	urine	urine	NN
cord-003403-ypefqm71	166	45	Prolonged	prolonged	JJ
cord-003403-ypefqm71	166	46	detection	detection	NN
cord-003403-ypefqm71	166	47	of	of	IN
cord-003403-ypefqm71	166	48	Zika	Zika	NNP
cord-003403-ypefqm71	166	49	virus	virus	NN
cord-003403-ypefqm71	166	50	RNA	rna	NN
cord-003403-ypefqm71	166	51	in	in	IN
cord-003403-ypefqm71	166	52	urine	urine	NN
cord-003403-ypefqm71	166	53	samples	sample	NNS
cord-003403-ypefqm71	166	54	during	during	IN
cord-003403-ypefqm71	166	55	the	the	DT
cord-003403-ypefqm71	166	56	ongoing	ongoing	JJ
cord-003403-ypefqm71	166	57	Zika	Zika	NNP
cord-003403-ypefqm71	166	58	virus	virus	NN
cord-003403-ypefqm71	166	59	epidemic	epidemic	NN
cord-003403-ypefqm71	166	60	in	in	IN
cord-003403-ypefqm71	166	61	Brazil	Brazil	NNP
cord-003403-ypefqm71	166	62	Congenital	congenital	JJ
cord-003403-ypefqm71	166	63	cerebral	cerebral	JJ
cord-003403-ypefqm71	166	64	malformations	malformation	NNS
cord-003403-ypefqm71	166	65	and	and	CC
cord-003403-ypefqm71	166	66	dysfunction	dysfunction	NN
cord-003403-ypefqm71	166	67	in	in	IN
cord-003403-ypefqm71	166	68	fetuses	fetus	NNS
cord-003403-ypefqm71	166	69	and	and	CC
cord-003403-ypefqm71	166	70	newborns	newborn	NNS
cord-003403-ypefqm71	166	71	following	follow	VBG
cord-003403-ypefqm71	166	72	the	the	DT
cord-003403-ypefqm71	166	73	2013	2013	CD
cord-003403-ypefqm71	166	74	to	to	IN
cord-003403-ypefqm71	166	75	2014	2014	CD
cord-003403-ypefqm71	166	76	Zika	Zika	NNP
cord-003403-ypefqm71	166	77	virus	virus	NN
cord-003403-ypefqm71	166	78	epidemic	epidemic	NN
cord-003403-ypefqm71	166	79	in	in	IN
cord-003403-ypefqm71	166	80	French	french	JJ
cord-003403-ypefqm71	166	81	Polynesia	Polynesia	NNP
cord-003403-ypefqm71	166	82	Detection	Detection	NNP
cord-003403-ypefqm71	166	83	and	and	CC
cord-003403-ypefqm71	166	84	sequencing	sequencing	NN
cord-003403-ypefqm71	166	85	of	of	IN
cord-003403-ypefqm71	166	86	Zika	Zika	NNP
cord-003403-ypefqm71	166	87	virus	virus	NN
cord-003403-ypefqm71	166	88	from	from	IN
cord-003403-ypefqm71	166	89	amniotic	amniotic	JJ
cord-003403-ypefqm71	166	90	fluid	fluid	NN
cord-003403-ypefqm71	166	91	of	of	IN
cord-003403-ypefqm71	166	92	fetuses	fetus	NNS
cord-003403-ypefqm71	166	93	with	with	IN
cord-003403-ypefqm71	166	94	microcephaly	microcephaly	NNS
cord-003403-ypefqm71	166	95	in	in	IN
cord-003403-ypefqm71	166	96	Brazil	Brazil	NNP
cord-003403-ypefqm71	166	97	:	:	:
cord-003403-ypefqm71	167	1	A	a	DT
cord-003403-ypefqm71	167	2	case	case	NN
cord-003403-ypefqm71	167	3	study	study	NN
cord-003403-ypefqm71	167	4	Collaborative	Collaborative	NNP
cord-003403-ypefqm71	167	5	Study	Study	NNP
cord-003403-ypefqm71	167	6	to	to	TO
cord-003403-ypefqm71	167	7	Evaluate	evaluate	VB
cord-003403-ypefqm71	167	8	a	a	DT
cord-003403-ypefqm71	167	9	Candidate	Candidate	NNP
cord-003403-ypefqm71	167	10	World	World	NNP
cord-003403-ypefqm71	167	11	Health	Health	NNP
cord-003403-ypefqm71	167	12	Organization	Organization	NNP
cord-003403-ypefqm71	167	13	International	International	NNP
cord-003403-ypefqm71	167	14	Standard	Standard	NNP
cord-003403-ypefqm71	167	15	for	for	IN
cord-003403-ypefqm71	167	16	Zika	Zika	NNP
cord-003403-ypefqm71	167	17	Virus	Virus	NNP
cord-003403-ypefqm71	167	18	for	for	IN
cord-003403-ypefqm71	167	19	Nucleic	Nucleic	NNP
cord-003403-ypefqm71	167	20	Acid	acid	NN
cord-003403-ypefqm71	167	21	Amplification	amplification	NN
cord-003403-ypefqm71	167	22	Technique	technique	NN
cord-003403-ypefqm71	168	1	(	(	-LRB-
cord-003403-ypefqm71	168	2	NAT)-Based	NAT)-Based	NNP
cord-003403-ypefqm71	168	3	Assays	Assays	NNP
cord-003403-ypefqm71	168	4	FDA	FDA	NNP
cord-003403-ypefqm71	168	5	FDA	FDA	NNP
cord-003403-ypefqm71	168	6	provides	provide	VBZ
cord-003403-ypefqm71	168	7	new	new	JJ
cord-003403-ypefqm71	168	8	tools	tool	NNS
cord-003403-ypefqm71	168	9	for	for	IN
cord-003403-ypefqm71	168	10	the	the	DT
cord-003403-ypefqm71	168	11	development	development	NN
cord-003403-ypefqm71	168	12	and	and	CC
cord-003403-ypefqm71	168	13	proper	proper	JJ
cord-003403-ypefqm71	168	14	evaluation	evaluation	NN
cord-003403-ypefqm71	168	15	of	of	IN
cord-003403-ypefqm71	168	16	tests	test	NNS
cord-003403-ypefqm71	168	17	for	for	IN
cord-003403-ypefqm71	168	18	detecting	detect	VBG
cord-003403-ypefqm71	168	19	Zika	Zika	NNP
cord-003403-ypefqm71	168	20	virus	virus	NN
cord-003403-ypefqm71	168	21	infection	infection	NN
cord-003403-ypefqm71	168	22	Current	current	JJ
cord-003403-ypefqm71	168	23	status	status	NN
cord-003403-ypefqm71	168	24	of	of	IN
cord-003403-ypefqm71	168	25	Zika	Zika	NNP
cord-003403-ypefqm71	168	26	vaccine	vaccine	NN
cord-003403-ypefqm71	168	27	development	development	NN
cord-003403-ypefqm71	168	28	:	:	:
cord-003403-ypefqm71	169	1	Zika	Zika	NNP
cord-003403-ypefqm71	169	2	vaccines	vaccine	NNS
cord-003403-ypefqm71	169	3	advance	advance	VBP
cord-003403-ypefqm71	169	4	into	into	IN
cord-003403-ypefqm71	169	5	clinical	clinical	JJ
cord-003403-ypefqm71	169	6	evaluation	evaluation	NN
cord-003403-ypefqm71	169	7	Preliminary	preliminary	JJ
cord-003403-ypefqm71	169	8	aggregate	aggregate	JJ
cord-003403-ypefqm71	169	9	safety	safety	NN
cord-003403-ypefqm71	169	10	and	and	CC
cord-003403-ypefqm71	169	11	immunogenicity	immunogenicity	NN
cord-003403-ypefqm71	169	12	results	result	NNS
cord-003403-ypefqm71	169	13	from	from	IN
cord-003403-ypefqm71	169	14	three	three	CD
cord-003403-ypefqm71	169	15	trials	trial	NNS
cord-003403-ypefqm71	169	16	of	of	IN
cord-003403-ypefqm71	169	17	a	a	DT
cord-003403-ypefqm71	169	18	purified	purify	VBN
cord-003403-ypefqm71	169	19	inactivated	inactivate	VBN
cord-003403-ypefqm71	169	20	Zika	Zika	NNP
cord-003403-ypefqm71	169	21	virus	virus	NN
cord-003403-ypefqm71	169	22	vaccine	vaccine	NN
cord-003403-ypefqm71	169	23	candidate	candidate	NN
cord-003403-ypefqm71	169	24	:	:	:
cord-003403-ypefqm71	169	25	Phase	phase	NN
cord-003403-ypefqm71	169	26	1	1	CD
cord-003403-ypefqm71	169	27	,	,	,
cord-003403-ypefqm71	169	28	randomised	randomised	JJ
cord-003403-ypefqm71	169	29	,	,	,
cord-003403-ypefqm71	169	30	double	double	JJ
cord-003403-ypefqm71	169	31	-	-	HYPH
cord-003403-ypefqm71	169	32	blind	blind	JJ
cord-003403-ypefqm71	169	33	,	,	,
cord-003403-ypefqm71	169	34	placebo	placebo	NN
cord-003403-ypefqm71	169	35	-	-	HYPH
cord-003403-ypefqm71	169	36	controlled	control	VBN
cord-003403-ypefqm71	169	37	clinical	clinical	JJ
cord-003403-ypefqm71	169	38	trials	trial	NNS
cord-003403-ypefqm71	169	39	Safety	Safety	NNP
cord-003403-ypefqm71	169	40	,	,	,
cord-003403-ypefqm71	169	41	tolerability	tolerability	NN
cord-003403-ypefqm71	169	42	,	,	,
cord-003403-ypefqm71	169	43	and	and	CC
cord-003403-ypefqm71	169	44	immunogenicity	immunogenicity	NN
cord-003403-ypefqm71	169	45	of	of	IN
cord-003403-ypefqm71	169	46	two	two	CD
cord-003403-ypefqm71	169	47	Zika	Zika	NNP
cord-003403-ypefqm71	169	48	virus	virus	NN
cord-003403-ypefqm71	169	49	DNA	dna	NN
cord-003403-ypefqm71	169	50	vaccine	vaccine	NN
cord-003403-ypefqm71	169	51	candidates	candidate	NNS
cord-003403-ypefqm71	169	52	in	in	IN
cord-003403-ypefqm71	169	53	healthy	healthy	JJ
cord-003403-ypefqm71	169	54	adults	adult	NNS
cord-003403-ypefqm71	169	55	:	:	:
cord-003403-ypefqm71	170	1	Randomised	randomised	JJ
cord-003403-ypefqm71	170	2	,	,	,
cord-003403-ypefqm71	170	3	open	open	JJ
cord-003403-ypefqm71	170	4	-	-	HYPH
cord-003403-ypefqm71	170	5	label	label	NN
cord-003403-ypefqm71	170	6	,	,	,
cord-003403-ypefqm71	170	7	phase	phase	NN
cord-003403-ypefqm71	170	8	1	1	CD
cord-003403-ypefqm71	170	9	clinical	clinical	JJ
cord-003403-ypefqm71	170	10	trials	trial	NNS
cord-003403-ypefqm71	171	1	This	this	DT
cord-003403-ypefqm71	171	2	article	article	NN
cord-003403-ypefqm71	171	3	is	be	VBZ
cord-003403-ypefqm71	171	4	an	an	DT
cord-003403-ypefqm71	171	5	open	open	JJ
cord-003403-ypefqm71	171	6	access	access	NN
cord-003403-ypefqm71	171	7	article	article	NN
cord-003403-ypefqm71	171	8	distributed	distribute	VBN
cord-003403-ypefqm71	171	9	under	under	IN
cord-003403-ypefqm71	171	10	the	the	DT
cord-003403-ypefqm71	171	11	terms	term	NNS
cord-003403-ypefqm71	171	12	and	and	CC
cord-003403-ypefqm71	171	13	conditions	condition	NNS
cord-003403-ypefqm71	171	14	of	of	IN
cord-003403-ypefqm71	171	15	the	the	DT
cord-003403-ypefqm71	171	16	Creative	Creative	NNP
cord-003403-ypefqm71	171	17	Commons	Commons	NNP
cord-003403-ypefqm71	171	18	Attribution	Attribution	NNP
cord-003403-ypefqm71	171	19	(	(	-LRB-
cord-003403-ypefqm71	171	20	CC	CC	NNP
cord-003403-ypefqm71	171	21	BY	by	IN
cord-003403-ypefqm71	171	22	)	)	-RRB-
cord-003403-ypefqm71	171	23	license	license	NN